   
 
 A5279  
 
Phase III Clinical Trial of Ultra -Short -Course Rifapentine/Isoniazid for the 
Prevention of Active Tuberculosis in HIV -Infected Individuals  with Latent 
Tuberculosis Infection 
 
A Multic enter Trial of the AIDS Clinical Trials Group (ACTG)  
 
 
Sponsored by:  
 
The National Institute of Allergy  
and Infectious Diseases 
 
 
Pharmaceutical Support Provided by : 
sanofi -aventis  
 
 
IND # : 112,339  
 
 
 
The ACTG  Tuberculosis  
Transformative Science Group:   Richard E. Chaisson, MD, Chair  
 
Protocol Co- Chair s: Richard E. Chai sson, MD  
 Susan Swindells, MBBS  
  
Protocol Vice Chair:      Amita Gupta, MD , MHS  
  
DAIDS Clinical Representative:    Daniel H. Johnson, MD  
 
Clinical Trials Specialist:  Laura E. Moran, MPH  
  
 
 
 
 
FINAL Version 2.0  
August 28, 2014  
A5279 
  FINAL Version 2.0  
  08/28/14  
 CONTENTS  
  Page  
 
SITES PARTICIPATING IN THE STUDY  .................................................................................... 4 
PROTOCOL TEAM ROSTER  ..................................................................................................... 5 
STUDY MANAGEMENT  ............................................................................................................. 9 
GLOSSARY OF TERMS ........................................................................................................... 11 
SCHEMA  .................................................................................................................................. 13 
1.0 HYPOTHESIS AND STUDY OBJECTIVES  ...................................................................  15 
1.1 Hypothesis  ......................................................................................................... 15 
1.2 Primary Objective  ............................................................................................... 15 
1.3 Secondary Objectives  ........................................................................................ 15 
1.4 Supportive/Exploratory Objectives  ..................................................................... 15 
2.0 INTRODUCTION  ........................................................................................................... 16 
2.1 Background  ........................................................................................................ 16 
2.2 Rationale ........................................................................................................... 23 
3.0 STUDY DESIGN  ........................................................................................................... 29 
4.0 SELECTION AND ENROLLMENT OF PARTICIPANTS  ................................................ 30 
4.1 Inclusion Criteria  ................................................................................................ 30 
4.2 Exclusion Criteria  ............................................................................................... 32 
4.3 Study En rollment Procedures ............................................................................. 33 
4.4 Coenrollment Guidelines  .................................................................................... 34 
5.0 STUDY TREATMENT  ................................................................................................... 34 
5.1 Regimens, Administration, and Duration  ............................................................ 35 
5.2 Study Pro duct Formulation and Preparation ....................................................... 36 
5.3 Pharmacy: Product Supply, Distribution, and Accountability  .............................. 36 
5.4 Concomitant Medications  ................................................................................... 37 
5.5 Adherence Assessment  ..................................................................................... 38 
6.0 CLINICAL AND LABORATORY EVALUATIONS  ........................................................... 39 
6.1 Schedule of Events  ............................................................................................  39 
6.2 Timing of Evaluations  ......................................................................................... 42 
6.3 Instructions for Evaluations  ................................................................................ 43 
7.0 CLINICAL MANAGEMENT ISSUES  .............................................................................. 47 
7.1 Toxicity  .............................................................................................................. 48 
7.2 Pregnancy .......................................................................................................... 49 
8.0 CRITERIA FOR DISCONTINUATION  ........................................................................... 49 
8.1 Permanent Treatment Discontinuation  ............................................................... 49 
8.2 Premature Study Discontinuation ....................................................................... 49 
9.0 STATISTICAL CONSIDERATIONS  ............................................................................... 50 
9.1 General Design Issues  ....................................................................................... 50 
A5279 
  FINAL Version 2.0  
  08/28/14  
 CONTENTS (Cont’d)  Page  
 
9.2 Endpoints  ........................................................................................................... 50 
9.3 Randomization and Stratification ........................................................................ 51 
9.4 Sample Size and Accrual  ................................................................................... 51 
9.5 Monitoring .......................................................................................................... 53 
9.6 Analyses  ............................................................................................................ 54 
9.7 Cost-Effectiveness Analysis  ............................................................................... 56 
10.0  PHARMACOLOGY PLAN  .............................................................................................. 56 
10.1  Pharmacology Objectives  .................................................................................. 56 
10.2  Pharmacology Study Design  .............................................................................. 57 
10.3  Primary and Secondary Data, Modeling, and Data Analysis  .............................. 61 
10.4  Anticipated Outcomes  ........................................................................................ 65 
11.0  DATA COLLECTION AND MONITORING AND ADVERSE EVENT REPORTING  ........ 65 
11.1  Records to Be Kept  ............................................................................................  65 
11.2  Role of Data Management  ................................................................................. 65 
11.3  Clinical Site Monitoring and Record Availability  .................................................. 66 
11.4  Expedited Adverse Event (EAE) Reporting ........................................................ 66 
12.0  HUMAN PARTICIPANTS  .............................................................................................. 67 
12.1  Institutional Review Board (IRB) Review and Informed Consent  ........................ 67 
12.2  Participant Confidentiality  ................................................................................... 67 
12.3  Study Discontinuation ........................................................................................ 67 
13.0  PUBLICATION OF RESEARCH FINDINGS  .................................................................. 68 
14.0  BIOHAZARD CONTAINMENT  ...................................................................................... 68 
15.0  REFERENCES  .............................................................................................................. 69 
 
APPENDIX I:   SAMPLE INFORMED CONSENT  
 
 
 4 A5279 
  FINAL Version 2.0  
  08/28/14  
 SITES  PARTICIPATING IN THE STUDY  
 
A5279 is a multicenter study open to all US and non- US ACTG clinical research sites (CRS s). 
 
 
 
 
 
 5 A5279 
  FINAL Version 2.0 
  08/28/14  
 PROTOCOL TEAM ROSTER  
 
Co-Chairs  
Richard E. Chaisson, MD  
Division of Infectious Diseases  
Johns Hopkins University  
1503 E. Jefferson Street  
Baltimore, MD 21231  
Phone: (410) 955- 1755  
FAX: (410) 955 -0740  
E-mail: rchaiss@jhmi.edu   
 
Susan Swindells, MBBS  
Infectious Diseases/Internal Medicine 
University of Nebraska Medical Center  
988106 Nebraska Medical Center  
Omaha , NE 68198- 8106  
Phone: (402) 559- 5392  
FAX: (402) 553 -5527  
E-mail: sswindells@unmc.edu   
 
Vice Chair  
Amita Gupta, MD , MHS   
Division of Infectious Diseases  
Johns Hopkins University  
Jefferson Street Building, Room 2 -121B  
600 North Wolfe Street  
Baltimore, MD 21287  
Phone: (410) 502- 7696  
FAX: (443) 287 -6440  
E-mail: agupta25@jhmi.edu   
 
DAIDS Clinical Representative   
Daniel H. Johnson, MD  
TCRB/TRP/DAIDS/NIAID/NIH  
5601 Fishers Lane  
Room 9E39, MSC 9830  
Rockville MD 20852  
Phone: 240-627-3066  
E-mail: daniel.johnson@nih.gov  
 Clinical Trials Specialist  
Laura E. Moran, MPH  
ACTG  Network Coordinating  Center  
Social & Scientific Systems  
8757 Georgia Avenue, 12th Floor  
Silver Spring, MD 20910- 3714  
Phone:  (301) 628- 3373  
FAX:  (301) 628 -3302  
E-mail: lmoran@s -3.com  
 
Statistician s 
Janet Andersen, Sc D  
Statistical & Data Analysis Center  
Harvard School of Public Health  
FXB Building, Room 621  
651 Huntington Avenue  
Boston, MA 02115- 6017  
Phone: (617) 432- 2814  
FAX: (617) 432 -2843  
E-mail: andersen@sdac.harvard.edu   
 
Yajing Bao, MS   
Statistical and Data Analysis Center  
Harvard School of Public Health  
FXB Building, Room 601  
651 Huntington Avenue 
Boston, MA 02115- 6017  
Phone: (617) 432- 1115  
FAX: (617) 432 -2843  
E-mail: ybao@sdac.harvard.edu  
 
Site Support  Specialist  
Christina Blanchard- Horan, PhD, MA, 
CCRP  
ACTG Network Coordinating Center  
Social & Scientific Systems Inc.  
8757 Georgia Avenue, 12th floor  
Silver Spring, MD 20910  
Phone: (301) 628- 3339 
FAX: (301) 628 -3302  
E-mail:  cblanchardhoran@s -3.com  
 
 
 6 A5279 
FINAL Version 2.0  
 PROTOCOL TEAM ROSTER (Cont’d)  08/28/14  
 
Data Manager  
Ann Walawander, M A  
Frontier Science & Technology Research 
Foundation, Inc.  
4033 Maple Road  
Amherst, NY 14226- 1056  
Phone: (716) 834- 0900  x7290  
FAX: (716) 834 -8432  
E-mail: walawander.ann@fstrf.org  
 
DAIDS Pharmacist  
Katherine Shin, PharmD  
Pharmaceutical Affairs Branch  
DAIDS/NIAID/NIH  
Pharmaceutical Affairs Branch 
5601 Fishers Lane.  
Room 9D30A  
Rockville MD 20852  
Phone: 240-627-3047  
FAX: 301-402-1506  
E-mail: kashin@niaid.nih.gov  
 
Pharmacologist s 
Courtney V. Fletcher, PharmD  
University  of Nebraska Medical Center  
College of Pharmacy  
986000 Nebraska Medical Center  
Omaha, NE 68198- 6000  
Phone: (402) 559- 4333  
FAX: (402) 449 -5060  
E-mail: cfletcher@unmc.edu  
 
Anthony T. Podany, Pharm D 
University of  Nebraska Medical Center  
College of Pharmacy  
986045 Nebraska Medical Center  
Omaha, NE 68198- 1945  
Phone: (402) 559 -1346  
E-mail: apodany@unmc.edu  
 
 
 
 
 
 
 
 
 Investigator s 
Constance A. Benson, MD  
University of California , San Diego  
Antiviral Research Center  
220 Dickinson Street, Suite A #8208  
San Diego, CA 92103 -8208 
Phone: (619) 543- 8080  
FAX: (619) 543 -5066  
E-mail: cbenson@ucsd.edu  
 
David P. Holland, MD  
Division of Infectious Diseases  
Duke University Medical Center  
Box 102359 
Durham, NC 27710  
Phone: (919) 613- 5160  
FAX: (919) 684 -8902  
E-mail: david.p.holland@duke.edu  
 
Marc Antoine Jean Juste, MD  
GHESKIO Centers  
33, Boulevard Harry Truman  
Port-au-Prince  
HAITI  
Phone: (509) 3408- 4091  
E-mail: mjeanjuste@gheskio.org 
 
Eric Nuermberger, MD  
Division of Infectious Diseases  
Johns Hopkins University  
Center for TB Research  
1550 Orleans St., Room 107 
Baltimore, MD 21231 
Phone: (410) 502-0580  
FAX: (410) 614-8173  
E-mail: enuermb@jhmi.edu  
 
Sandy Pillay, MB ChB  
Nelson R. Mandela School of Medicine  
University of KwaZulu- Natal  
302 DDMRI Building  
719 Umbilo Road  
Durban , 4001  
SOUTH AFRICA  
Phone: 27 31 260 4668  
FAX: 27 82 602 3872  
E-mail: pillay@ukzn.ac.za  
 7 A5279 
FINAL Version 2.0  
 PROTOCOL TEAM ROSTER (Cont’d)  08/28/14  
 
Investigators (Cont'd)  
Ian M. Sanne, MD, FCP, DTM&H  
Wits Health Consortium  
Clinical HIV Research Unit  
Helen Joseph Hospital  
Themba Lethu Clinic  
Perth Road Westdene  
Johannesburg, 2193  
SOUTH AFRICA  
Phone: 27 11 276 8801  
FAX: 27 11 482 2130  
E-mail: isanne@witshealth.co.za   
 
Field Representative 
Janet Nicotera,  RN, BSN 
Vanderbilt University Medical Center  
Institute for Global Health 
2525 West End Ave, Suite 750  
Nashville, TN 37203- 1738 
Phone: (615) 343-6556  
FAX: (615) 343-7797  
E-mail: janet.nicotera@vanderbilt.edu  
 
Laboratory Technologist  
David L. Shugarts , MA 
University of Colorado Denver  
Mail Stop B -168, Room P15- 11006 
12700 E. 19th Avenue 
Aurora, CO  80045  
Phone: (303) 724-2981  
FAX: (303) 724-4926  
E-mail: David.Shugarts@ucdenver.edu  
 
CSS Representative  
Amina M. Shali  
Moi University International  
Clinical Trials Unit  
P.O. Box 2066  
Eldoret, 30100  
KENYA  
Phone: 011 254 720 858 553  
E-Mail: aminashali@yahoo.co.ukLaboratory Data Coordinator  
Jimi Tutko, BS  
Frontier Science & Technology Research 
Foundation, Inc.  
4033 Maple Road  
Amherst, NY 14226  
Phone: (716) 834- 0900 x7382 
FAX: (716) 833 -0655  
E-mail: tutko@fstrf.org  
 
Industry Representative 
Marilyn Maroni, MD  
sanofi -aventis  
9, rue du Président ALLENDE  
94256  Gentilly Cedex  
FRANCE  
Phone: 33 (0)  1 41 24 5 9 48 or 33 (0)  6.86 
38 86 06   
E-mail: marilyn.maroni@sanofi.com  
 
Site Investigators  
Site 11301:  
Jorge L. Sanchez, MD , MPH  
E-mail: jsanchez@impactaperu.org  
 
Site 11302:  
Javier R. Lama, MD, MPH  
E-mail: jrlama@impactaperu.org  
 
Site 12001:  
Mitch Matoga, MBBS  
E-mail: mmatoga@unclilongwe.org.mw  
 
Site 12101:  
Guilherme do Amaral Calvet, MD, MSc  
E-mail: guilherme.calvet@ipec.fiocruz.br  
 
Site 12301:  
Lerato Mohapi, MD  
E-mail: mohapil@phru.co.za  
 
Site 12601:  
Ronald Kibet Tonui, MB ChB  
E-mail: rktonui@mu.ac.ke   
 
 8 A5279 
FINAL Version 2.0  
 PROTOCOL TEAM ROSTER (Cont’d)  08/28/14  
 
Site Investigators (Cont’d)  
Site 12701:  
Taolo Modise, GNM  
E-mail: tmodise@bhp.org.bw  
 
Site 12801:  
Margaret Kasaro, MB ChB  
E-mail: Error! Hyperlink reference not 
valid. 
 
Site 31422:  
Kogieleum Naidoo, MB ChB  
E-mail: naidook45@ukzn.ac.za  
 
Site 31441:  
Deelip Kadam, MD  
E-mail: dileep.kadam@gmail.com  
 
Site 31470:  
William Burman, M D 
E-mail: bburman@dhha.org  
 
 9 A5279 
FINAL Version 2.0  
  08/28/14  
 STUDY MANAGEMENT  
 
All questions concerning this protocol should be sent to actg. core A5279@fstrf.org  via e -mail. 
The appropriate team member will respond with a "cc" to the team . A response should generally 
be received within 24 hours (Monday -Friday).  
 
Protocol e -mail Group   
Sites planning to register to this study m ust contact the Computer Support Group at the Data 
Management Center (DMC) to have the relevant personnel at the site added to the 
actg.protA5279 e- mail group. Include the protocol number in the email subject line.  
• Send an e- mail message to actg.user.support@fstrf.org   
 
Clinical Management  
For questions concerning entry criteria, toxicity management, concomitant medications, and 
coenrollment, contact the protocol Co-Chair s/Vice Chair.  Send an e- mail message to 
actg. core A5279@fstrf.org  (ATTN: Richard Chaisson, MD; Susan Swindells, MBBS; Amita 
Gupta, MD , MHS ). Include the protocol number, patient identification number (PI D), and a brief 
relevant history.  
 
Laboratory  
For questions specifically related to pharmacologic laboratory tests, contact the protocol 
Pharmacologist.  Send an e- mail message to actg. coreA5279@fstrf.org  (ATT N: Courtney 
Fletcher, PharmD , Anthony Podany, PharmD ). 
 
Data Management  
For nonclinical questions about transfers, inclusion/exclusion criteria, case report forms (CRF s), 
the CRF schedule of events, randomization/registration, delinquencies, and other data 
management issues, contact the Data Manager.  
• For transfers, reference the Patient Transfer from Site to Site SOP 11 9, and contact Ann 
Walawander, MA  directly.  
• For other questions, s end an e -mail message to actg. core A5279@fstrf.org  (ATTN: Ann 
Walawander, MA ).   
• Include the protocol number, PID, and a detailed question.  
 
Randomization /Participant Registration  
For randomization/participant registration questions or problems and study identification number 
(SID) lists.  
• Send an e- mail message to rando.support@fstrf.org   
• or call the Statistical and Data Analysis Center (SDAC)/DMC Randomization Desk at (716) 
898-7301.    
 
Computer and Screen Problems   
Contact the SDA C/DMC programmers : 
• Send an e- mail message to actg.support@fstrf.org    
• or call (716) 834- 0900 x7302.  
 
Protocol Document Questions  
For questions concerning the protocol document, contact the Clinical Trials Spec ialist. Send an 
e-mail message to actg. coreA5279@fstrf.org  (ATTN:  Laura Moran, MPH ). 
 10 A5279 
FINAL Version 2.0  
 STUDY MANAGEMENT (Cont'd)  08/28/14  
 
Copies of the Protocol  
To request hard copies of the protocol, send  a message to ACTGNCC@s -3.com  (ATTN: Diane 
Delgado) via e- mail. Electronic copies can be downloaded from the ACTG Web site 
(https://www.actgnetwork.org ). 
 
Product  Package Inserts  
To request copies of product  package i nserts , contact the DAIDS Regulatory Support  Center 
(RSC): 
• Send an e- mail message to RIC@tech -res.com   
• or call (301) 897- 1708 . 
 
Protocol Registration  
For protocol registration questions:  
• Send an e- mail message to Protocol@tech- res.com   
• or call (301) 897- 1707.  
 
Study Product  
For questions or problems regarding study product , dose, supplies, records, and returns, 
contact  Katherine Shin , PharmD , Protocol Pharmacist :  
• Send an e- mail message to kashin@niaid.nih.gov  
• or call (301) 594- 1517 .  
 
IND (Investigational New Drug)  Number or Questions  
For any questions about the IND, c ontact the DAIDS  RSC:  
• Send an e-mail message to Regulatory@tech- res.com   
• or call (301) 897- 1706.  
 
Study Product Orders  
Call the Clinical Research Products Management Center at (301) 294- 0741.  
 
Expedited Adverse Event  (EAE) Reporting/ Ques tions   
To report an EAE or for questions related to EAE reporting, c ontact DAIDS through the R SC 
Safety Office :  
• Send an e- mail message to DAIDSRSCSafetyOffice@tech -res.com   
• or call 1 -800-537-9979 or 301-897-1709 or fax 1-800-275-7619 or 301-897-1710.  
 
Phone Calls  
Sites are responsible for documenting any phone calls made to protocol team members. Send 
an e- mail to actg. coreA5279@fstrf.org  
 
Protocol -Specifi c Web Page 
Additional information about the study may be found on the A5279 protocol -specific web page 
(PSWP).
 11 A5279 
FINAL Version 2.0  
  08/28/14  
 GLOSSARY OF TERMS 
 
AE  Adverse Event  
ALT  Alanine Aminotransferase 
ANC   Absolute Neutrophil Count  
ART  Antiretroviral Therapy  
AST  Aspartate Aminotransferase 
ATS  American Thoracic Society   
AUC   Area under the Concentration- Time  Curve  
BCG   Bacille Calmette -Guerin (TB vaccine)  
CDC   Center s for Disease Control and Prevention 
CFU  Colony -forming Units  
CI  Confidence Interval  
COD  Cause of Death  
CLIA   Clinical Laboratory Improvement Amendments  
CMV   Cytomegalovirus  
CRF  Case Report Form  
CRPMC  Clinical Research Products Management Center  
CRS   Clinical Research Site  
CSS  Community Scientific Subcommittee  
DAERS  DAIDS Adverse Event Reporting System  
DAIDS   Division of AIDS  
DMC   Data Management Center  
DOT   Directly Observed Therapy  
DSMB   Data and Safety Monitoring Board  
EAE  Expedited Adverse Event  
EC  Ethics Committee  
E/CIA   Enzyme or chemiluminescence  
EMB   Ethambutol  
EFV  Efavirenz  
FDA  Food and Drug Administration  
HBM   Human Biological Materials  
IATA   International Air Transport Association  
ICF  Informed Consent Form  
ICH   International Conference on Harmonisation  
IDSA   Infectious Diseases Society of America  
IGRA   Interferon  Gamma  Release Assay  
IND  Inves tigational New Drug  
INH  Isoniazid  
IPT  INH Preventive Therapy  
IRB  Institutional Review Board 
ITT  Intent ion-to-Treat  
LTBI   Latent Tuberculosis Infection  
LFU  Loss  to Follow -Up 
MAC   Mycobacterium Avium  Complex  
MDR TB  Multi -Drug -Resistant Tuberculosis  
MTB   Mycobacterium tuberculosis  
NIAID   National Institute of Allergy and Infectious Diseases  
 12 A5279 
FINAL Version 2.0  
 GLOSSARY OF TERMS (Cont'd)  08/28/14  
 
NNRTI   Non-Nucleoside Reverse Transcriptase Inhibitor  
NRTI   Nucleoside Reverse Transcriptase Inhibitor  
NVP  Nevirapine  
NWCS   New Work Concept Sheet  
OHRP   Office for Human Research Protections  
PBMC   Peripheral Blood Mononuclear Cell  
PD   Pharmacodynamic  
PI  Protease Inhibitor  
PID  Patient Identification Number  
PK  Pharmacokinetic  
PPD  Purified Protein Derivative 
PRO   Protocol Registration Office 
PSWP   Protocol -Specific Web Page 
PY  Person- Year  
PZA  Pyrazinamide 
RE  Regulatory Entity  
RFB   Rifabutin   
RIF  Rifampin  
RPT  Rifapentine 
RR  Relative Risk  
RSC   Regulatory Support Center  
SAE  Serious Adverse Event  
SGOT   Serum Glutamic Oxaloacetic Transaminase  
SGPT   Serum Glutamic P yruvic Transaminase  
SID  Study  Identification Number  
SOC   Standard of Care  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
TB  Tuberculosis  
TBTC   Tuberculosis Trials Consortium  
TST  Tuberculin Skin Test  
ULN  Upper Limit of Normal  
U.S.  United States  
WHO  World Health Organization 
XDR TB  Extensively Drug -Resistant Tuberculosis  
 
 
 13 A5279 
FINAL Version 2.0  
  08/28/14  
 SCHEMA  
 
 
A5279 
 
Phase III Clinical Trial of Ultra -Short -Course Rifapentine/Isoniazid for the Prevention of Active 
Tuberculosis in HIV -Infected Individuals  with Latent Tuberculosis Infection  
 
DESIGN  This study is a multicenter, randomized, open- label, phase III clinical trial 
comparing a 4 -week daily rifapentine (RPT)/isoniazid (INH) regimen to a 
standard 9- month daily INH regimen  for the prevention of tuberculosis (TB) 
in HIV -infected pa rticipants  without evidence of active TB . The primary 
objective will be efficacy of TB prevention. The study will also assess safety 
and tolerability of the regimens, adherence to the treatments, and patterns 
of antibiotic resistance among Mycobac terium  tuberculosis  (MTB ) isolates 
in participants who fail on these prophylactic regimens.  
 
DURATION  Each participant will be followed for 3 years ( 156 weeks ) after the last 
participant is enrolled.  
 
SAMPLE SIZE 3000 participants  
 
POPULATION  HIV-1 infecte d men and women ≥13 years old and ≥30 kg without evidence 
of active TB who:  
1. Have tubercul in skin test (TST) reactivity ≥ 5 mm or a positive interferon  
gamma  release  assay (IGRA), OR   
2. Live in high TB burden areas, defined as areas with an estimated or 
report ed TB prevalence of 60/100,000 , according to the WHO or 
national or local health authorities. (Please refer to the A5279 
protocol -specific web page [PSWP ] for the WHO link to TB 
prevalence information by country. T he protocol core team 
[actg.corea5279@fstrf.org ] should be consulted if a site has data 
to suggest that the local TB burden differs significantly from the 
WHO country estimates and, therefore, should be considered in 
the application of this inclusion  criterion. ) 
 
If taking antiretroviral therapy (ART) at study entry , only approved 
nucleoside reverse transcriptase inhibitor s (NRTI s) with efavirenz (EFV) or 
nevirapine (NVP)  for at least 4 weeks are permitte d. A list of approved 
antiretroviral drugs  is located on the A5279 PSWP. Participants on  
NVP must be dosed at 200 mg twice daily (BID).   
 
NVP trough levels will be evaluated in the first 90 participants in Arm 
A who are receiving NVP at entry and who meet other criteria in 
section 10.0, after which enrollment for participants on NVP may  be 
temporarily halted. NVP pharmacokinetic (PK) data will be evaluated 
to determine whether standard NVP dosing results in adequate PK 
drug exposure in the presence of RPT treatment. If the A5279 team 
 14 A5279 
FINAL Version 2.0  
 SCHEMA (Cont'd)  08/28/14  
 
determines that concomitant dosing of NVP and RPT results in 
adequate drug exposure, the study may continue enrollment of  
participants receiving NVP.    
 
EFV concentrations and pharmacogenetics will be evaluated in the 
first 90 participants  who enroll  in Arm B under Version 2.0 who are 
receiving EFV at entry and who meet other criteria in s ection 10.0.  
Additionally, under Version 2.0, EFV concentrations and 
pharmacogenetics will be evaluated in an additional 30 participants 
from Arm A who will undergo PK sampling at weeks 0,  2, 4, and 16.  
 
NOTE:  Participants randomized to Arm A may initiate any ART 
regimen after completing 4  weeks of RPT/INH.  Participants 
randomized to Arm B may initiate any ART regimen after study entry.  
 
STRATIFICATION  Participants will be stratified based on (1) the most recent CD4+ cell count 
obtained within 180 days prior to entry  (<100, 100- 250, and >250 
cells/mm3) and (2) ART use at entry (Yes/No).  
 
REGIMEN  Participants will be randomized within strata in a 1:1 ratio to receive either:  
 
Arm A: 4-week daily regimen of weight -based RPT and INH, plus 
pyridoxine ( vitamin B 6) 
OR 
Arm B: 9-month ( 36-week ) daily INH regimen , plus pyridoxine ( vitamin B 6) 
 
 15 A5279 
FINAL Version 2.0  
  08/28/14  
 1.0 HYPOTHESIS AND STUDY OBJECTIVES  
 
1.1 Hypothesis  
 
Ultra -short -course  (4-week)  daily rifapentine  (RPT) /isoniazid ( INH) is not inferior to a 
standard 9-month  (36-week)  daily INH regimen  for the prevention of tuberculosis (TB) in 
HIV-infected individuals . 
 
1.2 Primary Objective  
 
To compare the efficacy of a 4 -week daily regimen of weight -based RPT/INH to a 
standard 9 -month  (36 week)  daily INH regimen for TB  prevention in HIV -infected 
individuals .  
 
1.3 Secondary Objectives  
 
1.3.1  To compare safety and tolerability of the regimens  
 
1.3.2  To compare overall  and non- TB mortality rates among participants receiving the 
two regime ns 
 
1.3.3  To compare adherence rates in the two regimens  
 
1.3.4  To investigate patterns of antibiotic resistance among Mycobacterium 
tuberculosis  (MTB ) isolates in participants  failing prophylaxis  
 
1.4 Supportive/Exploratory Objectives  
 
The following objectives will be defined in detail in separate analysis plans . 
 
1.4.1  To inform public health policy by comparing estimated costs and cost -
effectiveness of the two regimens in various populations  
 
1.4.2  To investigate  the effect of RPT/INH on efavirenz ( EFV)  and nevirapine ( NVP) 
plasma concentrations    
 
1.4.3  To describe  exposure- outcome  relationships among EFV and NVP 
pharmacokinetic (PK) parameters and virologic failure, and safety and tolerance 
related to EFV and NVP   
 
1.4.4  To investigate relationships among genetic characteristics of drug metabolizing 
enzymes and drug transporters and the PK characteristics of EFV, NVP , and 
RPT.   
 
1.4.5  To d etermine the PK characteristics of EFV and its 7 -OH-EFV and 8 -OH-EFV 
metabolites when given in combination with RPT+INH (Arm A) and when 
given with INH alone (Arm B).   
 
 16 A5279 
FINAL Version 2.0  
  08/28/14  
 
1.4.6  To compare EFV PK data obtained from combination therapy with RPT+INH 
and INH alone with a control group consisting of a set of plasma samples 
with participants receiving ART containing EFV but not RPT or INH, which 
will be collected from indi viduals in Arm A who have completed RPT/INH 
therapy and have allowed for a washout period.  
 
 
2.0 INTRODUCTION  
 
2.1 Background  
 
The World Health Organizat ion (WHO) estimates that in 2009, the last full year for which 
data collection is complete, there were 9. 4 million new incident cases of TB, and 1. 68 
million deaths  [1]. Amon g new incident cases of TB, 1.1  million were HIV -coinfected, and 
35% of TB deaths were among HIV -coinfected individuals. In Africa, where AIDS is the 
leading cause of death  (COD)  from a ny disease, TB is the leading AIDS -related 
opportunistic infection [ 2]. South Africa has the highest national HIV burden in the world, 
with an estimated 1 of every 6 of the world’s cases occurring there; South Africa also 
has the second  highest estimated T B incidence rate per capita globally [ 3]. 
 
INH Treatment of Latent TB Infection (LTBI)  
INH has been the cornerstone of treatment for LTBI to prevent active TB for more than 
30 years; the first report of successful prevention of TB wit h INH was published in  1956 
[4, 5]. In placebo -controlled trials of INH treatment of LTBI in persons in contact with 
persons with active TB who converted their tuberculin skin tests (TST) from negative to 
positive, the rate of developing active TB in the placebo groups was 12.9  cases/1000 
person- years  (PY) in the first year of follow -up, and 1.6 cases/1000 PY  in the 
subsequent 7 years of follow -up [6]. Other placebo- controlled studies have further 
elucidated the background rates of developing active TB. Among British schoolchildren 
enrolled in a vaccine trial, placebo recipients who converted their TST from negative to 
positive during follow -up, the incidence of TB in the 15 years of follow -up was 4.7%, with 
the highest risk in the first 3 years a fter TST conversion [7]. Numerous  randomized, 
placebo- controlled studies of the efficacy of INH given for 12 months were conducted in 
the 1950s and 1960s in countries with both high and low TB prevalence and across a 
broad spectrum of patient populations at risk for active TB. The efficac y based on the 
overall reduction in the incidence of active TB in these studies ranged from 25% to 92%; 
the protective efficacy when measured among those who completed a full course of 
treatment was approximately 90% [ 5]. Five-year TB incidence in the plac ebo groups of 
these trials ranged from 11.6 to 21.3/1000 PY. The effectiveness of INH preventive 
therapy  (IPT)  in non- HIV-infected populations is directly associated with duration of 
treatment with a reduction in development of active TB of 21% after 3 mon ths, 65% after 
6 months, and 75% after 12 months, although completion rates for 6 -9 months of INH 
are unacceptably low, ranging from 20% to 70% [ 8]. Despite high levels of success and 
strong recommendations for use of INH for LTBI in high -resource countries where TB 
risk is low to moderate, uptake and completion of treatment remains less than optimal. In 
a recent study in the U nited States  (US) and Canada, 17.1% of persons at risk who were 
offered INH after a positive TST declined treatment; persons recentl y in contact with 
persons with active TB were less likely to de cline LTBI treatment [9]. Of those who 
 17 A5279 
FINAL Version 2.0  
  08/28/14  
 
started INH treatment, 52.7% failed to complete the recommended course, with the 
recommendation of a 9 -month regimen, residence in congregate settings, and injection 
drug use being among the strongest predictors of failure to com plete LTBI treatment [9].  
 
INH Treatment of LTBI in HIV -Infected Individuals  
HIV infection contributes significantly to an increased risk of progression of LTBI to 
active TB. Publi shed rates of progression based on data from a variety of studies range 
from 35 to 162 cases/1000 PY of observation, with an annual risk among HIV -infected 
persons with a positive TST of 45 cases/1000 PY [5, 10]. Debate also continues 
regarding the efficac y of LTBI treatment among HIV -infected individuals. In a Cochrane 
Database review of 12 randomized clinical trials of LTBI treatment in 8578  randomized 
HIV-infected persons, preventive therapy with any anti -TB drugs administered for 6- 12 
months versus plac ebo resulted in an overall 32% reduction in the incidence of active TB 
(relative risk [ RR] 0.68; 95% confidence interval [ CI] 0.54, 0.85) [11]. The effect was 
greater for those with a positive TST (62% reduction; RR 0.38; [95% CI 0.25, 0.57]) than 
for thos e with a negative TST (11% reduction; RR 0.89 ; [95% CI 0.64 , 1.24]).  
 
The efficacy was similar for all regimens but waned over time regardless of regimen. 
There was no reduction in all- cause mortality, but a favorable trend for mortality 
reduction among t hose with a positive TST. Among those studies reporting incidence 
rates for HIV -infected individuals in the placebo arm, they varied by population as 
indicated below:  
 
Study  TST Status  TB Rate/  
100 person -
years 
Haiti, 1986 -92 Purified Protein 
Derivative ( PPD)+ 10.0 
 PPD- 5.7 
Uganda, 1993 -97 PPD+  3.4 
 Anergic  3.06 
Kenya, 1992 -96 PPD+  8.03 
 PPD- 2.73 
Zambia, 1992 -96 PPD+/ - 8.06 
U.S., 1991 -96 Anergic  0.9 
Zambia, 1998  PPD+/ - 4.94 
Haiti, 2001  PPD- 1.5 
Spain, 2003  Anergic  3.1 
South Africa, 2007  Anergi c 11.6 
 
Antiretroviral therapy (ART) was not available to participants followed in the majority of 
these trials. While more recent studies have indicated that INH administered for 6 
months reduced the relative rate of TB by 55% to 67% when compared to placebo, the 
effect waned substantially within 6 months to 2.5 years a fter discontinuing INH [12, 13]. 
In a recently published study from South Africa, two clinical cohorts were evaluated in 
the context of incident TB during exposure to I PT and/or ART [14]. There were 267 
incident TB cases diagnosed among 2778 HIV -infected patients followed for 4287 PY, 
 18 A5279 
FINAL Version 2.0  
  08/28/14  
 
with an incident rate ratio of 6.2/100 PY . Compared to ART- naïve patients, those who 
received ART alone had a 64% decreased hazard for development of TB, and patients 
who received ART after receiving I PT had an 89% reduced hazard. In another recently 
reported study conducted in Botswana, 2000 HIV -infected patients were randomized to 
receive either 6 months or 36 months of INH to evaluate whether a longer duration of 
INH might have a more durable effect in reducing  the incidence of TB [ 15]. The TB 
incidence rate was 2.22/ 100 PY in the 6-month INH arm and 0.57/ 100 PY in the 36-
month arm, representing a 57% reduction overall in the 36 -month INH arm. The percent 
reduction was largely driven by those who entered with a positive TST; those 
participants with a positive TST had a 92% reduction in the incidence of active TB after 
36 months of INH. When evaluated according to t he use of ART, those with a positive 
TST at ent ry who received both 36 months of INH and ART  had an overall reduction of 
96% in the annual incidence of TB. The effect of 6 months of INH began to wane 
immediately after discontinuation; the TB rate in this arm for those with a positive TST 
rose to 6.5/ 100 PY within approximately 1.5 years after stopping INH; the annual 
incidence in this arm was 2.5%. Conversely, in a randomized, controlled trial of 6 months 
of INH /ethambutol (EMB) versus 36 months of INH alone in 712 HIV -infected patients 
without evidence of active TB, the incidence rate of TB in the INH/EMB arm was 2.4 /100 
PY versus 1.6 /100 PY for INH alone [16]. The historical background rate of TB in the 
population in the absence of INH was reported to be 7/ 100 PY. Similar to the Botswana 
study, the benefit for either arm was lost within 6 months after stopping preventive 
therapy. In both of these studies, there was no significant difference in TB rates between 
arms for those with a negative TST, and overall adverse event (AE) rates were low and 
not significantly different among the treatment arms, suggesting that all regimens tested 
were relatively safe.  
 
Despite the favorable findings of these and previous studies, there has been little uptake 
of preventive therapy in regions of the world where it is m ost needed. Although longer 
courses of up to 36 months of IPT may further reduce the incidence rates of TB among 
HIV-infected individuals, the poor rates of uptake and the hig h proportion of individuals 
who fail to complete even 6  months of IPT highlight t he need for alternative,  more 
effective short -course approaches for treatment of LTBI. The TB rate per annum in 
persons living with HIV in high prevalence areas is still estimated to range from 2- 7% 
depending on the geographic region, the coverage of ART, and the uptake of IPT.  
 
Shortened Courses of LTBI Treatment  
Alternative shortened courses of LTBI treatment have been evaluated in HIV -infected 
individuals. In a randomized clinical trial conducted prior to the advent of highly active 
ART [17] evaluated a 2-month regimen of daily rifampin (RIF) and pyrazinamide (PZA) 
compared with a 12- month regimen of daily INH in 1583 HIV -infected persons with a 
positive TST. Only 69% of patients completed 12 months of INH versus 80% for those 
randomized to RIF/ PZA. Howe ver, there were no differences in rates for confirmed or 
probable TB, HIV disease progression,  or death, although drug discontinuation rates 
were slightly higher in the RIF/ PZA arm. This study was conducted in the U S, Mexico, 
Haiti, and Brazil, and more than 70% of the patients were enrolled in the US; thus, it was 
not a test of short -course LTBI treatment in resource- limited settings with high endemic 
rates of TB. However, despite showing comparable results to I PT, there has been little 
uptake of this shor tened course regimen in the US or other countries. This may reflect 
 19 A5279 
FINAL Version 2.0  
  08/28/14  
 
ongoing uncertainty based on two other studies that evaluated short -course RIF /PZA in 
high TB endemic regions; one in Zambia where the regimen was administered twice 
weekly for 3 months, and one in Haiti where the regimen was administered twice weekly 
for 2 months [18, 19] . In both studies, the overall rate of TB was higher in the short -
course LTBI treatment arms compared to the INH arms, although both studies used 
intermittent RIF /PZA.  It is also possible that the lack of uptake reflects cases of severe 
liver injury associated with a 2-month regimen of RIF/PZA  (albeit mostly in HIV -negative 
participants) after more widespread implementation of American Thoracic Society  
(ATS)/Centers for Dis ease Control and Prevention ( CDC) /Infectious Diseases Society of 
America  (IDSA ) guidelines in 2000 [5].    
 
Although these data support the benefit of LTBI treatment in HIV -infected individuals, 
including with the use of short -course RIF /PZA, data from lar ge randomized clinical trials 
in HIV -infected patients exposed to TB in high TB prevalence resource- limited settings 
have only recently emerged. In a recently completed phase III clinical trial comparing 12 
weeks of weekly RPT/INH (900 mg/ 900 mg) to 6 months of daily INH (300 mg)  in South 
Africans with HIV and LTBI, t he hazard of TB or death in the RPT/INH arm was 14% 
lower than for INH (HR=0.86, 95% CI 0.5 -1.3, p=0.35)  [20]. Although the difference was 
not statistically significant, the study was only pow ered to detect a 50% difference, and it 
is encouraging that RPT/INH given only once- weekly for 12 weeks could have similar 
efficacy to daily INH for 6 months. ACTG 5259/TBTC Study 26: “A Study of the 
Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for Three Months Versus 
Daily Isoniazid for Nine Months for the Treatment of Latent Tuberculosis Infection” has 
recently completed its preliminary analysis of more than 7500 patients at high risk for TB 
who were randomized to either 12 weekly doses of RPT 900 mg and INH 900 mg or 9 
months of daily INH. The study found that RPT/INH was noninferior to standard INH and 
had significantly higher rates of treatment completion and lower rates of adverse events. 
The rates of TB in TBTC Study 26 were 0.13 cas es per 100 PY in the INH arm and 0.07 
cases per 100 PY in the RPT/INH arm. Only about 200 HIV -infected patients were 
included in this analysis, but a preliminary Cox proportional hazards analysis indicates 
that HIV was associated with an 8 -fold increase in  the hazard of TB, regardless of 
treatment arm. The ACTG has enr olled an additional approximately 200 HIV/TB -
coinfected patients whose outcomes will be analyzed in several years; data from this trial 
will further inform the field. However, the HIV substudy  is powered for tolerability rather 
than efficacy in the coinfected cohort. People receiving or planning to receive ART within 
90 days of enrollment are excluded because of the lack of PK/safety data with RPT and 
antiretroviral agents. Therefore, the study  will provide limited  information about this 
regimen in HIV -infected patients in resource- limited settings with high TB burden. At this 
point, the TB Trials Consortium ( TBTC ) is not planning more trials for LTBI. Building on 
this work, an efficacy trial by  the ACTG in areas of high TB burden and in patients 
requiring ART is the next logical step.  
 
Pre-clinical models of TB disease suggest that more frequent administration of RPT can 
lead to higher cure rates and shorter treatment duration. Although mice do not develop 
LTBI, a model in which mice are aerosol -immunized with Bacille Calmette -Guerin (BCG) 
vaccine prior to low -dose aerosol challenge with MTB produces an infection similar to 
human LTBI, based on the relatively small population (ie, 104 CFU [colony -forming 
units]) of non- multiplying bacilli that is contained by host immunity rather than TB drugs 
 20 A5279 
FINAL Version 2.0  
  08/28/14  
 
[21]. A 3- month regimen of weekly RPT/INH in this model was shown to be equivalent to 
daily INH for 6 -9 months and was subsequently demonstrated to have sim ilar efficacy in 
humans [22, 23]. In the murine model of active TB, daily dosing of RPT was associated 
with substantially higher rifamycin exposure when compared with RIF, and reduced the 
duration of treatment needed to prevent relapse [24, 25]. Current ex periments using a 
refined murine model of LTBI that reliably produces a lower bacterial burden by 
immunizing with recombinant BCG vaccine provide early evidence of the superior 
activity of daily RPT as compared to daily INH or other therapies. In the first  experiment, 
mice received RPT 10 mg/kg administered 5 days/week (5/7), in doses comparable to 
humans, alone and with INH, PZA, or both, for 8 weeks. Control mice received RIF 10 
mg/kg (5/7) alone and with INH, PZA, or both, for 8 weeks. The RPT -based regi mens 
were significantly more active than their corresponding RIF- based controls. These 
regimens sterilized cultures more rapidly, with the exception of the comparison of the 
RPT/PZA and RIF/PZA, for which the trend favored RPT, but did not quite reach 
statistical significance after adjusting for multiple comparisons (p=0.06 for that 
comparison). All mice became culture negative by weeks 4 -6 [26]. In a second 
experiment, RPT 10 mg/kg (5/7), with or without INH, was superior to INH alone, RIF 
alone, and RIF/I NH control regimens. One month of RPT/INH (5/7) resulted in relapse 
rates similar to 4 months of RIF (5/7), 3 months of RIF/INH (5/7), and 3 months of 
RPT/INH (1/7) [E. Nuermberger, unpublished data]. Comparison to 6 months of INH 
(5/7) is pending. Treatment of mice in this model suggests that daily high -dose RPT 
should eliminate LTBI more quickly than conventional regimens.  
 
These pre -clinical experiments serve as the basis for the ultra- short -course of RPT -
based therapy proposed in this clinical trial, s ince the murine model of LTBI was 
previously found predictive of efficacy for the 2 -month course RIF/PZA [27, 19, 17]. 
Furthermore, rifamycin PK is comparable between humans and mice. As indicated in the 
tables below, the 10 mg/kg dose in mice results in drug exposures that are remarkably 
similar to the exposures observed in healthy volunteers after the recommended human 
dose of 600 mg (ie, ~10 mg/kg). Steady -state RPT exposures observed in Ugandan TB 
patients receiving RPT 10 mg/kg (5/7) in combination wit h INH, PZA, and EMB in TBTC 
Study 29 were lower than exposures previously observed in mice and healthy volunteers 
(mean RPT AUC 0-24 = 179 µg -h/mL) [ 28]. A substantial portion of this difference could be 
due to the expected autoinduction of rifamycin metabolism with repeated dosing ; 
although no autoinduction could be demonstrated after 7 consecutive daily 
administrations of 600 mg RPT [29], more recent investigations documented changes 
consistent with RPT autoinduction after 7 thrice weekly administrations o f 900 mg RPT 
concomitant with daily moxifloxacin [30]. More importantly, RPT bioavailability being 
greatly increased (from 33 % to up to 86%) by food intake, fasting prior to drug 
administration in Study 29 is expected to have had a significant impact  [Priftin package 
insert 2009, 31] . In addition, these fasting conditions may have enhanced the RPT and 
INH physico -chemical interaction expected to occur in acid conditions [32].  
Pharmacogenetic differences also may underlie reduced RPT exposures among African 
patients, as recently observed for RIF [33]. An ongoing RPT dose escalation study 
among healthy volunteers (TBTC Study 29B) will determine safety, tolerability, and RPT 
exposures in fed patients receiving 7/7 dosing and should confirm the RPT dose 
necessary to produce in LTBI patients the same RPT exposures observed in mice 
receiving RPT 10 mg/kg (5/7). INH is cleared more rapidly in mice compared to humans, 
 21 A5279 
FINAL Version 2.0  
  08/28/14  
 
so a higher mg/kg dose is necessary to achieve similar area under the concentration-
time curve (AUC ) values. The 10 mg/kg dose in mice most closely represents the INH 
exposures observed in humans who are rapid acetylators of INH. Compared to INH 
exposures in humans who are slow acetylators, the C max in mice at this dose is 50% 
higher, but the AUC is 50- 60% lower.   
 
Mean PK parameter value in serum after a single RPT dose  
Species  Humans  [34] Mice [24] 
Dose  600 mg  10 mg/kg  
PK parameter    
      Cmax (µg/ml)  15.8 13.0 
      AUC* (µg -h/ml)  386 417 
 *AUC 0-∞ for humans, AUC 0-48h for mice  
 
Mean PK parameter value in serum after a single RIF dose  
Species  Humans  [35] Mice  [36] 
Dose  600 mg  10 mg/kg  
PK parameter    
      Cmax (µg/ml)  14.9 12.1 
      AUC 0-24h (µg-h/ml)  118 116 
 
Mean PK parameter value in serum after a single INH dose  
Species  Humans* [37] Mice  [ 38] 
Dose  300 mg  10 mg/kg  
PK parameter    
      Cmax (µg/ml)  5.3-6.2 7.5 
      AUC 0-24h (µg-h/ml)  11.4-23.7 9.3 
 *Range shown is for rapid and slow acetylators of INH.  
 
TB/HIV Drug Interactions 
Rifamycin drugs such as RPT have the potential to cause drug- drug interactions 
of clinical importance. Rifampin (RIF), the most commonly -used rifamycin, is a 
potent inducer of multiple metabolizing enzymes, including cytochrome P450 
enzymes, as well as P -glycoprotein and phase 2 enzymes [39]. Since most 
protease inhibitors (PI) and non-nucleoside reverse transcriptors  (NNRTIs ) are 
metabolized by cytochrome P450 3A4 isoenzyme (CYP3A4), induction of CYP3A4 
by RIF can lead to reduced serum concentrations of antiretrovirals (ARVs) with a 
risk for treatment failure or emergence of resistance to ARVs. NVP and EFV are 
both subject to drug- drug interactions with RIF. EFV is cleared by CYP2B6 and 
CYP3A4 metabolizing enzymes, and EFV may act as a 3A4 inhibitor or inducer. 
NVP is eliminated via CYP3A4 and CYP2B6 and induces CYP3A4.  
  
In patients who must be treated with RIF- based therapy for TB and require 
concurrent HAART, EFV  is the NNRTI of choice. Since the PK of EFV 600 mg daily 
is similar to that  of EFV 800 mg daily when coadministered with RIF in HIV/TB 
coinfected patients [40, 41] , some recommend  that EFV dosing should be 
 22 A5279 
FINAL Version 2.0  
  08/28/14  
 
increased in patients taking RIF ; the US Food and Drug Administration (FDA) has 
recently approved a change in the label for EFV to increase dosage to 800 mg 
daily for patients weighing >50 kg when taking RIF. Despite somewhat diminished 
plasma concentrations of EFV in PK studies in patients taking RIF, h owever, 
pharmacodynamic (PD) studies in Brazil, South Africa, Thailand, and India in 
HIV/TB-coinfected patients receiving RIF have shown durable virologic and 
immunologic responses at the standard EFV dose of 600 mg daily [ 41--46].  These 
study findings suggest that a daily dose of 600 mg of EFV is safe and likely to be 
efficacious in patients being treated concurrently for HIV and TB with a RIF -based 
regimen. The effect of the physiological changes of pregnancy combined with RIF -
based therapy on EFV concent rations and treatment outcomes among pregnant 
women is unknown.  
 
NVP is frequently used in pregnancy and is widely available in fixed -dose 
combinations. When the standard dose of 200 mg twice daily is coadministered 
with RIF, serum concentrations of NVP ar e decreased by 20- 30% [47]. One group 
found that coadministration of RIF with NVP caused significant decreases in the 
Cmax (42%), trough concentration (53%) , and AUC (46%) of NVP  as well as  
significant increases in NVP oral clearance (Cl/F) [48] . However, studies 
evaluating the consequences of reduced NVP concentrations when given with RIF 
have yielded variable results. In one study, long- term CD4+ T -cell and HIV viral 
load values were similar in patients on NVP who had received a RIF -based 
regimen compared to those who had not. [47]. Conversely, two other studies have 
shown higher risk of virologic failure in patients taking NVP together with RIF [49]; 
The Thai Red Cross evaluated the efficacy of 600 mg NVP coadministered with 
RIF-containing TB regimen. The y found the efficacy at 48 weeks to be similar to 
standard 400 mg dose, but there was a higher rate of NVP hypersensitivity in the 
higher dose group [50] . A recent study by Swaminathan and colleagues found 
higher rates of treatment failure and death in pat ients treated with RIF- based TB 
therapy and a NVP -based HIV regimen compared to patients receiving EFV -based 
HAART [51]. At this point, the optimal NVP dose when NVP is given together with 
a RIF -containing TB regimen is unclear.  
 
It has long been thought that RPT causes less induction of P450 enzymes than 
RIF, but a new study  in healthy volunteers by Dooley et al. has found that daily 
dosing of RPT is a more potent inducer than daily RIF [52] . Using midazolam (a 
CYP3A4 -metabolized drug) as a substrate, the se investigators found that RPT at 
doses of 5- 20 mg/kg daily reduced AUCs by >90%, compared to a 75% reduction 
with RIF. Thus, coadministration of RPT with CYP3A4- metablized drugs such as 
PIs, raltegravir, and NNRTIs could result in clinically significant reductions in 
these agents.  
 
INH inhibits CYP 2C19, 3A4 and, weakly, 2D6 [53] . INH is primarily metabolized via 
n-acetyl -transferase 2 (NAT2) to the inactive metabolite acetylisoniazid. The rate at 
which acetylisoniazid is formed is highly dependent on ind ividual NAT2 genetics. 
INH is not currently recognized as having an interaction with EFV. However, 
studies performed in human liver microsomes have shown INH to inhibit CYP 1A2 
and 2A6 [54] . Additionally, data recently presented by Bertrand et al . from pat ients 
 23 A5279 
FINAL Version 2.0  
  08/28/14  
 
taking RIF and INH have shown there to be a concentration dependent inhibition 
effect of INH on EFV clearance, particularly  evident in individuals with the CYP  
2B6 516TT genotype and NAT2 slow acetylators [55] . These data allow the 
hypothesis that when EFV is coadministered with RIF (or RPT) and INH, then the 
inductive effect of RIF or RPT may be offset in some patients by the inhibitory 
effect of INH. This provides a plausible explanation for the contradictory results, 
seen largely between EFV -RIF PK studies in healthy volunteers and PK 
evaluations of EFV -RIF-INH coadministration in patients [56] . Whether or not the 
interaction between INH and the secondary metabolizing pathway of EFV 
(CYP2A6) is clinically significant in individuals taking RPT, INH , and EFV is 
unknown and requires investigation in HIV -infected persons.  
 
Currently , there are no published data on the effects of RPT when administered 
with EFV in HIV- infected persons. Additionally, there are no data on plasma 
concentrations of EFV when g iven with RPT and INH. The possible interaction 
between INH and EFV in a select genotypic group of individuals may decrease or 
even cancel out the interaction between EFV and RPT caused by the enzyme 
inducing properties of RPT.  
 
2.2 Rationale 
 
Successful population -level treatment of LTBI has been hindered by several factors: (1) 
poor adherence to long courses of therapy; (2) the administrative burden of directly 
observed therapy (DOT); (3) toxicities related to INH; and (4) concerns related to the 
inabilit y to effectively rule out subclinical TB and the attendant risk of drug resistance in 
the setting of possible INH monotherapy. In resource- limited settings with high TB 
prevalence, uptake of IPT remains dismally low as well, especially among HIV -infected 
patients. Estimates from the WHO indicate that in 2009, among HIV -infected persons 
screened and found not to have active TB, fewer than 1% were started on IPT [1]. 
Although longer durations of IPT may be more effective than conventional 6- 12 month 
courses, similar considerations are likely to continue to impede implementation of IPT. 
New regimens that shorten treatment duration will improve adherence and, if more 
effective regimens are employed, will substantially reduce the burden on public health 
clinics a ssociated with providing and monitoring prolonged DOT, and reduce the risk for 
the development and transmission of active TB in the most vulnerable settings.  
 
While it is clear that adherence is better with shorter regimens, and that safety and 
efficacy in  TB prevention is comparable to those measured in comparator arms with INH 
administered for 6 -12 months, uptake of either INH or short -course RIF- containing 
regimens has been minimal in the very settings in which treatment for LTBI is most 
needed. Whether even shorter course LTBI treatment will be more acceptable and cost -
effective in public health settings and sufficiently so to trigger broad uptake remains to 
be established. As well, the safety and efficacy of and adherence to a 1 -month daily 
RPT/INH regi men have yet to be evaluated. We propose a randomized, controlled trial to 
compare the safety, tolerability, efficacy, and adherence of short -course, daily RPT/INH 
with the standard regimen for LTBI, 9 months of INH, in patients at high risk of 
developing active TB. As detailed in the package insert, RPT is an inducer of CYP450 
enzymes [Priftin package insert 2009] . Concomitant use of RPT with other drugs 
 24 A5279 
FINAL Version 2.0  
  08/28/14  
 
metabolized by these enzymes, such as PI s and NNRTI, may cause a significant 
decrease in plasma concent rations and loss of therapeutic effect of the PI or NNRTI. For 
this reason, patients requiring PI -based therapy during the first month of the trial will be 
excluded, and PK analyses of NNRTI levels will be performed as part of the study for 
those persons on a NNRTI regimen. In summary, development of a potent, ultra -short, 
effective treatment for LTBI could dramatically reduce the global incidence of active TB.  
 
Cost-Effectiveness Analysis  
The uptake of any new therapy is highly dependent on several factor s, of which cost is 
one of the most significant. New therapies (especially those containing new drugs) are 
frequently significantly more expensive than standard regimens. Therefore, in programs 
with fixed and limited resources, these new regimens must be expected to provide either 
significant improvements in efficacy or long- term savings when compared to the current 
standard of care. Cost -effectiveness analysis performed in conjunction with a clinical trial 
can assist with this latter comparison and is most  effective when performed in 
conjunction with the clinical trial [57]. 
 
We plan to examine the cost -effectiveness of RPT/INH compared with both 9 months of 
INH and other regimens. We would expect that the shorter regimen would lead to more 
patients complet ing a course of therapy, which should result in fewer cases of active TB 
over time. Also, because the costs of the RPT/INH regimen in most areas with high TB 
incidence are largely unknown, we can use modeling to determine price thresholds 
above which RPT/I NH will no longer be cost -effective; these thresholds can be used by 
public health officials in setting local policy. Furthermore, while study participants will all 
be HIV -positive, any new regimen proven to be effective in this population will likely be 
used in other populations as well. Because most of these populations will have 
significantly lower baseline risk of  TB activation than the study population, the benefits of 
a shorter -course regimen may not be as marked. Therefore, we will seek out cost -
effectiveness thresholds for cost, efficacy, and underlying risk.  
 
By performing this analysis in conjunction with the clinical trial, we will be able to collect 
detailed treatment data that can be used to estimate costs in a wide variety of settings. 
More importantly, if the study regimen proves effective, we will be able to provide 
guidance to public health officials as soon as study results become available.  
 
Rationale for Choice of RPT 
The rifamycins are the chief sterilizing drugs in the modern short -cours e regimen for 
treatment of active TB. Compared to RIF, RPT is more potent against MTB in vitro (MIC, 
0.06 vs. 0.25 mg/L) [58]  and provides greater drug exposures at a given mg/kg dose in 
mice and in humans, owing largely to its longer serum half -life (see below). In murine 
models of both active and latent TB infection, the increased rifamycin exposure obtained 
with substitution of RPT for RIF results in greater sterilizing activity and significant 
shortening of the duration of treatment  needed to prevent relapse [36, 25, 26] . For 
example, in a murine model of active TB, substitution of RPT 10 mg/kg in place of RIF 
10 mg/kg administered in combination with INH/PZA 5 days/week shortens the time 
needed to prevent relapse from 6 months to 3 months or less in all mice [ 24, 25 ]. In a 
murine model of latent TB infection, which provided the pre -clinical evidence base for 
clinical trials that proved the efficacy of the 2- month RIF/PZA combination for LTBI in 
 25 A5279 
FINAL Version 2.0  
  08/28/14  
 
HIV-infected persons [17, 19, 27] , RPT 10 mg/kg and the combination of RPT/INH 
administered 5 days/week were significantly more effective in reducing the rate of active 
TB than t he same dose of RIF alone or RIF/INH [26]. In this experiment, all mice 
receiving RPT alone were rendered culture negative after 6 weeks, and 40%, 7%, and 
0% of mice, respectively, developed culture- positive TB infection in the 3 months after 
completing tr eatment for 4, 6, or 8 weeks. RPT/INH rendered 4 of 5 mice culture 
negative after 4 weeks, and 86%, 14%, and 0% of mice, respectively, developed culture -
positive TB infection in the 3 months after completing treatment for 4, 6, or 8 weeks. 
Among mice treat ed with RIF/INH, 100% and 47% of mice, respectively, developed 
culture- positive TB infection in the 3 months after completing treatment for 4 or 8 weeks 
(the efficacy of 6 weeks of RIF/INH was not assessed), consistent with the 3- month 
treatment duration r ecommended when RIF/INH is used for LTBI in humans [ 59]. RIF 
alone was less effective than RIF/INH. These results suggest that a regimen containi ng 
RPT at 10 mg/kg/day may treat LTBI in 2 months or less. Daily RPT/INH for 6 -8 weeks 
(42-56 doses) would not offer cost -benefit advantage when compared to the upcoming 
3-month once -weekly administration (12 doses) evaluated in TBTC Study 26.  Data 
generat ed in the murine model at 4 weeks indicated that sterilization had occurred in a 
proportion of infected mice, suggesting that a 4- week regimen of daily RPT/INH could be 
sufficient to prevent development of active TB in patients. In a second experiment  in the 
same model, one month of RPT/INH (5/7) resulted in relapse rates similar to 4 months of 
RIF (5/7), 3 months of RIF/INH (5/7), and 3 months of RPT/INH (1/7).These unpublished 
data showing comparable outcomes with three efficacious LTBI regimens provide f urther 
support for a 1- month treatment duration of RPT/INH treatment [E. Nuermberger, 
unpublished data].  
 
The safety and tolerability of daily RPT has been evaluated in a phase I PK study in 
healthy volunteers [29]. Twenty -three healthy males were randomiz ed to receive two of 
the following treatments in a 2 -period, 4- treatment, incomplete block, cross -over design: 
single once -daily oral RPT at 150 mg, 300 mg, or 600 mg on study days 1 and 4 through 
10, or single oral RPT 600 mg doses given every 3 days for 4 doses. All regimens 
reached steady state RPT concentrations and RPT was well tolerated in all four 
treatment periods. Urine discoloration was the most common AE, and occurred in all 
study participants. Other treatment -related AEs were upset stomach (n=4) , 
lightheadedness (n=3), dry mouth (n=2), diarrhea (n=2), flatulence (n=1), and headache 
(n=1). No abnormalities of liver chemistries were reported.   
 
TBTC Study 29, Evaluation of a Rifapentine- Containing Regimen for Intensive Phase 
Treatment of Pulmonary  Tuberculosis, is a phase II trial comparing daily RPT (5 days 
per week) at 10 mg/kg to standard dose RIF in patients with newly diagnosed, smear -
positive pulmonary TB.  All patients also receive standard INH, PZA, and EMB. The 
primary endpoint is sputum culture conversion after 8 weeks.  As of August 16, 2010, the 
study had recruited 465 patients and undergone six Data and Safety Monitoring Board 
(DSMB) reviews since enrollment began.  No serious and unanticipated toxicities had 
been reported as of that date.  
 
The safety and tolerability of RPT used daily has also been evaluated by the 
manufacturer in clinical phase II studies in AIDS patients with bacteremia caused by 
Mycobacterium avium  complex (MAC):  
 26 A5279 
FINAL Version 2.0  
  08/28/14  
 
Multicenter Dose Escalation Study to Evaluate Tolerance, Safety, and Activity of 
Rifapentine Alone and in Combination Therapy in AIDS Patients with MAC Bacteremia 
(Hoechst Marion Roussel protocol number 000473PR0005).  
The primary objective of this phase II, open- label, multicenter, dose -escalation study 
was to determine the tolerance and safety of escalating RPT doses alone and in 
combination therapy for disseminated MAC bacteremic patients with AIDS. This study 
started in 1995 and ended in 1996. Patients were treated with RPT monotherapy for 14 
days and then randomized to combination therapy with clarithromycin or combination 
therapy with clarithromycin/EMB. The combination therapy phase lasted 28 days. RPT 
was dosed once daily. Thirty patients were enrolled in the study; 8 received RPT 450 
mg/day, and 22 received RPT 300 mg/day. All patients experienced one or more 
nonserious AEs; the high incidence was “indicative of the poor health status of this 
patient population”. Seventeen (56.7%) patients had one or more treatment -related AEs 
(AEs defined by the investigat or as “definitely”, “probably”, or “possibly” related to study 
medication). Among these 17 patients, 6 (20% of total) had a hematologic AE (2 patients 
with anemia, 3 with neutropenia, and 1 with hemoglobin/hematocrit disease), 6 patients 
had a hepatic/bili ary AE (5 with bilirubinemia, 1 with cholestatic hepatitis), 4 patients 
(13% of total) had a body -as-a-whole AE (3 with abdominal pain and 1 with ascites), and 
3 (10% of total) had a gastrointestinal AE (2 with nausea and 1 with vomiting). There 
were 13 serious AEs (SAEs), 7 of which were death, and 6 of which were nonfatal. None 
of the deaths were judged to be related to study medication. Among the 6 nonfatal 
SAEs, 1 was judged not related to study medication, 1 was judged unlikely to be related 
to study m edication (blindness in a patient known to have cytomegalovirus [ CMV] 
retinitis); 2 were judged possibly related to study medication (depression and suicide 
attempt in 1 patient, and hepatic failure in 1 patient receiving 450 mg/day), and 2 were 
judged probably related to study medication (neutropenia in 1 patient receiving 300 
mg/day, and dysarthria/confusion and AIDS in 1 patient). The rate of patient 
discontinuation due to treatment -related AEs was higher among patients receiving 450 
mg/day (4 patients a mong 8 who received this dose) than among patients receiving 300 
mg/day (5 patients among 22 who received this dose). However, among the 4 patients 
receiving 450 mg/day who discontinued, in only 1 patient was the AE attributed to study 
medication, and this  AE was listed as “dysarthria/confusion/AIDS”.    
 
Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in 
AIDS Patients with Mycobacterium avium  complex (MAC) Bacteremia (Hoechst Marion 
Roussel protocol number 000473PR0018).  
The primary objective of this phase II, open- label, multicenter trial was to determine the 
tolerability of RPT alone and in combination therapy in disseminated MAC bacteremic 
patients with AIDS. This study started in 1995 and ended in 1997; enrollment was closed 
in 1997 because of the marked decrease in the incidence of disseminated MAC infection 
following the widespread availability of potent combination ART. Twenty -one patients 
were enrolled in this study. Four patients were enrolled to RPT monotherapy (3 received 
300 mg/day and 1 received 450 mg/day); 3 patients completed 21 days of monotherapy 
and went on to complete 42 days of RPT -containing combination therapy. Seventeen 
patients were enrolled to RPT combination therapy only (11 received RPT 300 mg/day 
and 6 received RPT 450 mg/day); 13 completed 42 days of combination therapy. Twenty 
of 21 patients had ≥ 1 AE. As in the prior study, this was felt to be “indicative of the poor 
health status of this patient population.” Seven patients (33.3%) had ≥ 1 treatm ent-
 27 A5279 
FINAL Version 2.0  
  08/28/14  
 
related nonserious AE.  Among these, 5 patients (23.8% of total patients) had a 
gastrointestinal AE, and 3 (14.3%) had a dermatologic AE. There were 17 SAEs (10 
patients). Included among these SAEs were 3 deaths, none of which was judged by the 
investi gator to be related to study drugs. There were 14 nonfatal SAEs, none of which 
was judged by the investigator to be related to study drugs. There were 4 permanent 
discontinuations due to AEs (3 deaths, plus 1 additional discontinuation due to an AE not 
related to study drugs), and 1 temporary discontinuation (due to rash; study drugs were 
stopped, and then reintroduced without return of the rash). Study conclusions were that 
AEs were overwhelmingly symptoms associated with AIDS and few were attributable to 
study drugs, and that RPT was well -tolerated at either dose level given as monotherapy 
or as combination therapy.  
 
An Open -Label, Multicenter Extended Treatment Phase Study with Rifapentine in AIDS 
Patients Who Have Completed Protocol 000473PR0018 (Hoechs t Marion Roussel 
protocol number 000473PR0019).  
The primary objective of this study was to provide RPT for extended treatment to 
patients who, in the opinion of the investigator, responded to treatment during the 
preceding RPT protocol (000473PR0018). Eight patients were enrolled in this extended 
use study, and the duration of treatment for a given patient was based on individual 
response. Seven patients received RPT 300 mg/day, and one patient received RPT 450 
mg/day. Median number of weeks of RPT use in t his study was 18 (range 4 to 52 weeks, 
mean 24.5 weeks). Four nonserious AEs were judged to be related (possibly, probably, 
or definitely) to study drugs: one patient each with dry mouth, conjunctival erythema, 
burning eyes, and erythematous ear canal. There were 14 SAEs including 3 deaths; 
none of the 14 SAEs was judged to be related to study drugs. Study conclusions were 
that AEs were overwhelmingly symptoms associated with AIDS and that RPT was well 
tolerated.  
 
Importantly, individuals in the above studies had advanced AIDS complicated by 
disseminated MAC, each of which is associated with substantial morbidity and mortality. 
For example, Chaisson et al. reported in 1992 that the median duration of survival after 
disseminated MAC diagnosis in AIDS patient s was 221 days, and that the probability of 
1-year survival from the time of disseminated MAC diagnosis was 0.29 (95% CI 0.24 -
0.34) [60]. More recently, Benson et al. reported results of an ACTG study of three 
contemporary, clarithromycin- based regimens fo r treatment of disseminated MAC in 
AIDS patients [ 61]. Among the treatment groups, 8- 25% died during the first 4 months of 
the study, and 28- 50% died during the 48 -week study period. Furthermore, 9- 14% of 
patients stopped therapy due to protocol -defined toxicity, 9 -25% had Grade 3 or higher 
anemia, and 6- 14% had Grade 3 or higher hepatitis.   
 
Impact of New PK Data on A5279  
Previous research using intermittent doses of RPT had shown that P450 
cytochrome induction was approximately 75- 80% the magnitude of that caused by 
RIF. On this basis, Version 1.0 of the A5279 protocol originally excluded patients 
taking PI -containing ART regimens, but allowed enrollment of patients taking EFV - 
or NVP -containing regimens, and planned to include the first 90 of each group in a 
PK substudy of the interaction of RPT on trough concentrations of these agents. 
Recent data from TBTC Study 29B [ 62] reveal that daily dosing of RPT results in 
 28 A5279 
FINAL Version 2.0  
  08/28/14  
 
greater induction of cytochromes than with RIF. The protocol pharmacologist and 
leadership team, as well as independent pharmacol ogists,  reviewed the new data 
and concluded that while it is reasonable and safe to continue plans to enroll 
patients taking EFV, it would be most prudent to hold off on enrollment of patients 
taking NVP until more dat a were available. EFV is metabolized largely by CYP2B6 
and to a lesser extent by CYP3A4,  the isoenzyme induced by RPT. NVP, however, 
is largely metabolized by CYP3A4.  
 
The protocol team accelerated the collection and analysis of PK data from the EFV 
subst udy of A5279 to determine the potential effect that RPT might have on NVP 
PK. These PK analyses showed that concomitant dosing of EFV and RPT re sults 
in adequate drug exposure. Thus, patients taking NVP will be enrolled and similar 
PK analyses will be conducted.  
 
RPT in Children  
This study proposes to evaluate a shortened course of daily RPT and INH in adults and 
adolescents of age 13 and older. Data evaluating use of RPT in children are limited. 
However, PK data in children aged 2- 12 years are available [ 63]. In this study, 24 were 
enrolled in a two- dose level, multicenter, PK study of orally administered RPT tablets. 
Single -dose PK data for children weighing 10 -30 kg who received 150 mg RPT and 
children weighing 30 -60 kg who received 300 mg RPT resulted in doses of 5- 15 mg/kg, 
which approximates the labeled adult dose of RPT 600 mg. Overall, the mean peak RPT 
level was 7.26 +/ - 2.64 mcg/mL; 6.87 +/ - 2.82 mcg/mL among children who received 150 
mg and 7.63 +/ - 2.52 among children who received 300 mg (p=0.50).  The mean time to 
peak level was 3.2 +/ - 1.2 hours, and the t ½ was 20.5 +/ - 18.0 hours. When stratified 
according to children who received 5- 8.5 mg/kg vs. 8.6 -11 mg/kg, there was no 
difference in peak concentration (7.36 vs. 7.19 mcg/mL; p=0.89), t ½ (18. 9 vs. 21.8 
hours; p=0.71), or AUC (117.8 vs. 119.0). There was no clear relationship between RPT 
dose and exposure, due primarily to a large degree of inter -individual variability. PK 
evaluation conducted in healthy patients 12 -15 years old revealed PK par ameters similar 
to those observed in healthy adults [ Priftin package insert 2009; 64 ]. In this latter study, 
12 adolescents with a mean age of 13.3 years were administered RPT 450 mg if <45kg, 
or 600 mg if ≥45 kg.  The average weight of participants was 54. 8 ± 10.4 kg.  The RPT 
Cmax and AUC 0- ∞ were 9.66 to 18.63 µg/mL and 397 ±  148 µg.h/L, respectively. 
Additional data will be available from TBTC Study 26, which is enrolling children and 
adolescents 2 -18 years old.  
 
Sample Storage  
The protocol team feels it  is important to store specimens on this study for future 
secondary work and New Work Concept Sheets (NWCS) in this population. However, 
the team also recognizes that storage of 5 years or more of longitudinal samples on 
3000 participants, most of whom wil l not have TB on study, is not warranted nor cost -
effective. The study will store plasma, serum, and peripheral blood mononuclear cells 
(PBMC) at entry and every 48 weeks on the first 30 participants enrolled by each site in 
a country with a high TB burden and on the first 50 participants enrolled by all U.S. sites 
combined. Samples will also be stored at TB diagnosis in any participant who develops 
active TB. This strategy will result in storage of longitudinal samples on a maximum of 
about 650 participant s. Not all sites will enter 30 participants, and 40- 50 of those with 
 29 A5279 
FINAL Version 2.0  
  08/28/14  
 
longitudinal samples stored will be TB cases. Thus, this plan will store longitudinal 
samples on about 500 participants (controls) who never develop TB on study and about 
40-50 participants (cases) who do develop TB. This will also provide one- time storage at 
the diagnosis of TB on about 200 other participants (cases) who do develop TB on 
study. This provides about a 2:1 ratio of controls to TB cases which will allow matching 
and subgroup analyses, as well as high power to detect differences if all participants are 
used. This also provides longitudinal storage on a reasonable number of eventual TB 
cases for intensive analyses. We envision the ACTG reserving the latter for targeted 
high-profile work and encouraging proposers to do pilot and developmental work on the 
larger group of TB cases with one- time storage.   
 
 
3.0 STUDY DESIGN  
 
This study is a m ulticenter, randomized, open- label , phase III clinical trial of an 
experimental TB treatment  regimen (Arm A) of RPT/INH daily for 4 weeks compared to a 
standard TB treatment regimen (Arm  B) of INH daily for 36  weeks  in HIV -infected 
participants who do not have evidence of active TB . Randomization will be 1:1. 
Participants will be stratified based on (1) the most recent CD4+ cell count obtained 
within 180 days prior to entry  (<100, 100- 250, and >250 cells/mm3) and (2) ART use 
at entry (Yes/No). Each participant will be followed for 3 years (156 weeks) after the last  
participant is enrolled.  
 
Weeks  Arm A  (Experimental)  Arm B  (Standard)  
1 – 4 RPT weight -based dosing*/  
INH 300 mg daily INH 300 mg daily  
5 – 36 No treatment  INH 300 mg daily  
37-close to follow -up No treatment  No treatment  
*For weight 30 to <35 kg: RPT 300 mg once daily  
*For weight 35 to <45 kg: RPT 450 mg once daily  
  *For weight >45 kg: RPT 600 mg once daily  
*Average RPT dos age of ~10 mg/kg/administration 
 
Participants must receive pyridoxine ( vitamin B 6) 25 or 50 mg with each dose of INH . 
Sites will be expected to provide participant s with the vitamin B 6 necessary for the study.  
 
Under Version 1.0, EFV concentrations were  evaluated early in the first 90 
participants in Arm A who were receiving EFV at entry and who met other criteria 
in Section 10.0. EFV PK data w ere evaluated on an on -going basis, as described in 
Section 10.3, to determine whether standard EFV dosing results in adequate PK 
drug exposure in the  presence of RPT treatment. The A5279 team determined that 
concomitant dosing of EFV and RPT results in adequate drug exposure; thus,  the 
study was opened to participants receiving NVP. NVP concentrations will be 
evaluated in the first 90 participants in Arm A who are receiving NVP at entry and 
 30 A5279 
FINAL Version 2.0  
  08/28/14  
 
meet other criteria in Section 10.0.  
 
At th e implementation of Version 2.0:  
 
1. EFV concentrations and pharmacogenetics  will be evaluated in an additional 
30 participants from Arm A. These 30 participants will undergo PK sampling at 
weeks 0, 2, 4, and 16.  
 
2. EFV concentrations and pharmacogenetics will be evaluated in the first 90 
participants i n Arm B who are receiving EFV at entry and who meet other 
criteria in Section 10.0. PK sampling  will be performed at weeks 0, 2,  and 4.  
 
 
4.0 SELECTION AND ENROLLMENT OF PARTICIPANT S 
 
4.1 Inclusion Criteria  
 
4.1.1  HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme  or 
chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry 
and confirmed by a licensed Western blot or a second antibody test by a method 
other than the initial rapid HIV and/or E/CIA, or by HIV -1 antigen, plasma HIV -1 
RNA viral load . Two or more HIV -1 RNA viral loads of > 1,000 copies/mL are  
also acceptable as documentation of HIV infection.  
 
NOTE: The term ‘licensed’ refers to a FDA -approved kit which is required for all 
IND studies, or for sites located in countries other than the US, a kit that has 
been certified or licensed by an oversight body within that country and validated 
internally. Non- U.S. sites are encouraged to use FDA -approved methods for IND 
studies.  
 
WHO and CDC guidelines mandate that conf irmation of the initial test result must 
use a test that is different from the one used for the initial assessment. A reactive 
initial rapid test should be confirmed by either another type of rapid assay or an 
E/CIA that is based on a different antigen preparation and/or different test 
principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV -1 
RNA viral load.  
 
4.1.2  TST reactivity ≥ 5 mm , or a positive interferon gamma release assay (IGRA)  at 
any time prior to study  entry, OR living in a high TB burden area  
 
NOTE  A: In general, high TB burden areas are defined as areas with an 
estimated or reported TB prevalence of 60/100,000, according to the WHO or 
national or local health authorities. (Please refer to the A5279 protocol -
specific web page [PSWP ] for the WHO link to TB prevalence information 
by country. T he protocol core team [ actg.corea5279@fstrf.org ] should be 
consulted if a site has data to suggest that the local TB burden differs 
significan tly from the WHO country estimates and, therefore, should be 
considered in the application of this inclusion criterion. )   
 31 A5279 
FINAL Version 2.0  
  08/28/14  
 
 
NOTE B:  At entry, all participants must  have a TST performed unless one 
has been performed within 60 days prior to entry, regardless  of whether 
they live in a high TB burden area.  
 
4.1.3  Laboratory values obtained within 30 days prior to entry  
 
• Absolute neutrophil count  (ANC)  >750 cells /mm3 
• Hemoglobin ≥7.4 g/dL 
• Platelet count ≥50,000/mm3 
• Aspartate aminotransferase ( AST) (serum glutami c oxaloacetic transaminase 
[SGOT])  and alanine aminotransferase ( ALT) (serum glutamic pyruvic 
transaminase [SGPT ]) ≤3 X upper limit of normal ( ULN)  
• Total b ilirubin ≤ 2.5 X ULN  
 
4.1.4  Chest radiograph or chest computed tomography (CT) scan without 
evidence of acti ve tuberculosis, unless one has been performed within 30 
days prior to entry.  
 
4.1.5  Female participants of reproductive potential must have a negative serum or 
urine pregnancy test performed within 7 days prior to study entry.  
 
NOTE: Female partici pants of repr oductive potential  are defined as women who 
have reached menarche or who have not been post -menopausal for at least 24 
consecutive months (i.e., who have had menses within the preceding 24 months) 
or have not undergone surgical steril ization (e.g., hysterectomy, bilateral 
oophorectomy , or bilateral tubal ligation).  
 
4.1.6  All participants must agree not to participate in a conception process (e.g., active 
attempt to become pregnant or to impregnate, donate sperm, in vitro fertilizat ion) 
while receiving RPT and for 6 weeks after stopping this  drug.  
 
4.1.7  Female participants who are participating in sexual activity that could lead to 
pregnancy must agree to use one reliable non- hormonal form of contraceptive 
(i.e., condoms, IUD, diaphragm with spermicide, or cervical cap with 
spermicide)  while receiving RPT and for 6 weeks after stopping this drug.   
 
NOTE: Female participants who are not of reproductive potential, as defined 
above, or whose male partner(s) have undergone successful vasectomy with 
documented azoospermia or have documented azoospermia for any other 
reason, are eligible without requiring the use of contraceptives. Participant -
reported history is acceptable documentation of menopause, hysterectomy, or 
bilateral oophorectomy or  bilateral tubal ligation.  
 
4.1.8  Men and women age ≥13 years  
 
4.1.9  Weight ≥30 kg 
 
 32 A5279 
FINAL Version 2.0  
  08/28/14  
 
4.1.10  Ability and willingness of participant  or legal  guardian  to provide informed 
consent  
 
4.2 Exclusion Criteria  
 
4.2.1  Treatment for active  or latent  TB (pulmonary or extrapulmonary) within 2 years 
prior to study entry  or, at screening, presence of any confirmed or probable TB 
based on criteria listed in the current ACTG Diagnosis Appendix  
 
4.2.2  History of multi- drug resistant (MDR) or extensively -drug resistant (XDR) TB at 
any time prior to study entry  
 
4.2.3  Known exposure to MDR or XDR TB (e.g., household member of a person with 
MDR or XDR TB) a t any time prior to study entry  
 
4.2.4  Treatment for >14 consecutive days with a rifamycin or >30 consecutive days 
with INH at any time during the 2 years prior to enrollment . 
 
4.2.5  For partici pants taking ART  at study entry , only approved NRTI s with EFV or 
NVP for at least 4 weeks are permitted. Any other regimens at entry are 
exclusionary. A list of approved antiretroviral drugs is located on the A5279 
PSWP.  Participants on NVP must be dosed at 200 mg twice daily (BID).   
 
NOTE  A: NVP trough levels will be evaluated in the first 90 participants in 
Arm A who are receiving NVP at entry and who meet other criteria in 
Section 10.0, after which enrolment for participants on NVP may  be 
temporarily halted. NVP PK data will be evaluated to determine whether 
standard NVP dosing results in adequate PK drug exposure in the 
presence of RPT treatment. If the A5279 team determines that concomitant 
dosing of NVP and RPT results in adequate drug exposure, the study may 
continue enrollment of participants receiving NVP.    
 
NOTE B: Participants randomized to Arm A may initiate any ART regimen 
after completing four weeks of RPT/INH. Participants randomized to Arm B 
may initiate any ART regimen after study entry.  
 
4.2.6 History of liver cirrhosis at any time prior to study entry  
 
4.2.7  Evidence of acute hepatitis, such as abdominal pain, jaundice, dark urine, and/or 
light stools within 90 days prior to entry  
 
4.2.8  Diagnosis  of porphyria at any time prior to study entry  
 
4.2.9  Peripheral neuropathy ≥Grade 2 according to the December 2004 (Clarification, 
August 2009) Division of AIDS ( DAIDS ) Toxicity Table, within 90 days prior to 
study entry  
 
 33 A5279 
FINAL Version 2.0  
  08/28/14  
 
4.2.10  Known allergy/sensitivity or any hypersensitivity to components of study drugs or 
their formulation  
 
4.2.11  Active drug or alcohol use or dependence that, in the opinion of the site 
investigator, would interfere with adherence to study requirements  
 
4.2.12  Serious illness requiring systemic treatment and/or hospitalization within 30 days 
prior to entry  
 
4.2.13  Breastf eeding 
 
4.3 Study Enrollment Procedures  
 
4.3.1  Prior to implementation of this protocol , and any subsequent full version 
amendments , each site must have the protocol and the protocol  consent form 
approved, as appropriate,  by their local institutional review boar d (IRB)/ethics 
committee (EC) and any other applicable regulatory entity (RE) . Upon receiving 
final approval, sites will submit all required protocol registration documents to the 
DAIDS Protocol Registration Office (PRO) at the Regulatory Support  Center 
(RSC). The DAIDS PRO will review the submitted protocol registration packet to 
ensure that all of the required documents have been received. Protocol activation 
is also required before each non- U.S. site can enroll participants into the study, 
and may be req uired before each U.S. site can enroll any participants.  
 
Site-specific informed consent forms (ICFs)  will be reviewed and approved by the 
DAIDS PRO  and sites will receive an Initial Registration Notification from the 
DAIDS PRO that indicates successful co mpletion of the protocol registration 
process. A copy of the Initial Registration Notification should be retained in the 
site's regulatory files.  
 
Upon receiving final IRB/EC and any other applicable RE approval s for an 
amendment, sites should implement the amendment immediately. Sites are 
required to submit an amendment registration packet to the DAIDS PRO at the 
RSC. The DAIDS PRO will review the submitted protocol registration packet to 
ensure that all the required documents have been received. Site -spec ific ICFs 
WILL NOT  be reviewed and approved by the DAIDS PRO and sites will receive 
an Amendment Registration Notification when the DAIDS PRO receives a 
complete registration packet. A copy of the Amendment Registration Notification 
should be retained in t he site's regulatory files.  
 
For additional information on the protocol registration process and specific 
documents required for initial and amendment registrations, refer to the current 
version of the DAIDS Protocol Registration Manual.  
 
Once a candidate for study entry has been identified, details will be carefully 
discussed with the participant . The participant  (or, when necessary, the parent or 
legal guardian if the participant  is younger than 18 years of age or under 
guardianship) will be asked to read  and sign the  approved protocol consent form .  
 34 A5279 
FINAL Version 2.0  
  08/28/14  
 
 
For participant s from whom a signed informed consent has been obtained, an 
ACTG Screening Checklist  must be entered through the Data Management 
Center (DMC) Par ticipant  Enrollment System.  
 
For candidates fro m whom informed consent has been obtained, but who are 
deemed ineligible or who do not enroll into the protocol, an ACTG Screening 
Failure Results form must be completed and keyed into the database.  
 
4.3.2  Randomization  
 
Participants who meet eligibility criter ia for A5279 will be randomized to A5279 
according to standard ACTG DMC procedures.  
 
4.4 Coenrollment Guidelines  
 
Sites are encouraged to coenroll participant s in A5128 or A5243. Coenrollment in 
A5128,  “Plan for Obtaining Informed Consent  to Use Stored  Human Biological Materials  
(HBM) for Currently  Unspecified  Analyses,”  or A5243, “ Plan for Obtaining Human 
Biological Samples at Non -U.S. Clinical Research Sites for Currently Unspecified 
Genetic Analyses,” does not require permission from the A5279  protocol chairs. For 
specific questions and approval  for coenrollment in other studies,  sites must contact the 
protocol chairs via e- mail as described in the Study Management section.  
 
 
5.0 STUDY TREATMENT  
 
Study treatment for Arm A participants is RPT plus I NH for  4 weeks, followed by no 
treatment through week 36. Study treatment for Arm B participants is INH for a total of 
36 weeks. All participants will be followed for 3 years (156 weeks) after enrollment of the 
last participant.  
 
The study -provided products are rifapentine (RPT ) and isoniazid (INH).  
 
 35 A5279 
FINAL Version 2.0  
  08/28/14  
 
5.1 Regimens, Administration, and Duration  
 
5.1.1  Regimens and Duration  
 
At entry, participants will be randomized (1:1) to one of the following two arms:  
Weeks  Arm A (Experimental)  Arm B (Standard)  
1 – 4 Rifapentine (RPT , Priftin®),  
based on weight at entry  
For weight 30 to <35 kg: 300 mg once daily*  
For weight 35 to <45 kg: 450 mg once daily*  
 For weight >45 kg: 600 mg once daily*  
PLUS  
Isoniazid (INH) 300 mg once daily  Isoni azid (INH) 
300mg once daily  
 
5 – 36 No treatm ent Isoniazid (INH) 
300mg once daily  
* Average dosage of ~10 mg/kg/administration  
 
All participants must  receive pyridoxine ( vitamin B 6) 25 or 50 mg with each dose 
of INH  based on the current local, national, or international dosing guidelines . 
Sites will be expected to provide participants with the vitamin B 6 necessary for 
the study.  
 
ART will not be provided by this study. Study clinicians, in conjunction with 
participants, should determine the optimal ART regimen for each participant, if 
indicated. However, for participants taking ART who are randomized to Arm A, 
only approved NRTI s with EFV or NVP are permitted for the first 4 weeks of 
study treatment with RPT; a list of approved antiretroviral drugs is located 
on the A5279 PSWP . If a participant must s witch to an ART regimen that 
includes an antiretroviral drug  that is not on the approved list  while on 
RPT/INH, then RPT/INH must be discontinued; this participant will be followed off 
treatment, on study.  
 
At the entry visit, the site pharmacist will dispense enough study products to last 
until the next study visit. Participants must return any remaining study product 
after the completion of randomized therapy . Participants  in Arm A will have 8 
weeks from enrollment to complete 4 weeks of treatment, and those in Arm B will 
have 54 weeks to complete 36 weeks of treatment . 
 
5.1.2  Administration  
 
RPT 300 mg: will be administered as two 150 mg tablets orally once daily with 
INH and is to be taken with food.  
 
RPT 450 mg: will be administered as three 150 mg tabl ets orally once daily with 
INH and is to be taken with food.  
 
RPT 600mg: will be administered as four 150 mg tablets orally  once daily with 
 36 A5279 
FINAL Version 2.0  
  08/28/14  
 
INH and is to be taken with food.  
 
INH 300 mg: will be administered as one 300 mg tablet or three 100 mg  tablets  
orally once daily*.  
 
*NOTE: For Arm A participants, when INH is administered with RPT, both 
products will be taken together with food. For Arm B participants, when INH is 
administered alone (i.e., without RPT), INH may be taken with or without food.  
 
Pyrido xine (vitamin B 6) 25 mg: will be administered as one 25 mg tablet orally 
once daily with INH.  
 
Pyridoxine (vitamin B 6) 50 mg: will be administered as two 25 mg tablets or one 
50 mg tablet orally once daily with INH.  
 
5.2 Study Product Formulation and Prep aration 
 
Rifapentine will be supplied as tablets for oral administration, each containing 150  mg of 
rifapentine. Store at 25°C (77°F); excursions permitted from 15° –  30°C (59° – 86°F).  
Protect from excessive heat and humidity.  
 
Isoniazid provided through the study  will be supplied as tablets for oral administration, 
each containing 300 mg of isoniazid. Store below 30°C (86°F).  
   
Isoniazid 100 mg or 300 mg tablets locally procured by the site and approved for 
use in A5279 by the protocol team must be stor ed in accordance with the 
manufacturer’s instructions. INH locally procured by the site must be the same 
strength and formulation for the duration of the study.  
 
5.3 Pharmacy: Product Supply, Distribution, and Accountability  
 
5.3.1  Study Product Acquisition /Distribution  
 
Rifapentine (RPT, Prifitin®) will be supplied by sanofi -aventis. Isoniazid (INH) will 
be supplied through the study with support from sanofi -aventis. Rifapentine 
(RPT, Prifitin®) and isoniazid (INH) will be available through the National Institute 
of Allergy and Infectious Diseases (NIAID) Clinical Research Products 
Management Center (CRPMC ); however, if INH is not available through the 
CRPMC,  sites may obtain a supply of INH locally to be subsequently 
dispensed to the participant. The A5279 Site Implementation Plan (SIP) 
located on the A5279 PSWP must be completed by each site for protocol 
team notification and authorization of locally sourced INH.   
 
 37 A5279 
FINAL Version 2.0  
  08/28/14  
 
Any study product not provided by the study must comply with the NIAID 
(DAIDS) policy that outlines the process for authorizing the use of study 
products not marketed in the US in NIAID (DAIDS) -supported and/or 
sponsored clinical trials. This policy is available on the NIAID (DAIDS) 
website at: 
http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/D
ocuments/NonFDAapprovedProducts.pdf  
 
If sites have received registration approval for A5279 Version 1.0  LOA #4 or 
Version 2.0 , sites may order INH from the CRPMC and should begin to use 
that drug in lieu of any INH obtained locally (as previously outlined in 
A5279 Version 1.0, LOA #2). Sites may not order INH obtained from 
Macleods via the CRPMC until they have received registration approval for 
A5279 Version 1.0, LOA #4 or Version 2.0. Additionally, for sites switching 
from locally obtained INH to INH from the CRPMC, sites should document 
and notify the A5279 core team ( actg.corea5279@fstrf.org ) with the date 
that INH from Macleods Pharmaceuticals Limited is implemented at the 
site.  
 
The site pharmacist can obtain the study products for this protocol by following 
the instructions in the manual Pharmacy Guidelines and Instructions for DAIDS 
Clinical Trials Networks in the section Study Product Management 
Responsibilities.  
 
Pyridoxine (vitamin B 6) will not be supplied through the study and must be 
obtained locally by the site.   
 
5.3.2  Study Product Accountability  
 
The site pharmacist is required to maintain complete records of all study products 
received from the NIAID CRPMC or other sources and subsequently 
dispensed. At US CRSs, all unused study products must be returned to the 
NIAID CRPMC (or as otherwise directed by the sponsor) after the study is 
completed or terminated. The site pharmacists at non- US CRSs  must follow the 
instructions provided in the manual Pharmacy Guidelines and Instructions for 
DAIDS Clinical Trials Network s in the section Study Product Management 
Responsibilities  for the destruction of unused study -provided products.  
 
5.4 Concomitant Medications  
 
Whenever a concomitant medication or study agent is initiated or  a dose changed, 
investigators must review the concomitant medic ations ’ and study agents' most recent 
package inserts, Investigator ’s Brochures, or updated information from DAIDS to obtain 
the most current information on drug interactions, contraindications, and precautions.  
 
Additional drug information may be found on the ACTG Pharmacology drug table located 
at: https://member.actgnetwork.org/cms/dl/12692 . 
 
 38 A5279 
FINAL Version 2.0  
  08/28/14  
 
5.4.1  Required Medications  
 
While on INH, pyridoxine ( vitamin B 6) 25 or 50 mg  once daily  
 
5.4.2  Prohibited Medications  
 
The A5279 prohibited medications are listed on the A5279 PSWP.  
 
5.4.3  Precautionary Medications  
 
The A5279 precautionary medications are listed on the A5279 PSWP.  
To avoid adverse drug interactions, pack age inserts of anti -TB agents, 
antiretroviral agent s, and other concomitant medications should be referenced  
whenever a concomitant medication is initiated or dose changed, to avoid drug 
interaction AEs . 
 
5.5 Adherence Assessment   
 
Pill counts and self -report adherence interview s for both arms will be used to assess 
adherence during the treatment phase of each arm . Participants will also be asked to 
report on food consumption when taking RPT .
 39 A5279 
FINAL Version 2.0  
  08/28/14  
 6.0 CLINICAL AND LABORATORY EVALUATIONS  
 
6.1 Schedule of Events  
Evalu ation  Screening Entry  Treatment Phase  Post-
Treatment 
Phase (every 
12 weeks, 
starting at 
week 48)   Diagnosis 
of TB  Premature Study 
Discontinuation Arm A: 
RPT/INH  
(weeks 2, 4, 8, 
12,16, 20, 24, 
36) Arm B:  
INH-only  
(weeks 2, 4, 8, 
12, 16, 20, 24, 
36) 
Documentation of HIV  X       
Medical History/Medication 
History  X       
Clinical Assessment1 (including 
TB assessment, adverse events, 
concomitant medications)  X X X X X X X 
Chest Radiograph  or Chest CT  X2  If indicated  If indicated  If indicated  If indicated   
TST or IGRA  X3 TST 
only4      
Hematology  X X Week 4 and 
if indicated  Week 4 and 
if indicated  If indicated  If indicated  X 
Liver Function Tests  X X Week 4 and 
if indicated  Week 4 and 
if indicated If indicated  If indicated  X 
Chemistry  X X Week  4 and 
if indicated   Week 4 and 
if indicated  If indicated  If indicated  X 
Pregnancy Testing  X  If indicated  If indicated     
 
1 A complete physical exam is required at entry; at post -entry visits, a targeted physical exam is required.  
2 Chest radiograph  or chest CT  is requ ired unless one has been performed within 30 days prior to entry . 
3 For participants not living in a high TB burden area, if prior positive TST/IGRA results are not available.  
4 TST is required unless one has been performed within 60 days prior to entry  for all participants , regardless of whether they live in a high TB burden 
area. An IGRA cannot be substituted at entry.  
 
 40 A5279 
FINAL Version 2.0  
  08/28/14  
6.1 Schedule of Events (Cont'd)  
 
Evalu ation  Screening Entry  Treatment Phase  Post-
Treatment 
Phase (every 
12 weeks, 
starting at 
week 48)   Diagnosis 
of TB  Premature Study 
Discontinuation Arm A: 
RPT/INH  
(weeks 2, 4, 8, 
12,16, 20, 24, 
36) Arm B:  
INH-only  
(weeks 2, 4, 8, 
12, 16, 20, 24, 
36) 
CD4+  X5 X   Every 48 
weeks    
Plasma HIV -1 RNA for 
Participants on ART   X      
Sputum Acid Fast Bacilli Smear 
and/or Xpert plus  Sputum 
Culture  If indicated   If indicated  If indicated  If indicated  X  
Pill Count    Weeks 2 
and 4 only  X    
Adherence Interview    Weeks 2 
and 4 only  X    
Stored Plasma/PBMC/Serum6  X   Every 48 
weeks  X  
PK Samples7, 8  X Weeks 2  
and 4; plus 
week 16 for 
subset10  Weeks 2 
and 4     
Pharmacogenetic  Sample7, 9  X      
 
5 A screening CD4+ cell count will only be collected if not done within 180 days prior to study entry.  
6 These samples will be collected on a subset of participants; see section 6.3.13.  
7 Only for participants who meet criteria in section 10.0. See section 10.0 for PK sampling directions.  
8 A subset of the participants in the PK study will have a week 16 sample collected; see section 6.3.1 4.    
9 If not collected at entry, this sample may be collected at week 2 or 4.  
10Subset includes 30 patients in Arm A selected as EFV controls at implementation of protocol version 2.0  
 41 A5279 
FINAL Version 2.0  
  08/28/14  
6.1 Schedule of Events (Cont'd)  
 
Evalu ation  Screening Entry  Treatment Phase  Post-
Treatment 
Phase (every 
12 weeks, 
starting at 
week 48)   Diagnosis 
of TB  Premature Study 
Discontinuation Arm A: 
RPT/INH  
(weeks 2, 4, 8, 
12,16, 20, 24, 
36) Arm B:  
INH-only  
(weeks 2, 4, 8, 
12, 16, 20, 24, 
36) 
Stored Plasma for Virology7   Week 8  
only     
 42 A5279 
FINAL Version 2.0  
 08/28/14  
 
 6.2 Timing of Evaluations  
 
6.2.1  Screening Evaluations   
 
Screening evaluations must occur prior to the participant’s starting study 
medications . Screening evaluations to determine eligibility must be completed 
within 30 days prior to study entry unless otherwise specified.  
 
In addition to data being collected on participant s who enroll into the study, 
demographic, clinical, and laboratory data on screening failures will be captured 
in a screening log and entered into the ACTG database.  
 
6.2.2  Entry  Evaluations  
 
On-study evaluations will occur after randomization. E ntry ev aluations must 
occur  at least 24 hours  after screening  evaluations unless o therwise specified 
and be completed before initiating randomized treatment . Participant s must begin 
treatment within 72 hours after randomization.  
 
6.2.3  Post-Entry Evaluations  
 
On-Treatment Evaluations   
The window for the week 2 and week 4 study visits is  +/- 7 days. The window for 
all other study visits during the treatment phase is +/ - 14 days.  
 
Post-Treatment Evaluations   
During the follow -up phase, the window for study visits is +/ - 14 days.  
 
Diagnosis of TB  
This visit should  occur at the time of or as  soon as possible after the diagnosis of 
TB, preferably within 4 weeks.  
 
6.2.4  Discontinuation Evaluations  
 
Evaluations for Randomized Participant s Who Do Not Start Study Treatment  
All case report forms ( CRFs ) must be completed and keyed for the period up to 
and including week 0 (entry ). 
 
Premature Treatment Discontinuation Evaluations  
Participants who prematurely discontinue study treatment will continue to be 
followed on study, off study treatment for the remainder of the study follow -up, 
according to the schedule of e vents.  
 
Premature Study Discontinuation Evaluations  
Participants who prematurely discontinue the study will have evaluations  
performed as indicated in the s chedule of e vents.  
 
 43 A5279 
FINAL Version 2.0  
  08/28/14  
 
6.3 Instructions  for Evaluations  
 
All clinical and laboratory information required by this protocol is to be present in the 
source documents. Sites must refer to the Source Document Guidelines on the  DAIDS  
Web site for information about what must be included in the source document:  
http://www.niaid.nih.gov/labsandresources/resources/daidsclinrsrch/documents/sourced
ocappndx.pdf . 
 
All protocol -required evaluations are to be recorded on the CRF and keyed into the 
database unless otherwise specified. This includes events that meet the International 
Conference on Harmonisation (ICH) definitions for a SAE : 
 
• Results in d eath 
• Life threatening 
• Requires inpatient hospitalization or prolongation of existing hospitalization 
• Results in persiste nt or significant disability/in capacity  
• Congenital anomaly/birth defect  
• Other important medical event (may not be immediately life- threatening or 
result in death or hospitalization but may jeopardize the patient or may 
require intervention to prevent one of the events listed above. )   
 
To grade diagnoses, signs and symptoms, and laboratory results, sites must refer to the 
DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE 
Grading Table), Version 1.0, December 2004 (Clarification, August 2009), which can be 
found on the DAIDS RS C Web site:  http://rsc.tech -
res.com/safetyandpharmacovigilance/ . 
 
6.3.1  Documentation of HIV -1 
 
Please refer to section 4.1.1 regarding assay requirements for HIV -1 
documentation. HIV-1 documentation is not recorded on the CRF.  
 
6.3.2  Medical History  
 
The medical histor y must  include all prior TB, AIDS -defini ng events, and liver 
disease. In addition, it must include all diagnoses identified by the ACTG criteria 
for clinical events and other diagnoses  within 30 days prior to study entry . For 
current criteria, refer to the  appendix identified in the study CRF. A llergies to any 
medications and their formulations must be documented.   
 
6.3.3 Medication History  
 
A medication history including all prescription and nonprescription medications 
taken within 30 days prior to study entry must be present . Include actual or 
estimated start and stop dates. A complete HIV and active or latent TB treatment 
history must be present, with start and stop dates of any antiretroviral  or TB 
medication (estimated if the exact dates cannot be obtai ned), immune -based 
therapy, or HIV -related vaccines, including blinded study medications.  
 44 A5279 
FINAL Version 2.0  
  08/28/14  
 
6.3.4 Clinical Assessments  
 
Complete Physical Exam  
A complete physical examination at entry  is to include at a minimum an 
examination of the skin, head, mouth , and neck; auscultation of the chest; 
cardiac exam; abdominal exam; examination of the lower extremities for edema.  
The complete physical exam will also include signs and symptoms, diagnoses, 
vital signs  (temperature, pulse,  respiration rate,  and blood pressure ), height, and 
weight . 
 
TB Assessment    
To exclude active TB at study entry or to diagnose active TB on study, 
assessm ent of signs and symptoms should include at least the following:  
• Any cough, fever, night sweats and/or involuntary weight loss  
• Lymphadenopat hy and/or abnormalities on lung examination 
 
Targeted Physical Exam  
A targeted physical examination at post -entry visits is to include vital signs 
(temperature, pulse , respiration rate,  and blood pressure)  and weight. It should 
be driven by any previously identified or new  signs or symptoms including 
diagnoses that the participant  has experienced since the last visit.  
 
Signs and Symptoms  
At entry , signs and symptoms of all grades that occurred 30 days before entry 
must be recorded; post -entry,  only signs and symptoms Grade ≥3 must be 
recorded . Record all signs and symptoms that led  to a change in treatment, 
regardless of grade.  
 
Diagnoses  
Record all diagnoses identified by the ACTG  criteria for clinical events and other 
diseases.   
 
Concomitant Medications  
All new concomitant medications , including all antiretroviral medications,  taken 
since the last report and current concomitant medications modified since the last 
report should be recorded.  
 
Study Treatment Modifications  
Record all study drug modifications,  including initial doses , participant -initiated 
and/or protocol -mandated modifications , inadvertent and deliberate interruptions 
(i.e., 3 or more missed doses) at each visit . Record permanent discontinuation of 
treatment.  
 
6.3.5  Chest Radiograph  or Chest CT  
 
At screening, or within 30 days prior to study entry,  and whenever active TB is  
suspected, a chest radiograph or chest CT  should be performed.  
 
 45 A5279 
FINAL Version 2.0  
  08/28/14  
 
6.3.6 TST or IGRA   
 
For those participants who are not living in a high TB burden area, a T ST or a 
licensed IGRA assay will be performed at screening if prior positive test results 
are not already available . High TB burden areas are defined as areas with all 
cases of TB prevalence ≥60/100,000  of the country’s population,  according to the 
WHO ( http://apps.who.int/globalatlas/predefinedreports/tb/index.asp ). 
 
All participants require a TST performed within 60 days prior to study entry 
or on the day of entry. If a TST was done at screening within 60 days of 
study entry , a repeat TST is not needed. If TB exposure was documented 
through an IGRA, or a TST that was performed more than 60 days prior to 
study entry, or by living in a high burden country, a TST must be performed 
within 60 days prior to  study entry or at entry . Participants must return 
within 7 days to have the results read.  
 
6.3.7  Laboratory Evaluations  
 
At screening and entry, all  protocol -required laboratory values must be recorded. 
For post -entry assessments, record all Grade ≥3 protocol-required laboratory 
values. All laboratory toxicities that led to a change in treatment, regardless of 
grade, must be recorded.  
 
Hematology  
Hemoglobin, hematocrit, red blood cells, white blood cell count, ANC, and 
platelets.  
 
Liver Function Tests  
Total bilirubin, AST (SGOT), ALT (SGPT), and alkaline phosphatase.  These tests 
should be performed at any time during the treatment and post -treatment phase 
if the participant exhibits signs suggestive of hepatitis (e.g., fatigue, weakness, 
malaise, anorexia, nausea, vomiting, abdominal pain, pale stools, dark urine, 
chills) or has signs of jaundice.  
 
Blood Chemistries  
Sodium, potassium, chloride, bicarbonate, creatinine, and albumin.  
 
Pregnancy Test  
For women with reproductive potential: Serum or urine β-HCG (urine test must 
have a sensitivity of 15- 25 mIU/mL).  
 
6.3.8 Immunologic Studies  
 
CD4+ 
CD4+ cell counts (both absolute and percentage counts) will be performed 
throughout the study at the same DAIDS -approved laboratory, if possible.   
A screening CD4+ cell count will only be collected if not done within 180 
days prior to study entry.  A DAIDS -approved laboratory is not required for 
 46 A5279 
FINAL Version 2.0  
  08/28/14  
 
the screening CD4+ count.  
 
Because of the diurnal variation in CD4+  counts, determinations for individual 
participant s should be obtained consistently in either the morning or the 
afternoon throughout the study , if possible.  
 
NOTE: If the flow lab is using dual platform technology to obtain the results, each 
time a measurement is obtained, the local lab must perform a white blood cell 
count and differential from a sample collected at the same time.  
 
6.3.9 Virologic Studies  
 
Plasma HIV -1 RNA  for Participants on ART 
Quantitations must be  performed at a DAIDS -approved laboratory in real time 
using a licensed assay.  
 
6.3.10  Sputum Acid Fast Bacilli Smear and/or Xpert plus Sputum Culture  
 
Whenever active TB is suspected, sputum  AFB smear and/or Xpert plus sputum 
culture should be performed; additional tests may be performed.  Positive 
cultures should undergo speciation, and drug susceptibility  testing if positive for 
MTB. A regional or central reference laboratory may be used.  
 
6.3.11  Pill Cou nt 
 
Pill counts for INH and RPT study treatment should be performed during the 
treatment phase as indicated in the schedule of events.  
 
6.3.12  Adherence Interview  
 
Self-report interview s on adherence to INH and RPT study treatment should be 
performed  during the treatment phase as indicated in the schedule of events.  
 
6.3.13  Stored Plasma/PBMC/Serum  
 
Prior to June 1, 2014, the first 30 participants enrolled at each non- US site  
and the first 50 participants enrolled in the US were assigned to have 
plasma and serum stored at entry and every 48 weeks. Samples from these 
participants will continue to be collected for the duration of the study. In 
addition, at sites with the capabil ity, viable PBMCs are being stored for future 
testing at all time points specified above for participants assigned to have 
PBMC stored .  
 
Participants enrolled after May 31, 2014 will not be assigned to have 
plasma, serum, or PBMC samples collected at entr y and every 48 weeks.   
 
At the time of or as soon as possible after diagnosis (see section 6.2.3 of 
the protocol), all participants diagnosed with active TB, regardless of 
 47 A5279 
FINAL Version 2.0  
  08/28/14  
 
enrollment date, will have plasma, serum, and PBMCs collected (where 
possible) for future testing. Participants already selected for 
plasma/PBMC/serum storage will continue to have samples taken every 48 
weeks as previously scheduled. Otherwise, no additional 
plasma/PBMC/serum storage samples will be collected.  
 
Sites will follow storag e, testing, and shipping instructions provided on the A5279 
PSWP.  
 
6.3.14  PK Samples  
 
Under Version 1.0, samples were collected from the first  90 participants in Arm 
A who were  taking EFV at entry and meet other criteria in Section 10.0.   
 
Samples will be collect ed from the first 90 participants in Arm A who are taking 
NVP and meet other criteria in Section 10.0.  
 
Once Version 2.0 of this study is implemented:  
 
1. EFV concentrations will be evaluated in an additional 30 participants 
from Arm A. These 30 individuals w ill serve as controls for the EFV 
analysis. A PK sample will be collected in these 30 individuals at weeks 
0, 2 and 4 similar to the other EFV PK analysis; however, an additional 
week 16 sample will be collected as an “EFV only” sample. The week 16 
sample will allow for a washout period after completion of RPT and INH.  
 
2. Samples will also be collected in the first 90 participants in Arm B 
enrolled into Version 2.0 who are taking EFV at entry and meet other 
criteria in Section 10.0.  
 
6.3.15  Pharmacogenetic  Sample  
 
This sample will be collected from those participants in Arm A and Arm B who 
are taking part in the PK study . This will include those individuals in Arm A 
who are serving as controls  for EFV PK , and have consented to the collection 
of this sample . It should be collected at entry; however, if it is not collected at 
entry, it may be collected at week 2 or 4.  
 
6.3.16  Stored Plasma for Virology  
 
For those participating in the PK portion of the study, plasma will be collected at 
week 8  and stored for HIV virology . 
 
 
7.0 CLINICAL MANAGEMENT  ISSUES 
 
This study will use the DAIDS Table for Grading the Severity of Adult and Pediatric 
Adverse Events (DAIDS AE Grading Table), Version 1.0, December 2004 (Clarification, 
 48 A5279 
FINAL Version 2.0  
  08/28/14  
 
August 2009), which can be found on the DAIDS RSC Web site:  http://rsc.tech -
res.com/safetyandpharmacovigilance/ . 
 
7.1 Toxicity  
 
If study drugs are held for toxicity, participants in Arm A will have 8  weeks from 
enrollment to  complete 4 weeks of treatment , and those in Arm B will have 54 weeks to 
complete 36 weeks of treatment.  
 
Grades 1 and 2: Participants may continue INH and RPT, at the discretion of the site 
investigator with careful follow -up.  
 
Grades 3 and 4: Study drugs should be held until return to baseline (entry visit levels)  if 
baseline was >Grade 2, or until ≤ Grade 2 or within normal limits if baseline was ≤Grade 
2. Study drugs may be permanently discontinued at the discretion of site investigator.  
Gastrointestinal  
For nausea/vomiting and/or diarrhea ≥Grade 3 or Grade 2 toxicity if symptoms were not 
present at the previous visit, all study drugs should be held until the symptoms have 
resolved. Reintroduce study drugs with caution.  
 
Antiemetic and antidiarrheal medication may be used at t he site investigator's discretion.  
 
If nausea and vomiting occur as a result of hepatitis that is not due to study drugs, every 
effort should be made to reintroduce  the study drugs after the symptoms subside to 
baseline levels.  
 
Cutaneous  
If Grade 2 or 3 o r showing a significant increase over baseline, all study drugs should be 
held until the toxicity resolves. Study drugs should be reintroduced with caution. Grade 4 
cutaneous or Grade 4 mucocutaneous rash is a major toxicity , and all st udy drugs 
should be interrupted pending resolution of the toxicity. Study drugs may be permanently 
discontinued if believed to be the cause of toxicity. Study drugs may also be interrupted 
and reintroduced at the discretion of the site investigator.  
 
Drug-Associated Fever  
If ≥Grade 3, all study drugs should be held until the temperature  returns to normal.  Study 
drugs should be reintroduced with caution. Recurr ence of symptoms on reintroduction 
will result in permanent discontinuation of the responsible agent. No alteration of dose 
will occur.  
 
Elevated Liver -Associated Enzymes  
If AST (SGOT), ALT (SGPT), or total bilirubin increase two grades over baseline (if 
baseline is <Grade 2) to maximum of Grade 3, study drugs should be held until the 
levels return to baseline or Grade 2.  Reintroduce the study drug(s) with caution.  
 
If baseline was Grade 2 and liver -associated enzyme(s) increase to Grade 3, no action 
is required.  
 
 49 A5279 
FINAL Version 2.0  
  08/28/14  
 
Grade 4 is a major toxicity , and study drugs will be interrupted pending resolution of the 
toxicity. Permanent  discontinuation of study drugs is at the site investigator’s discretion.  
 
Peripheral Neuropathy  
Peripheral neuropathy associated with INH is usually avoided by the concurrent 
administration of vitamin B 6. In this study, all pa rticipant s will take vitamin B6 
concomitantly with INH. If peripheral neuropathy develops, every effort should be made 
to determine the etiology (i.e., whether the neuropathy is due to INH toxicity, alcohol, or 
other factors). Participants with peripheral neuropathy < Grade 2 may be entered into the 
study , but should be monitored carefully for any progression of peripheral neuropathy.  
 
For Grade 1 or 2, continue the study drugs and follow the participant more frequently for 
progression of peripheral neuropathy. Consider increase in vitamin B 6 dose.  For Grade 3  
or 4, discontinue INH until toxicity resolves to Grade < 2; then INH may be reintroduc ed 
at the site investigator's discretion. If peripheral neuropathy does not resolve despite 
discontinuation of INH, the INH may be reintroduced at the site investigator's discretion.  
 
7.2 Pregnancy  
 
Pregnant women will discontinue RPT and be treated according to in- country standard of 
care. They  will be encouraged to continue on study and complete the evaluations  per the 
schedule of events.  At the end of the pregnancy, the outcome and AEs  for the 
participant and the infant will be recorded on an outcome CRF.  
 
Disclosure of pregnancy to parents of participants who are minors  will be handled 
according to in- country standard of care . 
 
Pregnancies that occur on study in female participants  receiving ART should be reported 
by the CRS to The Antiretroviral Pregnancy Registry. More information is available at 
www.apregistry.com . For U.S. sites: Phone: 800 -258-4263;  Fax: 800- 800-1052. For non -
U.S. sites: Phone: 910- 679-1598; Fax: 44 1628 -789-666 or 910 -246-0637  
 
 
8.0 CRITERIA FOR DISCONTINUATION  
 
8.1 Permanent  Treatment Discontinuation  
• Drug -related toxicity (see section 7. 1) 
• Requirement for prohibited medications (see section 5.4)  
• Pregnancy or breastfeeding  while receiving RPT  
• Reaching  a defined clinical endpoint  
• Completion of  treatment phase as defined by  the protocol  
• Request by participant  to terminate treatment  
• Clinical reasons believed life threatening by the phys ician, even if not addressed in 
the toxicity section of the protocol  
 
8.2 Premature Study Discontinuation 
• 3 or more consecutive missed study visits 
• Request by the participant  to withdraw  
 50 A5279 
FINAL Version 2.0  
  08/28/14  
 
• Request of the primary care provider if s/he thinks the study is no l onger in the best 
interest of the participant  
• Participant  judged by the investigator to be at significant risk of failing to comply with 
the provisions of the protocol as to cause harm to self or seriously interfere with the 
validity of the study results  
• At the discretion of the ACTG, NIAID, IRB or EC, US FDA, Office for Human 
Research Protections (OHRP), investigator, pharmaceutical supporter , or other 
government agencies as part of their duties to ensure that research participants are 
protected.  
 
 
9.0 STATISTICAL CONSIDERATIONS  
 
9.1 General Design Issues  
 
This is an open -label, randomized, phase III study to evaluate whether a short -course, 4 -
week RPT/INH regimen is non- inferior to a standard 9 -month daily INH regimen (9- INH) 
for the prevention of active TB in HIV -infected participants. We intend to recruit 3000  
participants. Each participant will be followed until 3 years after entry of the last 
participant. We anticipate accrual to occur at the rate of approximately 100- 120 
participants per month , once a substantial number of sites that intend to participate have 
initiated accrual.  
 
9.2 Endpoints  
 
9.2.1  Primary Endpoint : time from randomization to  first diagnosis of active TB  
 
9.2.2  Secondary Endpoints  
 
9.2.2.1  Safety and tolerability:  
9.2.2.1.1  Safety endpoints:  
a) Occurrence of  one or more SAEs vs. no SAEs  
b) Highest reported grade of each new Grade 3 or 4 
laboratory value or sign or symptom that is at least one 
grade increase from baseline for targeted events [i.e., 
nausea and vomiting, cutaneous, drug -associated fever, 
elevated A ST (SGOT), ALT, (SGPT), or bilirubin, and 
peripheral neuropathy]  
9.2.2.1.2  Tolerability:  
Ordered categorical variable indicating most stringent level 
of study drug management due to toxicity that was required 
over the treatment period:  
1. Premature permanent treatment discontinuation  
2. Treatment hold for more than 7 consecutive days  
3. None of the above 
 
9.2.2.2  Time from randomization to death from any cause  
 
 51 A5279 
FINAL Version 2.0  
  08/28/14  
 
9.2.2.3  Time from randomization to death due to a non- TB event  
 
9.2.2.4  EFV plasma concentrations at weeks  0, 2 and 4 in the first 90 
partic ipants  randomized to Arm A  who enter the study taking EFV and 
who meet dose timing criteria;  and, under V ersion 2.0, at weeks 0, 2, 
4, and 16 in the first 30 participants randomized to Arm A who 
enter the study taking EFV and who meet dose timing criteria.  
 
9.2.2.5  NVP plasma concentrations at weeks  0, 2 and 4 in the first 90 
participants randomized to Arm A  who enter the study taking NVP and 
who meet dose timing criteria.  
 
9.2.2.6  Under V ersion 2.0, EFV plasma concentrations at weeks 0, 2,  and 4 
in the first 90 participants randomized to Arm B who enter the 
study taking EFV and who meet dose timing criteria.  
 
9.2.3  Additional secondary endpoints for supportive/exploratory analyses that will be 
defined in more detail in separate analysis plans:  
 
9.2.3.1  Adherence to TB treatment : self-report ed number of pills missed since 
last visit and pill count while on study drug 
 
9.2.3.2  Antibiotic resistance pattern of  MTB isolates in participants who develop 
active TB  
 
9.2.3.3  HIV-1 RNA changes from baseline to week 8 in the first 90 participants 
entering the study taking EFV and who meet PK analysis dose timing 
criteria and in the first 90 participants entering the study taking NVP and 
who meet PK analysis dose timing criteria (may be evaluated only in a 
subset, e.g., those with very low EFV or NVP levels)  
 
9.2.3.4  Polymorphisms in host genes involved in metabolism or transport of EFV, 
NVP, and RPT including: CYP2B6, CYP3A4/5, SLCO1B1, CYP2A6, 
UGT2B7, PXR (pregnane X receptor), CAR ( constitutive androstane 
receptor ), and HFN4A (hepatocyte nuclear factor).   
 
9.2.3.5  Cost-effectiveness measures  
 
9.3 Randomization and Stratification 
 
Participants will be randomized in a 1:1 ratio to the two arms using permuted blocks. 
Randomization will be stratified by: CD4+ cell coun t <100, 100-250, and  >250 cells/mL; 
ART, receiving ART at entry versus not.   
 
9.4 Sample Size and Accrual  
 
In a recently -completed phase III clinical trial comparing 6 months of daily INH (6- INH) to 
12 weeks of weekly RPT/INH or RIF/INH and to continuous INH, the rate of active TB 
 52 A5279 
FINAL Version 2.0  
  08/28/14  
 
(including death ascribed to TB) was 1.77/ 100 PY both in the 6 -INH arm (N=328) and in 
the study as a whole (N=1150) with no attenuation over time [65]. This study excluded 
participants with an indication for ART  and whose CD4+ cell counts were relatively high. 
A5279 will enroll participants with any CD4+ cell counts; thus,  the team anticipates a 
higher rate of active TB. In addition, a survey of ACTG studies conducted at non -U.S. 
sites found that approximately 15% of deaths occurring at non -U.S. sites had an 
unknown cause (including causes  such as “HIV disease” or “natural causes” as 
unknown). This is fewer deaths with unknown COD  than in the TB study referenced 
above [personal  communication] . Both because we anticipate entering participants with 
lower CD4+ cell counts and because we antici pate identification of nearly all TB -related 
deaths, we expect  the rate of active TB (including death ascribed to TB) will be at least 
2.00/100 PY , and possibly  higher. We will use a noninferiority design to test the 
hypothesis that the ultra- short -course RPT/INH regimen has efficacy that is no worse 
than the 9 -INH control arm (standard of care [SOC]) within  an accepted tolerance to 
define noninferiority. We will perform the study with a one -sided 0.025 significance level 
(i.e., 2 -sided 0.05- level) and will  target 90% power to confirm noninferiority if it is, in fact, 
true. Follow -up will continue to 3 years beyond entry of the last participant. Participants 
lost to follow -up and those who die from causes unrelated to TB will be censored. 
Participants with an unknown COD will be considered to be TB endpoints. Non- TB 
mortality (including unknown COD) is expected to be lower than the rate of active TB , 
and the number of deaths with unknown COD should be minimal: nonetheless, 
sensitivity analyses described below  will be conducted.   
 
The following table provides total sample sizes needed to confirm the noninferiority of 
short -course RPT/INH for TB incidence rates of 2.00 and 2.25/100 PY on the SOC arm 
and a range of tolerance expressed as TB incidence rate per 100  PY of observation. The 
9-INH arm is the SOC. To provide concrete numbers for comparison and to put the 
tolerance regions in scale, the table provides the 3-  and 5- year percentages of active TB 
for the control (9 -INH) arm and for a range of noninferiority tolerance rates of TB per 100 
PY. We anticipate accrual will be 2 years , but could be 1.5 to 2.5 years from the time 
when substantial sites have joined the study.   
 
 Rate/  
100PY  Active TB 
Percent  Total accrual given accrual duration and 
target baseline TB  rates/100PY  
  3yr %  5yr %  1.5yr acc  2.0yr acc  2.5yr acc  
    2.00 2.25 2.00 2.25 2.00 2.25 
SOC arm  2.00 5.9%  9.6%        
 2.25 6.6%  10.8%        
          
Tolerance  3.00 8.7%  14.1%  3723  6587  3410  6224  3335  5945  
 3.25 9.4%  15.2%  2596  4025  2452  3804  2326 3608  
 3.5 10.1%  16.3%  1950  2782  1842  2628  1747  2494  
 3.75 10.8%  17.4%  1544  2449  1459  1968  1383  1867  
 
This has been adjusted for 10% total loss to follow -up (LFU) and non- TB death by 3 
years which has been modeled as an exponential competing risk, and for interim 
monitoring (2% increase by multiplication).  
 
 53 A5279 
FINAL Version 2.0  
  08/28/14  
 
Given substantial issues of adherence,  which can lead to drug resistance, failure to 
complete the full 9 months of INH, and cost in use of 9- INH in clinical practice, the team 
feels an incidence rat e of 3.25/100 PY as the tolerance boundary for evaluation of short -
course RPT/INH would be acceptable. This leads to a sample size of around 2452 
participants . The team proposes to accrue 3000  participants to allow essential 
subgroups , such as the CD4+ cel l count and ART strata , to be evaluated with some 
degree of cer tainty. Should a stratum break 60:40, with 3000 participants, there is 80% 
power (2- sided alpha=0.05) to test non- inferiority within the larger  stratum with the same 
3.25/100  PY tolerance. With the larger sample size, the confidence bounds on the 
difference in the TB incidence rate between the arms in the full study will be narrower 
than required to rule out the tolerance of TB incidence of 3.25/100 PY. Thus, should the 
true difference be much s maller, this can be detected to inform the field.  
 
When setting the tolerance region for a study such as this, an important consideration is 
whether the tolerance region is therapeutic. Section 2.1 contains a table of studies 
reporting placebo arm TB inci dence rates in studies in HIV -infected individuals. A5279 
requires PPD or IGRA positivity or residence in an area with a high TB burden. This 
table presents the 3-  and 5- year percentages of active TB for a range of incidence rates 
for active placebo in par ticipants who were PPD+ or who were PPD+/ - in a country with 
a high TB burden.   
 
 Rate/  
100PY  Active TB 
Percent  
  3yr %  5yr %  
    
Placebo    5.00 14.3%  22.6%  
  8.00 22.1%  34.1%  
10.00  27.1%  41.0%  
 
The targeted tolerance region for this study demons trates a considerable reduction in 
active TB compared to the reported rates with placebo. It should also be remembered 
that the tolerance region represents the limits of a 95% CI ; that is, if noninferiority is 
confirmed, the ac tual observed rate in the sho rt-course regimen will be substantially less 
than the tolerance boundary.   
 
9.5 Monitoring 
 
This study will be reviewed at least annually by the NIAID African DSMB. For all reviews, 
the DSMB will be provided detailed information on safety (including mortality and 
regimen tolerability) and administrative aspects (screening failures, accrual, compliance 
with visits, specimen collection , and participant retention).   
 
We anticipate the first efficacy analysis will be performed at approximately the second 
annual review. Should accrual initiate rapidly, the review may be accelerated to ensure 
the DSMB  has considered early information on the rates of active TB before accrual 
closes. Especially early in the study, an important function of the DSMB  will be to 
consi der the consistency of the magnitude of event rates with the design assumptions. 
The timing of subsequent efficacy reviews will be decided in conjunction with the DSMB . 
 54 A5279 
FINAL Version 2.0  
  08/28/14  
 
A Peto use function will be employed for formal between- arm comparisons.   
  
The primar y focus of this study is relatively long -term outcomes. The team urges caution 
in considering early stopping or release of information on this study, especially if interim 
results  are based on short follow -up. The team suggests that the following guidance be 
considered in deliberations:  
 
• If there is early evidence of the noninferiority of short -course RPT/INH, the team 
intends that the study continue to full accrual and follow -up to confirm that long- term 
results are consistent with early evidence, and to evaluate the poss ible superiority of 
short -course RPT/INH.   
• If the 99.9% CI at early interim analysis excludes an IRD of 0.00/100PY in favor of 
the RPT arm (i.e. , early evidence of the superiority of RPT), the team intends that the 
study  continue to full ac crual and follow -up to confirm that long- term results are 
consistent with early evidence.  
• If the 99.9% CI at early interim analysis excludes an IRD of 0.00/100PY in favor of 
the 9 -INH arm, the team intends that the study continue with close monitoring.  
• If the 99.9% CI at interim analysis excludes an IRD of 1.25/100PY suggesting the 
RPT arm is significantly worse than the allowed tolerance boundary, the team 
intends that consideration be given to stopping the study.  
 
Reports on safety will be provided to the DAIDS Clinical Representative every 6 months. 
In addition, periodic reports of data pooled over arm will be provided to the team that 
detail accrual, participant status, and the delinquency of forms and specimens. The 
study co- chairs will receive pooled safety information periodically. The form and 
schedule of these will be detailed in the Monitoring Plan to be developed by SDAC, the 
DMC , and the team. Some secondary objectives will not be evaluated until the end of 
the study either because they are based  on subgroups that will be identified 
retrospectively or because they are not related to safety or the primary outcomes, but 
study monitoring will include assessment of the availability of data needed for identified 
analyses (eg, isolates from prophy laxis failures).  
 
The team will conduct monitoring for EFV and NVP PK as described in Section 10.0.  
 
9.6 Analyses  
 
Primary  
The primary objective will be evaluated by calculating a CI  around the difference 
between the observed TB incidence rates  with the confidence level adjusted for 
stratification and interim monitoring. Data from prior studies are consistent with a 
constant TB rate , but this will be confirmed in these data. If this assumption does not 
hold, other methods will be employed (e.g., piece -wise models ) to confirm whether non-
inferiority holds or not over the time frame of the study. As noted above, deaths 
attributed to TB will be considered to be endpoints. Deaths attributed to causes other 
than TB will be censored. Deaths from unknown causes are expec ted to be minimal. For 
the primary analysis, deaths from unknown causes will be coded as TB events. 
Sensitivity analyses will include censoring all deaths from unknown causes, including all 
nontraumatic deaths as events, and use of weighted modeling that a ttributes portions of 
 55 A5279 
FINAL Version 2.0  
  08/28/14  
 
deaths from unknown causes to be due to TB or non- TB causes based on predictors of 
COD in deaths with known COD.  
 
This is functionally a strategy study, comparing 9 months of treatment to an ultra -short -
course. While strict intention- to-treat (ITT) analyses are preferred in classical superiority 
studies, they can bias noninferiority studies to erroneously confirm noninferiority if non -
compliant participants in both arms dilute the treatment difference. However, in this 
study, clinical practice in long -term INH prophylaxis suffers from noncompliance both in 
terms of adherence and also drop- off. A 9-INH arm that includes participants with non-
adherence and courses that are shorter than 9 months is the true comparator arm. Thus, 
for this noninferiority study, the ITT analysis will be primary. An ‘as treated’ analysis 
confined to those with pre- specified adherence levels and/or full course treatment ( we 
anticipate poorer adherence in the 9- INH arm) will be performed for exploratory 
purposes.  
 
We will also perform multi -covariate analyses of predictors of active TB.  As required by 
NIH, interactions of gender and race/ethnicity with treatment will be formally tested and 
presented. As noted above, we will evaluate the noninferiority of short -course RPT/INH 
within the CD4 + cell count  and ART strata as differences could be important to inform 
the field. There will be no adjustment to the alpha level for multiple comparisons, and 
results will be presented cautiously.   
 
Secondary  
Safety analyses wi ll consider the rates and nature of SAEs and of Grades 3 and 4  
events , treatment modifications including temporary holds , and treatment 
discontinuations. These will be analyzed as dichotomous measures (percent of 
participants who meet a given event criteri on), failure time measures (eg, time to first 
treatment modification; time to first safety event ), and counts (eg,  number of combined 
SAE + Grade s 3 and 4  events per person).  
 
Overall mortality and non -TB mortality, including all deaths as events and possi bly 
censoring traumatic death, will be evaluated with log rank tests stratified by CD4+  count 
and ART use. If there are sufficient deaths, proportional hazards modeling will be 
performed to evaluate risk factors.  
 
Adherence will be evaluated with the resul ts of self -report interview s and pill counts. 
Associations of adherence and outcome will be explored using pre- defined levels of 
adherence. We will also explore whether there are adherence differences between the 
arms during the first month when both arms receive active intervention.   
 
The rate and pattern of antibiotic resistance among participants who are diagnosed with 
active TB will be described. Should active TB rates be around 2.00/100 PY in each arm, 
there will be about 8% TB overall on the study or  240 cases which will provide some 
opportunity to compare the rates of resistance, patterns of antibiotics to which the MTB 
organisms are resistant, and time trends in resistance.  
 
An exploratory analysis among participants in the PK study (see Section 10.0) will 
evaluate the association of HIV virologic outcomes (eg, ‘blips’, confirmed loss of virologic 
 56 A5279 
FINAL Version 2.0  
  08/28/14  
 
control) and safety with both the directly observed concentrations of EFV  and NVP and 
also the trough antiretroviral  levels and select PK parameters (eg, AUC) derived from the 
Bayesian modeling. The EFV and NVP parameters will be evaluated both as continuous 
measures and also dichotomized at 1 mg/L (EFV) and 3 mg/L (NVP), levels that define 
acceptance in Section 10.0.  
 
9.7 Cost-Effectiveness Analysis  
 
A previously described model of LTBI treatment will be used to estimate the costs and 
cost-effectiveness of RPT/INH as compared with other treatment strategies and no 
treatment [66]. Efficacy, adherence, and toxicity data for RPT/INH will be obtained from 
the trial, with other parameters taken from the available literature. The underlying 
probability of activation will be varied using a risk multiplier to simulate various high -risk 
populations not included in the study (HIV -negative contacts, diabetes mellitus, end -
stage renal disease, etc.).  
In the best -case scenario, costs for treatment of LTBI and active TB will be based on 
current U.S. practice. Because the costs of treating LTBI and active TB in most high-
incidence areas are largely unknown, we will make cer tain assumptions and then 
perform a sensitivity analysis over a wide range of estimates.  
 
Costs and cost -effectiveness (measured in cost per quality -adjusted life -years) will be 
calculated for all regimens. Analysis will focus on determining thresholds for  cost, 
efficacy, and adherence parameters above (or below) which the optimal strategy 
changes. Calculations will be repeated for other simulated high -risk populations to inform 
public health policy on the appropriate use of the new regimen in various TB control 
programs.  
 
 
10.0 PHARMACOLOGY PLAN  
 
10.1 Pharmacology Objectives  
 
10.1.1  Primary: To investigate the effects of concomitant  RPT/INH administration on 
EFV or NVP PK  and assess these concentrations relative to baseline values and 
historical controls wi th and without RIF , and accepted minimal effective EFV and 
NVP concentrations .  
 
For this study, the historical control for EFV PK data will be from the 
pharmacology substudy conducted as part of A5095. This study population 
consisted of HIV -infected persons who were treatment -naïve with plasma HIV 
RNA levels >400 copies/mL and not receiving concomitant agents that interact 
with EFV. The first choice for historical control data for NVP, like EFV, will be 
from ACTG studies. One published population PK study of NVP is from ACTG 
241, a study in HIV -infected persons  who also received ZDV and ddI [67].   
 
10.1.2  Secondary: To investigate the PK of RPT.   
 
 57 A5279 
FINAL Version 2.0  
  08/28/14  
 
10.1.3  Secondary: To investigate relationships among genetic characteristics of drug 
metabolizing enzymes and drug t ransporters and the PK characteristics of EFV, 
NVP, and RPT.   
 
10.1.4  Determine the PK characteristics of EFV and its 7 -OH-EFV and 8 -OH-EFV 
metabolites when given in combination with RPT+INH (Arm A) and when 
given with INH alone (Arm B).  
 
10.1.5  Compare EFV PK data obt ained from combination therapy with RPT+INH 
and INH alone with a control group consisting of a set of plasma samples 
with participants receiving ART containing EFV but not RPT or INH, which 
will be collected from individuals in Arm A that have completed RP T/INH 
therapy and have allowed for a washout period.   
 
10.2 Pharmacology  Study Design  
 
The pharmacologic evaluations are designed to provide information on whether RPT , 
because of its CYP3A -inducing properties, decreases the concentrations of the NNRTIs, 
EFV and NVP, which are both substrates for CYP3A. The hierarchy for rifamycin 
enzyme- inducing potency is: RIF  > RPT > rifabutin (RFB) . RIF reaches maximal enzyme 
induction at a dose of 600 mg once daily. RPT  enzyme induction exhibits dose 
dependency. At a R PT dose of 600 mg once daily, the enzyme induction appears close 
to that of RIF at 600 mg once daily; lower RPT  doses of 300 mg once daily or 600 mg 
every 3 days produce less enzyme induction than RPT at 600 mg once daily and RIF at 
600 mg once daily [ 30]. There is considerable information on the PK of EFV and NVP 
when given with RIF ; there are no data available on the effect of RPT  on the PK of EFV 
and NVP. The pharmacologic evaluations for A5279 are designed to provide data on the 
effects of RPT  on the PK of EFV and NVP.   
  
The effect of RPT on the PK of EFV was evalua ted before participants on NVP 
were allowed to enroll into this study. The A5279 team review ed the EFV PK data 
on an on -going basis, as described in section 10.3. Since these data show ed 
adequate EFV exposure in the presence of RPT treatment, the study is  open to 
participants on NVP, and NVP PK will be evaluated in the first 90 participants in 
Arm A taking NVP at entry. NVP PK will be evaluated in a similar manner as the 
EFV PK analysis was c onducted.  
 
Data are accumulating to suggest that INH affects EFV clearance primarily 
through the CYP2A6 pathway. The effect of RPT on EFV clearance is expected to 
occur through induction of the CYP2B6 pathway. Each of these two pathways 
leads primarily to different metabolites of EFV. The 8- hydroxy -efavirenz metabolite 
is the primary metabolite formed via the CYP2B6 pathway, while the 7- hydroxy -
efavirenz metabolite is the primary metabolite formed via the CYP2A6 pathway. 
Therefore, quantitation of these met abolites of EFV will allow investigation of the 
separate effects of RPT and INH on EFV metabolism.   
 
At the implementation of Version 2.0:  
1. EFV concentrations will be evaluated in an additional 30 participants from Arm 
 58 A5279 
FINAL Version 2.0  
  08/28/14  
 
A. These 30 participants will serve a s controls for the EFV analysis. A PK 
sample will be collected in these 30 individuals at weeks 0, 2,  and 4 similar  to 
 the other EFV PK analysis; however, an additional week 16 sample will be 
collected as an “EFV only” sample. The week 16 sample will allo w for a 
washout period after completion of RPT and INH.  
 
2. Additional pharmacologic assessments will be made in Arm B (INH only) to 
investigate the effect of INH on EFV metabolism.  Arm B participants receive 9 
months of daily INH therapy. Pharmacologic eval uations, similar to those 
performed in the first 90 participants in Arm A, will be made in the first 90 
subjects in Arm B who are taking EFV at entry at the time of implementation of 
protocol V ersion 2.0. These PK assessments will take place at weeks 0, 2,  and 
4, as they are in Arm A. EFV and its major metabolites, 7- OH-EFV and 8- OH-
EFV will be quantified in human plasma. Concentrations of EFV  and its 
metabolites will also be determined from the samples already collected from 
first 90 participants  in Arm A.  The addition of these assessments from Arm B 
patients will allow the team to better understand what role each of the anti -
tuberculosis drugs, INH and RPT, individually have on EFV metabolism. At 
present , there are no such data available.  
 
A sparse sampli ng approach will be used in A5279. The rationale for this approach is 
based on the following considerations. First, data exist on the PK of EFV and NVP in 
HIV-infected participants with and without concomitant RIF  administration  [67; 68, 69, 
70]; unpublished data from ACTG studies A5095/A5097s and A5221 ]. Second, RPT at a 
dose of 600 mg/day is not expected to produce enzyme induction any greater than that 
of RIF 600 mg/day [ 29]. Therefore, third, if RPT  indeed reduces EFV and NVP 
concentrations, this reduct ion should not be greater than that observed with RIF . These 
considerations allow a sparse sampling approach (versus an intensive dose- interval PK 
study) to investigate whether EFV and NVP concentrations in the presence of RPT  are 
more comparable to histor ical controls who are receiving RIF , or to historical controls 
who are not receiving RIF . 
 
Exposure- response relationships between EFV and NVP concentrations and virologic 
failure have been demonstrated. For example, Cohen recently reported that in an 
evaluation of 142 HIV -infected persons, EFV concentrations <1 mg/L were strongly 
associated with an increased risk for virologic failure (odds  ratio 12.5, 95% CI, 2.7 -57.3) 
[69]. The collective data for EFV indicate an increased risk of virologic failure if tr ough 
(or mid -interval) concentrations are less than 1 mg/L. EFV PK data from A5097 indicate 
that 21% of participants receiving the standard dose of EFV had trough concentrations 
less than 1 mg/L. These data provide a basis to select for this study that the  proportion 
of participants who have trough concentrations less than 1 mg/L when EFV is combined 
with RPT  is not greater than 20% . Several investigations have found relationships 
between low NVP trough concentrations and an increased risk of virologic fail ure. de 
Vries -Sluijs reported a 5- fold increased risk of virologic failure in participants who had 
NVP trough concentrations less than 3 mg/L. A NVP trough of less than 3 mg/L is the 
present consensus threshold for an increased risk of virologic failure [71]. In adults 
receiving the usual NVP dose of 200 mg twice daily, the proportion of participants who 
are expected to have concentrations less than 3 mg/L appears to range from 7% to 25%. 
 59 A5279 
FINAL Version 2.0  
  08/28/14  
 
These data form a basis, like that for EFV, that proportion of  partic ipants with trough 
NVP concentrations less than 3 mg/L  is not greater than 20% .   
 
Differences among patients in their PK characteristics of EFV, NVP , and RPT are known 
to arise as a result of differences in genes that encode for drug -metabolizing enzymes 
and drug transporters. Because PK variability has been associated with differences in 
drug response, understanding whether the differences in concentrations has a genetic 
basis in how the drug is metabolized, or a non genetic basis (e.g., patient medication 
adherence)  is important to understand the treatment outcomes of A5279. Participants 
will be asked to provide informed consent to study polymorphisms in host genes 
involved in metabolism or transport of EFV, NVP and RPT. Consent for genetic testing is 
optional, and a participant may refuse genetic sampling and still participate in the study. 
The genes of interest for A5279 are: CYP2B6, CYP3A4/5, SLCO1B1, CYP2A6, 
UGT2B7, PXR (pregnane X receptor), CAR ( constitutive androstane receptor ), and 
HFN4A (hepatocyte nuclear factor).   
 
1. EFV Sample Size: 90 participants receiving EFV and RPT/INH (Arm A)  sampled at 
weeks 0, 2, and 4.  
 
Version 2.0 will also include the following EFV evaluations:  
 
a. 30 additional participants receiving EFV from Arm A  sampled at weeks 0, 2,  
4, and 16, to serve as controls  
b.  90 participants receiving EFV and INH (Arm B)  sampled at weeks 0, 2, and 4.  
 
2. NVP Sample Size: 90 par ticipants receiving NVP and RPT/INH (Arm A) sampled at 
weeks 0, 2 , and 4.  
 
3. EFV Sampling Strategy  
The sampling strategy for  EFV assumes that EFV doses will be taken in the evening.  
Blood samples for quantitation of EFV will be obtained at three study visits: entry 
(prior to the start of RPT and INH, Arm A) and the week s 2 and 4 study visits . The 
control participants from Arm A (n=30), who will be enrolled with Version 2.0, 
will have an additional PK sample obtained at week 16 , in addition to weeks 0,2 
and 4.  One blood sample will be obtained at each visit . With the dose taken the night 
before, this sample should be approximately 12 hours post dose, but should not be 
drawn any sooner than 10 hours after the previous evening’s dose or any later than 
24 hours after the dose.  
 
If the study participant is taking EFV in the morning, the participant should change to 
evening dosing for  the PK studies. After completion of the week 4 PK study, the 
participant may then change back to morning dosing , with the excepti on of 
controls  who should wait until after the week 16 sample has been drawn to 
change their dosing time.  The following schedule may be used for the conversion 
from morning to evening dosing.  
 
Entry Day -4 Four days prior to the entry (week 0) PK visit, the morning 
dose should be taken as usual.  
 60 A5279 
FINAL Version 2.0  
  08/28/14  
 
Entry Day -3 Three days prior to the entry visit and the pre -RPT PK sample, 
a morning dose should be taken as usual.  Additionally on this 
day, a bedtime dose should be taken; this dose will be taken 
approximately 12 hours after the morning dose.  
Entry Day -2 NO morning dose should be taken. A bedtime dose of EFV 
should be taken.  
Entry Day -1 A bedtime dose should be taken.  
   
Entry/PK Study 
Day 0  Blood samples for the PK study will be taken as described 
above. A bedtime dose of EFV should be administered. The 
bedtime dosing schedule for EFV should be maintained 
through the week 4 PK sa mple , or week  16 for the controls .   
+1 day after week 
4 (or 16 in a 
subset) PK A morning dose of EFV should be taken; this dose will be 
approximately 12 hours after the evening dose given on Study 
Day 0. NO bedtime dose should be taken.  
+2 day after wee k 
4 (or 16 in a 
subset) PK The participant’s usual dosing schedule for EFV should be 
resumed.  
 
4. NVP Sampling Strategy  
The sampling strategy for NVP assumes twice daily administration with one dose in 
the morning  and one dose in the evening.  Blood samples f or quantitation of NVP will 
be obtained at three study visits: entry (prior to the start of RPT and INH, Arm A) and 
the week s 2 and 4 study visits. One blood sample will be obtained at each visit. This 
sample should be obtained before the morning dose of N VP is administered, and 
thus should be approximately 12 hours after the prior evening’s dose. This sample 
should not be taken any earlier than 10 hours or later than 14 hours after the prior 
dose.   
 
5. Medication Adherence  
In all cases, the time s and dates  of all doses of RPT and either EFV or NVP taken in 
the previous 3 days must be recorded on the CRF. Samples should not be collected 
from participants who have missed any doses of RPT and EFV, or NVP within 3 days 
prior to the study visit.  
 
6. EFV, 7-OH-EFV, 8 -OH-EFV, and NVP Quantitation 
EFV,  7-OH-EFV, 8 -OH-EFV, and NVP concentrations will be determined in a  Clinical 
Laboratory Improvement Amendments ( CLIA )-certified laboratory. The goal is for 
EFV and NVP concentration information from the entry and week s 2 and 4 (and 16 
in a subset) samples to be available for evaluation by the A5279 team  during the 
course of the study . 
 
7. RPT PK  
At the time that a blood sample is obtained for EFV or NVP at the week s 2 and 4 
visits, an additional blood sample will be obtained f or RPT. RPT has an approximate 
15-hour half -life which allows sampling at the same time that samples are collected 
for EFV or NVP.  
 
 61 A5279 
FINAL Version 2.0  
  08/28/14  
 
8. Pharmacogenetics.  
An optional blood sample for genetic testing of variations in drug metabolizing 
enzymes and drug transport ers for EFV, NVP,  and RPT will be collected at the entry 
visit (prior to the start of RPT and INH)  from participants who are also having an 
entry sample obtained for measurement of either EFV or NVP. If this sample is not 
collected at entry, it may be coll ected at week 2 or 4.   
 
10.3 Primary and Secondary Data, Modeling, and Data Analysis  
 
1. The EFV PK data  will be  judged acceptable if we have evidence that >80% of 
participants have EFV concentrations ≥1 mg/L.  
 
2. The NVP PK data will be judged acceptable if we have evidence that >80% of 
participants have NVP concentrations ≥3 mg/L.   
 
Any participant who has a baseline (pre- RPT) sample or a week 2 or 4 sample in 
which the concentration for the relevant ARV is below the limit of quantitation will be 
deemed to be non- adherent , and the PK data will not be evaluable. The observed 
concentrations of EFV and NVP and the times post dose that these concentrations were 
obtained will be summarized. In addition, because exact trough levels (pre- dose 
concentrations) are not requir ed to be obtained, the PK characteristics of EFV and NVP 
may be estimated for each individual participant and trough concentrations estimated 
using these EFV and NVP PK parameters. Parameter estimation will be accomplished 
using Bayesian estimation methods  implemented in ADAPT II (Biomedical Simulations 
Resource at the University of Southern California, Los Angeles, CA). This approach 
utilizes maximum a posterior Bayesian estimation (MAP) to estimate individual PK 
parameters utilizing prior information for the population mean and variances of the PK 
characteristics of EFV. Prior PK data for EFV indicate that its PK characteristics are 
sufficiently well described with a 1- compartment structural model. A proportional 
variance model will be used to describe the  output error associated with the 
concentration- time data (variance model). Each observation will be inversely weighted 
by the model -based estimated variance (of the corresponding predicted value), 
assuming the variance is proportional to the predicted val ue and coefficient of variation 
of 10% for the assay. The primary estimated PK parameters will include the volume of 
the distribution (V), and elimination rate constant (k e). Apparent oral clearance (CL/F), 
elimination half -life (T 1/2), and AUC will be cal culated from these parameters using 
standard equations.  
 
The team wishes to detect any issues that might exist with EFV or NVP 
concentrations very early in accrual of participants receiving these ARVs.  The 
team will assess the proportion of participants w ho have acceptable (as defined above) 
EFV and NVP concentrations up to four times  during the study for EFV and NVP 
separately. The first phase of the evaluation will be conducted in the first 31 
evaluable participants who are distributed across key geographic regions, 18 
years or older, and receiving an ARV.  The second phase assessment will be made 
when trough levels are available for a total of  approximately 90 evaluable participants at 
weeks 2 and 4. Samples in the first phase (first 31 evaluable participants who are 
18 years or older) will be shipped and assayed frequently to facilitate rapid 
 62 A5279 
FINAL Version 2.0  
  08/28/14  
 
evaluation and decision making in this early phase. Should early accrual of 
participants receiving EFV or NVP be so rapid that a substantial number of the 90 
would b e entered before the first 31 who are 18 years or older can be evaluated, 
accrual of participants receiving that ARV may be suspended pending results of 
the first phase assessment. Accrual of participants receiving that ARV would be 
resumed if the results in the first phase were acceptable.  
 
The first phase assessment will be conducted in 2 or 3 stages depending on the 
rate of accrual of evaluable participants. Accrual for the PK evaluation may pause 
within the first phase for evaluation of data, such as adherence or the metabolizer 
and transporter genes noted above, should early results be of concern. Assuming 
the first phase is conducted in three stages, the first evaluation for each agent will 
be made when weeks 2 and 4 trough levels are available for 9 evaluable 
parti cipants; if ≤4 of the 9 have acceptable ARV levels at both weeks 2 and 4, the 
team would consider this to be of concern. The second evaluation will be made 
when weeks 2 and 4 trough levels are available for 21 evaluable participants; if 
≤12 of the 21 have acceptable ARV levels at both weeks 2 and 4, the team would 
consider this to be of concern. The third evaluation will be made when weeks 2 
and 4 trough levels are available for 31 evaluable participants; if ≤20 of the 31 
have acceptable ARV levels at both weeks 2 and 4, the team would consider this 
to be of concern. This rule was developed to have a high likelihood (95% or 
higher) of continuing to accrue participants if the true underlying rate of having 
acceptable ARV concentrations is greater than 80% and meets both Optimum and 
Min/Max criteria [72; conducted with PASS 2011] . Should accrual of participants 
receiving an ARV be so rapid that the first phase evaluation with 21 participants 
would be uninformative, it will not be performed and the first and thi rd evaluation 
rules will apply: ie, the team would be concerned if ≤4/9 or ≤20/31 participants 
have acceptable ARV levels.   
 
The following table provides overall probabilities that ARV levels will be found 
acceptable in the first phase assessment  for a range of values for the true 
underlying proportion who fail to have acceptable ARV levels at weeks 2 and 4. 
These probabilities are provided for the 3 -stage and 2 -stage options in the first 31 
evaluable participants.  
 
Underlying rate  
Failing criteria  Prob fi nding  
Acceptable  
3-stage  Prob finding  
Acceptable 
2-stage  
0.20 0.951  0.954  
0.40 0.225  0.221  
0.45 0.096  0.098  
0.50 0.033  0.033  
0.60 0.001  0.002  
 
That is, if the true probability of failing to meet the ARV level is 20% (so greater 
than 80% having accep table drug levels), there is greater than 95% likelihood of 
finding the drug levels at weeks 2 and 4 to be acceptable. If, however, the true 
probability of failing to meet the ARV level criterion is 45% (so showing evidence 
 63 A5279 
FINAL Version 2.0  
  08/28/14  
 
that the true rate achieving acceptable levels might be only 55%), there is less 
than a 10% chance of erroneously concluding the drug levels at weeks 2 and 4 to 
be acceptable in the first 31 evaluable participants. This design has very low 
likelihood of failing to detect very high probabilities of low drug concentrations, 
and we will be conducting a second phase assessment in 90 participants that will 
have a high likelihood of detecting true smaller proportions with unacceptable 
drug levels. As noted above, PK samples in the first 31 part icipants will be 
assayed rapidly; should the pharmacologists note early issues before an 
assessment stage is accrued (e .g., if it becomes clear before 9 participants have 
data that only 4 or fewer evaluable participants will have acceptable drug levels), 
the A5279 core team will be notified. Of note, the 3-  and 2 -stage designs have very 
similar probabilities of finding various proportions acceptable; however, the 3 -
stage design provides an earlier time point to detect unacceptable levels should 
the accrual rate be modest.   
 
The second phase assessment will include all 90 participants with detectable ARV 
levels at baseline and weeks 2 and 4, and will also consider all participants with a 
detectable level at baseline. The primary evaluation will consist of constructing a 
lower 95% confidence interval (CI) on the proportion of participants who have 
acceptable drug levels at both weeks 2 and 4. The CI in all 90 will not be adjusted 
for the first phase assessment as the first phase is conducted only in those 18 
years of age or older. If the first 31 were a true subset of all 90, adjustment for the 
multi -phase (with 2 or 3 stages in the first phase) would ‘shift’ the lower 95% CI on 
the observed success rate upward in a more favorable direction. Thus, not making 
an adjustment in all 90 is conservative. We will confirm this by constructing an 
adjusted CI for the proportion who have acceptable drug levels in all participants 
18 years or older among the 90 in the primary analysis.  
 
The team may also apply a bioequival ence approach for an evaluation of the baseline 
(pre-RPT) and the weeks 2 and 4 samples. This approach will evaluate whether the 90% 
CIs of the ratios of plus RPT trough concentrations of EFV and NVP relative to the 
baseline (or no RPT) troughs are contained within a specified no effect boundary. The 
usual FDA no effect range is 0.80 to 1.25. However, where exposure- response data 
exist, these data may be used to establish the no effect boundary. The threshold troughs 
for EFV and NVP, which have clinical support, could be used as these no-effect 
boundaries. If the 90% CI for exposure ratios fall s entirely within the equivalence range 
we could conclude that a clinically significant effect of RPT on EFV and NVP is not 
found.  
 
Prior to the  implementation of V ersion 2.0 of the protocol, t he A5279 team 
reviewed the EFV PK data, as described in section 10.3. Since these data showed 
adequate EFV exposure in the presence of RPT treatment, the study wa s opened  
to participants on NVP, and NVP PK will be evaluated in the  first 90 participants in 
Arm A taking NVP at entry. NVP PK will be evaluated in a similar manner as the 
EFV PK analysis was conducted.  
 
Relationships between concentrations of EFV , its 7 and 8 hydroxy metabolites, 
and patient -specific genetic status will be gathered. The 7- hydroxy metabolite of 
 64 A5279 
FINAL Version 2.0  
  08/28/14  
 
EFV is predominantly formed via the CYP2A6 pathway whereas the 8 -hydroxy 
metabolite is formed via the CYP2B6 pathway. Metabolite profiles will yield insight 
into which pathway is the dominant metabolizing pathway in genetic subsets of 
individuals taking EFV and INH  ± RPT. Additionally, analyzing metabolite profiles 
will separate the interactions of INH and RPT with EFV. Geometric mean ratios 
(GMR) will be developed for estimated clearance values for the populations i n 
each study arm. The GMR of EFV clearance from the control group of participants  
on EFV (no RPT or INH) to the clearance of those participants on Arm B (INH) of 
the study will give the field important insight into what effect INH has on EFV 
clearance.  CY P2A6 status will be defined as a covariate for this analysis. 
Secondly, a GMR for control (EFV only) to Arm A (RPT+INH) participants’ 
clearance will be developed.  From this data , we will be able to test whether the 
induction effects of RPT on CYP2B6 are negated by INH inhibition of CYP2A6, and 
what the overall effect on EFV metabolism is, again using participants’  genotypes 
as covariates for the analysis. The control EFV participants will be established 
from a set of participants in Arm A on EFV containing regimens. These 
participants  will serve as the EFV only controls and will have a PK sample drawn 
at weeks 0,  2, 4, and additionally week 16.   
 
Pharmacodynamic  (PD) Modeling    
For this analysis, the PK characteristics of EFV and NVP will be evaluated using  
NONMEM version V (GloboMax, Hanover, MD), which uses mixed effects (random and 
fixed) regression to estimate population means and variances of PK parameters and to 
identify patient characteristics (covariates) that may influence these parameters. Base 
models will be developed using first -order conditional estimation with interaction (FOCE -
I). A stepwise procedure will be used to determine whether a 1 - or 2-compartment model 
best fits the plasma data under the principle of parsimony. An exponential error 
distribution will be assumed for the description of both interpatient and intrapatient 
(residual) PK parameter variability. Residual error will be modeled as an additive plus 
proportional error model. If necessary, poorly identified structural parameters, such as 
the absorption rate constant, may be fixed to usual adult values. Covariates including 
sex, age, weight , race, and genetic characteristics of drug metabolizing enzymes and 
transporters  will be investigated. The influence of each covariate on the PK 
characteristics of EFV and NVP will be tested sequentially. At the end of the analysis, all 
covariates that show an influence on the parameters will be evaluated again by 
comparison of the full model (with all factors included) with a model from which each of 
the factors is deleted sequentially. NONMEM uses extended least squares to calculate 
the objective function and the difference in the value of the objective function between 
models is approxim ately chi squared distributed. A difference in objective func tion of 
greater than 6.6 is considered significant (6.6 corresponds to a chi square for p=0.01 
with 1 degree of freedom) when one parameter is added or the covariate (e.g., body 
weight, HIV -1 RNA) is replaced. This is analogous to the commonly used F test to select 
among regression models. The outcome of this analysis is to identify the model that best 
describes the plasma PK of EFV and NVP, and to investigate whether any patient 
characteristics influence the PK of these antiretroviral agents. Following finding the 
model that best describes the plasma PK characteristics of EFV and NVP, we will next 
develop a linked PK and PD model to investigate relationships among the PK 
parameters of EFV and NVP, and virologic response (or loss of response) and measures 
 65 A5279 
FINAL Version 2.0  
  08/28/14  
 
of safety and tolerance such as liver function tests. These PD models may be in the form 
of a linear or a sigmoid E max relationship where, for example, lower EFV concentrations 
are related to detectable levels of HIV -1 RNA in plasma.   
 
RPT PK  
The observed concentrations of RPT and the times post dose that these concentrations 
were obtained will be summarized. The concentration data will be evaluated for evidence 
of adherence to RPT. Additionally, a population PK analysis using an approach as 
described above for EFV and NVP may be performed. Finally, RPT concentration 
information may be used in the evaluation of the primary (efficacy) and secondary 
(safety, adherence,  and resistance) endpoints of the A5279 study.   
 
10.4 Anticipated Outcomes  
 
At present, ther e are no data on the PK of EFV or NVP when combined with RPT. These 
PK evaluations will provide information on EFV and NVP concentrations when given 
concomitantly with RPT and whether the proportion of participants who have EFV or 
NVP concentrations less t han the accepted minimum values is higher than observed in 
participants taking EFV and NVP without inducers of drug metabolism. Information will 
be obtained as to whether host genetic differences contribute to differences among 
participants in EFV, NVP , and RPT concentrations. The pharmacologic data from A5279 
should provide guidance as to whether a significant drug -drug interaction exists that 
would warrant further evaluation, or in the absence of such a signal, information for 
clinicians that EFV and NVP may be combined with RPT.   
 
 
11.0 DATA COLLECTION AND MONITORING AND ADVERSE EVENT  REPORTING  
 
11.1 Records to Be Kept  
 
CRFs  will be provided for each participant . Participant s must not be identified by  name 
on any CRFs. Participant s will be identified by the patient identification number (PID) 
and study identification number (SID) provided by the ACTG DMC  upon randomization.  
 
11.2 Role of Data Manageme nt 
 
11.2. 1 Instructions concerning the recording  of study data on CRFs will be provided by 
the ACTG DMC . Each CRS  is responsible for keying the dat a in a timely fashion . 
 
11.2.2  It is the responsibility of the ACTG DMC  to assure the quality of computerized 
data for each ACTG study. This role extends from protocol development to 
generation of the final study databases.  
 
 66 A5279 
FINAL Version 2.0  
  08/28/14  
 
11.3 Clinical Site Monitoring and Record Availability  
 
11.3.1  Site monitors under contrac t to the NIAID will visit participating CRSs  to review 
the individual participant  records, including consent forms, CRFs, supporting 
data, laboratory specime n records, and medical records (physicians’ progress 
notes, nurses’ notes, individuals’ hospital charts), to ensure protection of study 
participant s, compliance with the protocol, and accuracy and completeness of 
records. The monitors also will inspect sit es’ regulatory files to ensure that 
regulatory requirements are being followed and sites’ pharmacies to review 
product storage and management.  
 
11.3.2  The site investigator will make study documents (e.g., consent forms, drug 
distribution forms, CRFs) and pertinent hospital or clinic records readily available 
for inspection by the local IRB  or EC , the site monitors, the U S FDA, the NIAID, 
the OHRP,  and the pharmaceutical supporter or designee, or other government  
agencies  for confirmation of  the study data.  
 
11.4 Expedited Adverse Event  (EAE)  Reporting   
 
11.4.1  AE Reporting to DAIDS  
 
Requirements, definitions , and methods for expedited reporting of AEs are 
outlined in Version 2.0 of the DAIDS EAE Manual, which is available on the R SC 
website at http://rsc.tech -res.com/safetyandpharmacovigilance/ . 
 
The DAIDS Adverse Events Reporting System ( DAERS ), an internet -based 
reporting system must be used for E AE reporting to DAIDS. In the event of 
system out ages or technical difficulties , EAEs  may be submitted via the DAIDS  
EAE Form. For questions about DAERS,  please contact DAIDS -ES at  DAIDS -
ESSupport@niaid.nih.gov . Site queries may also be sent  from withi n the DAERS 
application itself.  
 
Sites where DAERS has not been implemented will submit E AEs by 
documenting the information on the current DAIDS EAE Form. This form is 
available on the RS C website: http://rsc.tech -
res.com/safetyandpharmacovigilance/ . For questions about EAE reporting, 
please contact the RS C (DAIDSRSCSafetyOffice@tech -res.com ). 
 
11.4.2  Reporting Requirements for this Study  
 
The SAE Reporting Category, as defined in Version 2.0 of the DAIDS EAE 
Manual, will be used for this study  from the time of enrollment until 8 weeks after 
the participant permanently discontinues all study agents. After this time, the 
SUSAR Reporting Category will be used.  
 
The study agents for which expedited reporting are required are  rifapentine and 
isoniazid.  
 
 67 A5279 
FINAL Version 2.0  
  08/28/14  
 
11.4.3  Grading Severity of Events  
 
The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events 
(DAIDS AE Grading Table), Version 1 .0, December 2004 (Clarification dated 
August 2009)  must be used and is available on the DAIDS R SC Web site at: 
http://rsc.tech -res.com/safetyandpharmacovigilance/ . 
 
11.4.4  EAE Reporting Period  
 
The EAE reporting period for this study is the entire study duration for an 
individual participant (from study enrollment until study completion or 
discontinuation of the participant from study participation for any reason).  
 
After the protocol -defined AE reporting period, unless otherwise noted, only 
suspected unexpected serious adverse reactions ( SUSARs ) as defined in 
Version 2.0 of the EAE Manual will be reported to DAIDS if the study staff 
become aware of the events on a passive basis ( e.g., from publicly available 
information).  
 
 
12.0 HUMAN PARTICIPANT S 
 
12.1 Institutional Review Board (IRB) Review and Informed Consent  
 
This protocol and the informed consent document (Appendix I ) and any subsequent 
modifications will be reviewed and approved by the IRB or EC responsible for oversight 
of the study. A signed consent form will be obtained from the participant  (or parent  or 
legal guardian  for those below the legal age  of consent ). The consent form will describe 
the purpose of the study, the procedures to be followed, and the risks and benefits of 
participation. A copy of the consent form will be given to the participant , parent, or legal 
guardian, and this fact will be documented in the participant ’s record.  
 
12.2 Participant  Confidentiality  
 
All labo ratory specimens, evaluation forms, reports , and other records that leave the site 
will be identified by coded number only to maintain participant  confidentiality. All records 
will be kept locked. All computer entry and networking programs will be done wit h coded 
numbers only. Clinical information will not be released without written permission of the 
participant , except as necessary for monitoring by ACTG, IRB or EC , NIAID, US  FDA, 
OHRP,  the pharmaceutical supporter  or designee , or other government  agencies.   
 
12.3 Study Discontinuation 
 
The study may be  discontinued at any time by the ACTG, NIAID, IRB or EC , US FDA, 
OHRP, the pharmaceutical supporter , or other government  agencies as part of their 
duties to ensure that research participant s are protected.  
 
 
 68 A5279 
FINAL Version 2.0  
  08/28/14  
 
13.0 PUBLICATION OF RESEARCH FINDINGS  
 
Publication of the results of this trial will be governed by ACTG policies. Any 
presentation, abstract, or manuscript will be made available for review by the 
pharmaceutical supporter prior to submission.  
 
 
14.0 BIOHAZARD CO NTAINMENT  
 
As the transmission of HIV and other blood- borne pathogens can occur through contact 
with contaminated needles, blood,  and blood products, appr opriate blood and secretion 
precautions will be employed by all personnel in the drawing of blood and shipping and 
handling of all specimens for this study, as currently recommended by the CDC and the 
National Institutes of Health.  All dangerous goods materials, including diagnostic 
specimens and infectious substances, must be transported using  packaging m andated 
by CFR 42 Part 72.  
 
Please refer  to instructions detailed in the International Air Transport Association (IATA) 
Dangerous Goods Regulations.   
 69 A5279 
FINAL Version 2.0  
 08/28/14  
 
 15.0 REFERENCES  
 
1. World Health Organization. Global tuberculosis control - epidemiology, strategy, 
financ ing. 2010.WHO Press, Geneva, Switzerland.   
2. Raviglione MC, Harries AD, Msiska R, et al. Tuberculosis and HIV: current status in 
Africa. AIDS 1997; 11 Suppl B:S115- 23.  
3. World Health Organization. Global tuberculosis control - surveillance, planning, 
financing.  2008. WHO Press, Geneva, Switzerland.  
4. Ferebee SH, Palmer CE. Prevention of experimental tuberculosis with isoniazid. Am Rev 
Tuberc 1956;73(1):1 -18 
5. American Thoracic Society and the Centers for Disease Control and Prevention. 
Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir 
Crit Care Med 2000;161:S221- S247.  
6. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv 
Tuberc Res 1970;17:28- 106.  
7. Sutherland I. The ten- year incidence of clinical  tuberculosis following “conversion” in 
2550 individuals aged 14 to 19 years. 1968 TSRU Progress Report (KNCV, The Hague, 
Netherlands).  
8. International Union Against Tuberculosis. Efficacy of various durations of isoniazid 
preventive therapy for tuberculosis : five years of follow up in the IUAT trial. Bull World 
Health Organ 1982;60:555- 64.  
9. Horsburgh CR, Goldberg S, Bethel J, et al. Latent TB infection treatment acceptance 
and completion in the United States and Canada. Chest 2010;137:401 -09. 
10. Markowitz N, Ha nsen NI, Hopewell PC, et al. Incidence of tuberculosis in the United 
States among HIV -infected persons. The Pulmonary Complications of HIV Infection 
Study Group. Ann Intern Med 1997;126(2):123 -32. 
11. Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV 
infected persons.  Cochrane Database Syst Rev.  2010 Jan 20;(1):CD000171.  
12. Quigley M A, Mwinga A, Hosp M, et al. Long- term effect of preventive therapy for 
tuberculosis in a cohort of HIV -infected Zambian adults. AIDS 2001; 15(2):215- 22. 
13. Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent 
tuberculosis infection in HIV -infected adults. AIDS 2001;15(16):2137- 47. 
14. Golub JE, Pronyk  P, Mohapi  L, et al.  Isoniazid preventive therapy, HAART and 
tuberculosis risk in HIV -infected adults in South Africa: a prospecti ve cohort.  AIDS  
2009; 23(5):631 -6. 
15. Samandari T, Mosimaneotsile B, Agizew T, et al. Randomized, placebo- controlled trial of 
6 vs 36 months isoniazid TB preventive therapy for HIV -infected adults in Botswana. In: 
Program and Abstracts of the 17th Conference o n Retroviruses and Opportunistic 
Infections, San Francisco, CA, February 2010; Abstr. 104LB.  
16. Swaminathan S, Menon P, Perumal V, et al. Efficacy of a 6- month versus a 36- month 
regimen for prevention of TB in HIV -infected persons in India: a randomized clini cal trial. 
In: Program and Abstracts of the 17th Conference on Retroviruses and Opportunistic 
Infections, San Francisco, CA, February, 2010; Abstr. 103.  
 70 A5279 
FINAL Version 2.0  
  08/28/14  
REFERENCES (Cont'd)  
 
17. Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazinamide vs isoniazid for 
prevention of tuberc ulosis in HIV -infected persons: an international randomized trial. 
JAMA 2000;283:1445- 50. 
18. Mwinga A, Hosp M, Godfrey -Faussett P, et al. Twice weekly tuberculosis preventive 
therapy in HIV infection in Zambia.  AIDS 1998;18:2447- 57. 
19. Halsey NA, Coberly JS, Desormeaux J, et al. Randomized trial of isoniazid versus 
rifampicin and pyrazinamide for prevention of tuberculosis  in HIV -1 infection. Lancet 
1998;351:786 -92. 
20. Martinson N, Mohapi  L, Bakos  D, et al.  Costs of providing care for HIV -infected adults in 
an urban HIV clinic in Soweto, South Africa.  J Acquir Immune D efic Syndr 
2009; 50(3):327 -30. 
21. Nuermberger E, Yoshimatsu T, Tyagi S, et al. Paucibacillary tuberculosis in mice after 
prior aerosol immunization with Mycobacterium bovis  BCG. Infect Immun 2004; 72:1065 -
1071.  
22. Nuermberger E, Tyagi S, Williams KN, et al. Rifap entine, moxifloxacin, or DNA vaccine 
improves treatment of latent tuberculosis in a mouse model. Am J Respir Crit Care Med 
2005;172:1452 -56.  
23. Schechter M, Zajdenverg R, Falco G, et al. Weekly rifapentine/isoniazid or daily 
rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit 
Care Med 2006; 173:922 -26.  
24. Rosenthal IM, Zhang M, Williams KN, et al. Daily dosing of rifapentine cures tuberculosis 
in three months or less in the murine model. PLoS Med 2007;4:e344.  
25. Rosenthal IM, Zhang M, Almeida D, et al. Isoniazid or moxifloxacin in rifapentine- based 
regimens for experimental tuberculosis? Am J Respir Crit Care Med 2008; 178:989- 93. 
26. Zhang T, Zhang M, Rosenthal IM, et al. Short -course therapy with daily rifapentine in a 
murine model of latent tuberculosis infection. Am J Respir Crit Care Med 2009. 
doi:200905- 0795OC [pii];10.1164/rccm.200905 -0795OC [doi]  
27. Lecoeur HF, Truffot -Pernot C, Grosset JH. Experimental short -course preventive therapy 
of tuberculosis with rifampin and pyrazinamide. A m Rev Respir Dis 1989;140:1189- 93. 
28. Peloquin C, Weiner M, Engle M, et al. Pharmacokinetics of rifapentine in the TB patients 
receiving 600 mg daily. In: Program and Abstracts of the 3rd International Workshop in 
Clinical Pharmacology of TB Drugs. Boston, MA , 2010.  
29. Keung A, Reith  K, Eller MG, et al. Enzyme induction observed in healthy volunteers after 
repeated administration of rifapentine and its lack of effect on steady -state rifapentine 
pharmacoki netics: part I. Int J Tuberc Lung Dis 1999;3:426 -36. 
30. Dooley K, Flexner C, Hackman J, et al. Repeated administration of high -dose 
intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. 
AAC 2008;52(11):4037 -42. 
31. Zvada SP, Van Der  Walt J -S, Smith PJ, et al. Effect of four different meals types on the 
population pharmacokinetics of single dose rifapentine in healthy volunteers.  AAC 
2010;58(8):3390 -4. 
32. Prasad B, Bhutani H, Singh S. Study of the interaction between rifapentine and isoniazid 
under acid conditions. Pharmaceut  Biomed Anal 2006;41:1438- 41. 
 71 A5279 
FINAL Version 2.0  
  08/28/14  
REFERENCES (Cont'd)  
 
33. Weiner M, Prihoda TJ, Peloquin C, et al. Effects of tuberculosis, race, and human gene 
SLCO1BI polymorphisms on rifampin concentrations. Antimicrob Agents Chemother 
2010;54(10):4192 -200. 
34. Keung A, Eller MG, McKenzie KA, et al. Single and multiple dose pharmacokinetics of 
rifapentine in man: part II. Int J Tuberc Lung Dis 1999;3:437 -44. 
35. Kenny MT, Strates B. Metabolism and pharmacokinetics of the antibiotic rifampin. Drug 
Metab Rev 1981;12:159- 218. 
36. Rosenthal IM, Williams K, Tyagi S, et al. Potent twice- weekly rifapentine- containing 
regimens in murine tuberculosis. Am J Respir Crit Care Med 2006;174:94- 101. 
37. Peloquin CA, Jaresko GS, Yong CL, et al. Population pharmacokinetic modeling of 
isoniaz id, rifampin, and pyrazinamide. Antimicrob Agents Chemother 1997; 41:2670- 79. 
38. Almeida D, Nuermberger E, Tasneen R, et al. Paradoxical effect of isoniazid on the 
activity of rifampin -pyrazinamide combination in a mouse model of tuberculosis. 
Antimicrob Agent s Chemother 2009;53:4178- 84.  
39. Dooley KE, Flexner C, Andrade AS. Drug interactions involving combination 
antiretroviral therapy and other anti -infective agents: Repercussions for resource-
limited countries. J Infect Dis  2008;198(7):948 -61. 
40. Lopez -Cortes LF, Ruiz -Valderas R, Viciana P, et al. Pharmacokinetic interactions 
between efavirenz and rifampicin in HIV -infected patients with tuberculosis. Clin 
Pharmacokinet . 2002;41(9):681 -90. 
41. Manosuthi W, Chumpathat N, Chaovavanich A, Sungkanuparph S. Safety and 
toler ability of nevirapine- based antiretroviral therapy in HIV -infected patients 
receiving fluconazole for cryptococcal prophylaxis: A retrospective cohort study. 
BMC Infect Dis . 2005;5:67.  
42. Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Efavirenz levels and 24 -
week efficacy in HIV -infected patients with tuberculosis receiving highly active 
antiretroviral therapy and rifampicin. AIDS . 2005;19(14):1481 -86.  
43. Pedral -Sampaio DB, Alves CR, Netto EM, Brites C, Oliveira AS, Badaro R. Efficacy 
and safety of efavirenz in HIV patients on rifampin for tuberculosis. Braz J Infect 
Dis. 2004;8(3):211 -6. 
44. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) 
with rifampicin results in highly variable levels but excellent clinical outcomes in 
patien ts treated for tuberculosis and HIV. J Antimicrob Chemother . 
2006;58(6):1299 -1302.  
45.  Friedland G, Jack C, Khoo S, Lalloo U, Naidoo V. Efavirenz levels and clinical 
outcomes in patients with TB and HIV treated concomitantly with ART and 
rifampin -containing T B regimen, abstract 891. 12th Conference on Retroviruses 
and Opportunistic Infections (CROI), Boston, MA . 2007.  
46. Patel A, Patel K, Patel J, Shah N, Patel B, Rani S. Safety and antiretroviral 
effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral -
naive patients in india who are coinfected with tuberculosis and HIV -1. JAIDS  
2004;37(1):1166 -9. 
 72 A5279 
FINAL Version 2.0  
  08/28/14  
REFERENCES (Cont'd)  
 
47. Autar RS, Wit FW, Sankote J, et al. Nevirapine plasma concentrations and 
concomitant use of rifampin in patients coinfected with HIV -1 and tuberculosis. 
Antivir Ther . 2005;10(8):937- 43. 
48. Ramachandran G, Hemanthkumar AK, Rajasekaran S, et al. Increasing nevirapine 
dose can overcome reduced bioavailability due to rifampicin coadministration. J 
Acquir Immune Defic Syndr . 2006;42(1):36 -41. 
49. Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine-  and efavirenz -
based antiretroviral therapy when coadministered with rifampicin- based 
antitubercular therapy. JAMA . 2008;300(5):530 -9. 
50. Avihingsanon A, Manosuthi W, Kantipong P, et al. Pharmacokinetics and 48 -week 
efficacy of nevirapine: 400mg versus 600 mg per day in HIV -tuberculosis 
coinfection receiving rifampicin. Antivi Ther . 2008; 13 (4): 529- 36. 
51. Swaminathan S, Padmapriyadarsini C, Venkatesan P, et al. Efficacy and safety of 
once- daily nevirapine-  or ef avirenz -based antiretroviral therapy in HIV -associated 
tuberculosis: a randomized clinical trial. Clin Infect Dis. 2011 Oct;53(7):716- 24. 
52. Dooley K , Bliven -Sizemore EE , Weiner M , et al. Safety and pharmacokinetics of 
escalating daily doses of rifapentine, an anti -tuberculosis drug, in healthy 
volunteers. Clin Pharmacol Therapeu. 2012; 91: 881 -88. 
53. Self TH, Chrisman CR, Baciewicz AM, Bronze MS. Isoniazid drug and food 
interactions. Am J Med Sci. 1999;317(5):304.  
54. Wen X, Wang JS, Neuvonen PJ, Backman JT. Isoniazid is a mechanism -based 
inhibitor of cytochrome P 450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver 
microsomes. Eur J Clin Pharmacol. 2002;57(11):799- 804.  
55. Bertrand J, Verstuyft C, Chou M et al. Dependence of e favir enz- and rifampicin -
isoniazid- based antituberculosis treatment drug-drug interaction on CYP2B6 and 
NAT2  genetic polymorphisms: ANRS 12154 Study in Cambodia.  J Infect Dis. 2014 
Feb 1;209(3):399- 408. 
56. Luetkemeyer A, Rosenkranz SL, Lu D , et al.  Relationship between weight, 
efavirenz exposure and virologic suppression in HIV -infected patients on rifampin -
based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE 
study.  Clin Infect Dis 2013;57:586 -93 
57. Hlatky MA , Owens  DK, Sanders  GD. Cost -effectiveness as an outcome in randomized 
clinical trials. Clin Trials 2006;3(6):543 -51. 
58. Heifets LB, Lindholm -Levy PJ, Flory MA. Bactericidal activity in vitro of various 
rifamycins against Mycobacterium avium  and Mycobacterium tuberculosis . Am Rev 
Respir Dis 1990;141:626 -30. 
59. Joint Tuberculosis Committee of the British Thor acic Society. Chemotherapy and 
management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 
1998;53:536 -48. 
60. Chaisson RE, Moore RD, Richman  DD, et al. Incidence and natural history of 
Mycobacterium avium -complex infections in patients with advanced human 
immunodeficiency virus disease treated with zidovudine. Am Rev Respir Dis 
1992;146(2):285 -9. 
 73 A5279 
FINAL Version 2.0  
  08/28/14  
REFERENCES (Cont'd)  
 
61. Benson CA, Williams PL, Currier JS, et al. A prospective, randomized trial examining the 
efficacy and safety of clarithromycin  in co mbination with ethambutol, rifabutin, or both for 
the treatment of disseminated Mycobacterium avium  complex disease in persons with 
acquired immunodeficiency syndrome.  Clin Infect Dis 2003;37(9):1234 -43.  
62. Dooley K et al. CYP3A Induction by rifampin and ri fapentine: which drug and dose 
does it best? 4th International Workshop on Cli nical Pharmacology of TB Drugs, 
Chicago, IL,  September 2011.  
63. Blake MJ, Abdel -Rahman SM, Jacobs RF, et al. Pharmacokinetics of rifapentine in 
children. Pediatr Infect Dis J 2006: 25(5):405- 9. 
64. Marshall J, Abdel -Rahman S, Johnson K, et al. Rifapentine pharmacokinetics in 
adolescents. Ped Infect Dis J 1999;18(10):882- 8. 
65. Martinson N, Barnes G, Msandiwa R, et al. Novel regimens for treating latent TB in HIV -
infected adults in South Afri ca: a randomized clinical trial. In: Program and Abstracts of 
the 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 
February 2009; Abstr. 36bLB.  
66. Holland DP, Sanders GD, Hamilton CD, et al. Costs and cost -effectiveness of four 
treatment regimens for latent tuberculosis infection.  Am J Respir Crit Care Med  
2009;179(11):1055 -60. 
67. Zhou XJ, Sheiner  LB, D'Aquila  RT, et al. Population pharmacokinetics of nevirapine, 
zidovudine, and didanosine in human immunodeficiency virus -infected patients. 
Antimicrob Agents Chemother 1999; 43(1):121- 8. 
68. Ribera E, Pou L, Lopez RM, et al. Pharmacokinetic interaction between nevirapine and 
rifampicin in HIV -infected patients with tuberculosis. J Acquir Immune Defic Syndr 
2001; 28(5):450 -3. 
69. Cohen K, Grant A, Dandara C, et al. Effect of rif ampicin -based antitubercular therapy 
and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentration in 
adults in South Africa.  Antivir Ther 2009;14:687 -95. 
70. Elsherbiny D , Cohen K, Jansson B, et al. Population pharmacokinetics of nevirapine in 
combination with rifampicin- based short -course chemotherapy in HIV - and tuberculosis -
infected South African patients.  Eur J Clin Pharmacol  2009;65(1):71 -80. 
71. de Vries -Sluijs  TE, Dieleman  JP, Arts D, et al. Low nevirapine plasma concentrations 
predict virological failure in an unselected HIV -1-infected population. Cli n Pharmacokinet 
2003;42:599 -605. 
72. Chen TT. Optimal three -stage designs for phase II cancer clinical trials. StatMed  
1997; 16:2701- 11 
 
A5279 (08/28/14 ) 
FINAL Version 2.0  
Page 1 of 12 
 APPENDIX I  
 
DIVISION OF AIDS  
AIDS CLINICAL TRIALS GROUP (ACTG)  
 
SAMPLE INFORMED CONSENT  
 
For protocol:  
 
A5279: Phase III Clinical Trial of Ultra -Short -Course Rifapentine/Isoniazid for the Prevention of 
Active Tu berculosis in HIV -Infected Individuals  with Latent Tuberculosis Infection, FINAL 
Version 2.0 , dated 08/28/14  
 
SHORT TITLE FOR THE STUDY: Short -course RPT/INH for late nt TB in HIV -infected 
individuals  
 
INTRODUCTION  
 
You are being asked to take part in this research study because you are infected with HIV (the 
virus that causes AIDS) and either have tested positive for the bacteria that causes tuberculosis 
(TB) or live i n an area where TB infection occurs frequently. This study is sponsored by the 
National Institutes of Health (NIH). The doctor in charge of this study at this site is: ( insert name 
of Principal Investigator ). Before you decide if you want to be a part of t his study, we want you 
to know about the study.  
 
This is a consent form. It gives you information about this study. The study staff will talk with you 
about this information. You are free to ask questions about this study at any time. If you agree to 
take part in this study, you will be asked to sign this consent form. You will get a copy to keep.  
 
 
WHY IS THIS STUDY BEING DONE?  
 
Some people are infected with the bacteria that cause TB, but their immune systems (the 
system in a person’s body that helps fig ht infections) prevent the bacteria from multiplying and 
they do not have any symptoms from the infection; these people are said to have latent TB 
infection. Latent TB can develop into active disease and cause sickness, especially in people 
with weakened i mmune systems, such as those with HIV.  
 
The standard way to keep latent TB from becoming active is treatment with 6 to 9 months of 
daily isoniazid, an anti -TB drug. ACTG researchers are interested in seeing if shorter treatments 
work just as well  as this standard treatment . This study will compare the standard treatment with 
a much shorter treatment (4 weeks) of the anti -TB drugs rifapentine and isoniazid, to find if this 
shorte r treatment is as good.  The study will also compare the safety and tolerability  of the two 
treatments.  Both rifapentine and isoniazid are approved by the United States ( US) Food and 
Drug Administration (FDA).  
 
 
 A5279 (08/28/14 ) 
FINAL Version 2.0  
 APPENDIX I (Cont'd)  Page 2 of 12 
 
 WHAT DO I HAVE TO DO IF I AM IN THIS STUDY?  
 
If you decide to join this study, you will need to be seen in the clinic about 10 times in the first 9 
months and then about every 3 months for as long as you are on the study, which may be 3 to 5 
years or longer. The evaluations required at most visits will take about 1 hour to complete, 
although you may need to be at the clinic lon ger than this. The schedule of visits and study 
procedures are explained in Appendix I -A. 
 
If you do not join the study  
If you decide not to take part in this study or if you do not meet the eligibility requirements, we 
will still use some of your informat ion. As part of this screening visit, some demographic ( for 
example, age, gender, race), clinical ( for example, disease condition , diagnosis), and laboratory  
information is being collected from you so that ACTG researchers may help determine whether 
there are patterns or common reasons why people do not join a study.  
 
If you enter the study  
At the study entry visit, you will be assigned to one of these two treatment groups:  
 
 
 
 
 
 
 
 
 
 
Because your assignment is random, like the flip of a coin, you will have an equal chance of 
being in either group. You will not be able to choose your group, but you and the study doctor , 
as well as the study staff, will know which group you are in.  
 
If you are in  Group A, you will take  rifapentine and isoniazid for 4 weeks. Depending on your 
weight, you will tak e 2, 3 , or 4 tablets of rifapentine and one tablet of isoniazid with food once a 
day. Rifapentine and isoniazid will be provided to you.  
 
If you are in  Group B, you will take isoniazid for 9 months. You will take one tablet of isoniazid 
with or with out food once a day.  Isoniazid will be provided to you.  
 
Regardless of which group you are in , you must also take vitamin B 6 once a day while taking 
isoniazid , to help prevent possible side effects of isoniazid. Vitamin B6 will be provided to you.  
 
While you are in the study, you will be asked to  tell the study  doctor  if you have signs that you 
might have active TB. If you have symptoms such as cough, fev er, night sweats, or  weight loss, 
you should contact the study  doctor  right away.   
 Group A:  
Rifapentine plus Isoniazid 
for 4 weeks  Group B:  
Isoniazid for 9 months  Study Entry  
 A5279 (08/28/14 ) 
FINAL Version 2.0  
 APPENDIX I (Cont'd)  Page 3 of 12 
 
 Othe r 
If you are one of the first 90 people enrolled in Group A who is taking efavirenz, or one of the 
first 90 people enrolled in Group A who is taking nevirapine, an additional blood sample will be 
collected from you at entry and again a t weeks 2 and 4. This blood will be tested for levels of 
rifapentine and either efavirenz or nevirapine. In addition, at week 8, you will have some blood 
collected and stored for future testing to look at your HIV viral load (a test that shows how much 
HIV is in your blood)  and the levels of study drugs in your body.  
 
Once Version  2.0 of this study is started:  
 
1. If you are one of the first 90 people enrolled into Version 2.0 in Group B who is taking 
efavirenz, additional blood samples will be collected from you at entry and again at 
weeks 2 and 4. This blood will be tested for levels of efavirenz  and its metabolites.  
 
2. If you are one of the 30 efavirenz control participant s in Group A, blood samples will 
be collected at entry and again at weeks 0,  2, 4, and 16. This blood will be tested for 
concentrations of efavirenz and its major metabolites. At week 8, you will have some 
blood collected and stored for future testing to look at your HIV viral load and the 
levels of study drugs in your body.   
 
If you are part  of this group  of people who will have levels of rifapentine and either efavirenz or 
nevirapine tested, you will be asked to have another  blood sample collected and stored for 
genetic testing , to see if differences in certain genes may affect the levels of  some anti -HIV and 
study drugs in the  blood. The facilities where this  blood will be stored for genetic testing will not 
have information that identifies you. Since this  genetic testing is optional, please indicate below 
if you agree to have this blood col lected. If you do not agree, then this sample will not be 
collected. If you agree now and later change your mind, your sample will not be used for genetic 
testing . No matter what you decide, it will not affect your participation in th e A5279 study.  
 
________ YES, I agree to have blood collected and stored for this genetic testing.  
 
________ NO, I do not agree.  Do not collect this extra blood sample from me.  
 
If you agree, s ome of your blood that is left over after all required study testing is done may be 
stored (with usual protections of your identity) and used for future ACTG -approved research that 
is separate from this study. Genetic testing will not be done on these blood samples.  Samples 
collected from you will be stored  in the US.  These samples may be stored for an indefinite 
period of time. Results of testing performed on these samples will not be given to you.  You may 
withdraw your consent for research on stored specimens at any time and the specimens will be 
discarded.  No matter what you decide, it  will not affect your participation in the study.  
 
________ YES, I agree to have my leftover blood stored.   
 
________ NO, I do not agree.  
 
 A5279 (08/28/14 ) 
FINAL Version 2.0  
 APPENDIX I (Cont'd)  Page 4 of 12 
 
 HOW MANY PEOPLE WILL TAKE PART IN THIS STUDY?  
 
About 3000 people will take part in this study . 
 
 
HOW LONG WILL I BE I N THIS STUDY?  
 
This study will last for about 3 years after the last participant is enrolled. You will be in this study 
between 3 and 5 years, or maybe even longer, depending on the how long it takes the study to 
fill up  and when you join.   
 
 
WHY WOULD THE DOCTOR TAKE ME OFF THIS STUDY EARLY?  
 
The study doctor  may need to take you off the study early without your permission if:  
 
• The study is stopped or cancelled.  
• A Data Safety Monitoring Board (DSMB) recommends that the study be stopped early. (A 
DSMB is a n outside group of experts who monitor the study.)  
• You are not able to attend the study visits as required by the study.  
 
The study doctor may also need to take you off the study drugs without your permission if:  
 
• continuing the study drugs may be harmful to you  
• you need a treatmen t that you may not take while taking the study  drugs  
• you become pregnant or begin breastfeeding and are taking rifapentine  
 
If you must stop taking the study drugs before the study is over, the study doctor  may ask you to 
continue to be part of the study and return for study visits and procedures.  
 
If you must permanently stop taking study -provided rifapentine and/or isoniazid before your 
study participation is over, the study staff will discuss other options that may be of benefi t to 
you. 
 
After you have completed your study treatment period, the study will not be able to continue to 
provide you with rifapentine and/or isoniazid. If continuing to ta ke these or similar drugs  would 
be of benefit to you, the study staff will discuss how you may be able to obtain them.  
 
 
WHAT ARE THE RISKS OF THE STUDY?  
 
The drugs used in this study may have side effects, some of which are listed below. Please note 
that these lists do not include all the side effects seen with these drugs. These lists include the 
more serious or common side effects with a known or possible relationship. If you have 
questions concerning the additional study drug side effects, please ask the medical staff at your 
site. 
 A5279 (08/28/14 ) 
FINAL Version 2.0  
 APPENDIX I (Cont'd)  Page 5 of 12 
 
 Risks of Antibacterials  
Some medications used to trea t TB are antibacterials that may be associated with diarrhea, 
including bloody diarrhea, which may be severe.  
 
Isoniazid (INH)  
The following side effects have been associated with the use of isoniazid:  
 
Serious  and sometimes life threatening liver damage m ay develop even after many months of 
treatment. Older age, already having some liver disease, drinking alcohol regularly and using 
injection drugs are all associated with an increased risk of developing liver damage. Woman, 
particularly black and Hispanic woman, or if they are pregnant or recently gave birth to a baby, 
may also be at increased risk of life threatening liver damage. If you develop any of the following 
symptoms, you should call your doctor right away:  
• unexplained loss of appetite  
• nausea and o r vomiting  
• pale colored stools  
• yellowing of the eyes or skin  
• pain in the upper abdomen 
• dark urine 
 
Additional side effects may include:  
• tingling and numbness in the hands and feet  
• memory loss, confusion, trouble sleeping , changes in behavior or mood  
• unsteadiness or dizziness  
• seizures  
• low blood counts  
• rash and itching 
• high blood sugar  
• joint pain  
• reduced vitamin B 6 levels  (a vitamin that helps with many functions in your body)  
 
Rifapentine (RPT, Priftin)  
The following side effects have been associated with the use of rifapentine:  
 
• reddish coloring of urine, sweat, sputum, saliva, tears, and breast milk. Contact lenses 
and dentures may be permanently stained.  
• liver damage that may include abnormal liver function tests. If you develop any of the 
following symp toms of liver damage, you should call your doctor right away:  
• unexplained loss of appetite  
• nausea and/ or vomiting  
• pale- colored stools  
• yellowing of the eyes or skin  
• pain in the upper abdomen 
• dark urine 
• loss of appetite  
 A5279 (08/28/14 ) 
FINAL Version 2.0  
 APPENDIX I (Cont'd)  Page 6 of 12 
 
 • low blood counts  
• low blood sugar  
• upset  stomach or vomiting  
• decreased effectiveness of hormonal contraceptives and other medications , including 
some anti -HIV medications. Tell your doctor about all medications that you are taking . 
 
Non-Study Medications  
There is a risk of serious and/or life- threatening side effects when non- study medications are 
taken with the study drugs. For your safety, you must tell the study doctor  or nurse about all 
medications you are taking before you start the study and also before starting any new 
medications while on the study. In addition, you must tell the study doctor  or nurse before 
enrolling in any other clinical trials while on this study.  
 
Risks of Drawing  Blood 
Taking blood may cause some discomfort, bleeding, or bruising where the needle enters the 
body, lightheadedness, and in rare cases, fainting or infection.  
 
Risks of TB Skin Test  
In rare cases, a  TB skin test can cause severe redness and swelling of the arm in people who 
had a positive TB skin test in the past. T here have even been a few cases where this reaction 
was seen in people who had not had this test before.  
 
Risks of Chest X -ray 
The amount of high -energy radiation used in a chest x -ray is relatively small and does not pose 
any significant risk to you.  
 
Risks of Social Harm  
It is possible that part icipating in this study will make it difficult for you to keep your HIV or TB 
status secret from people close to you. This may lead to unwelcome discussions about or 
reactions to your HIV or TB status. Please talk with the study  staff if you have any concerns in 
this regard.  
 
 
ARE THERE RISKS RELATED TO PREGNANCY?  
 
Rifapentine may be unsafe for unborn babies. If you are having sex that could lead t o 
pregnancy, you must agree not  to become pregnant while you are taking rifapentine and for 6 
weeks after stopping this drug. You must use one of the following barrier methods of birth 
control that y ou discuss with the study staff:  
 
• male or female condoms  
• diaphragm or cervical cap with a cream or gel that kills sperm  
• intrauterine device (IUD)  
 
 A5279 (08/28/14 ) 
FINAL Version 2.0  
 APPENDIX I (Cont'd)  Page 7 of 12 
 
 A barrier method of birth control is required because rifapentine can prevent birth control pills 
and other hormonal birth control methods from working.  
 
[Insert language describing how your site will handle pregnancies in minors.]   
 
 
ARE THERE BENEFITS TO TAKING PART IN THIS STUDY?  
 
If you take part in this study, there may be a direct benefit to you, but no guarantee can be 
made.  For example, the TB treatment you receive could help prevent you from developing TB.  It 
is also possible that you may receive no benefit from being  in this study. Information learned 
from this study may help others who have HIV  and risk the possibility of having TB . 
 
 
WHAT OTHER CHOICES DO I HAVE BESIDES THIS STUDY?  
 
Instead of being in this study you have the choice of:  
 
• treatment with prescription drugs available to you 
• treatment with experimental drugs, if you qualify  
• no treatment  
 
Please talk to your doctor about these and other choices available to you. Your doctor or the 
study doctor  will explain the risks and benefits of these choices.  
 
 
WHAT ABOUT CONFIDENTIALITY?  
 
For US Sites: We will do everything we can to protect your privacy. In addition to the efforts of 
the study staff to help keep your personal information private, we have gotten a Certificate of 
Confidentiality from the U.S. Federal Government. This certificate means that researchers 
cannot be forced to tell people who are not connected with this study, such as the court system, 
about your participation. Also, any publication of this study will not use your name or identify you 
personally.   
 
People who may review your records include the ACTG, Office of Human Research Protections 
(OHRP ), FDA, (insert name of site) Institutional Review Board ( IRB) or Ethics Committee  (EC), 
NIH, study staff, study monitors, the drug company supporting this study, and its  designees. 
Having a Certificate of Confidentiality does not prevent you from releasing information about 
yourself and your participation in the study.  
 
Even with the Certificate of Confidentiality, if the study staff learns of possible child abuse and/or 
neglect or a risk of harm to yourself or others, we will be required to tell the proper authorities.  
 
OR 
 
 A5279 (08/28/14 ) 
FINAL Version 2.0  
 APPENDIX I (Cont'd)  Page 8 of 12 
 
 For Non- US Sites: Efforts will be made to keep your personal information confidential. We 
cannot guarantee absolute confidentiality. Your personal information may be disclosed if 
required by law. Any publication of this study will not use your name or identify you personally.  
 
Your records may be reviewed by the ACTG, OHRP, FDA, ( insert name of site)  IRB or EC , NIH, 
national regulatory/ health agencies, study staff, study monitors, and the drug company 
supporting this study, and its  designees.  
 
A description of this clinical trial will be available on www.ClinicalTrials.gov , as required 
by U.S . law. This Website will not include information that can identify you. At most, the 
Website will include a summary of the results. You can search this Website at any time.  
WHAT ARE THE COSTS TO ME?  
Taking part in this study may lead to added costs to you and your insurance company. In some 
cases, it is possible that your insurance company will not pay for these costs because you are 
taking part in a research study.   
WHAT HAPPENS IF I AM INJURED?  
If you are injured as a result of being in this study, you will be given immediate treatment for 
your injuries. The cost for this treatment will be charged to you or your insurance company. 
There is no program for compensation either through this institution or the NIH. You will not be 
giving up any of your legal rights by signing this consent form.  
WHAT ARE MY RIGHTS AS A RESEARCH PARTICIPANT?  
Taking part in this study is completely voluntary. You may choose not to t ake part in this study 
or leave this study at any time. Your decision will not affect medical care you receive at this site.  
 
We will tell you about new information from this or other studies that may affect your health, 
welfare, or willingness to stay in this study. If you want the results of the study, let the study staff 
know.  
WHAT DO I DO IF I HAVE QUESTIONS OR PROBLEMS?  
For questions about this study or a research -related injury, contact:  
 
• name of the investigator or other study staff  
• telephone number of above  
 
For questions about your rights as a research participant, contact:  
 
• name or title of pe rson on the IRB, EC, or other organization appropriate for the site  
• telephone number of above  
 A5279 (08/28/14 ) 
FINAL Version 2.0  
 APPENDIX I (Cont'd)  Page 9 of 12 
 
 SIGNATURE PAGE  
 
If you have read this consent form (or had it explained to you), all your questions have been 
answered,  and you agree to take part in this study,  please sign your name below.  
 
 
 
____________________________ _________________________________________ 
Participant’s Name (print)  Participant’s Signature and Date  
 
 
____________________________ _________________________________________ 
Participant’s Legal  Guardian (print)  Legal Guardian’s Signature and Date  
(As appropriate)  
 
 
____________________________ _________________________________________ 
Study Staff Conducting Study Staff’s Signature and Date  
Consent Discussion (print)  
 
 
____________________________ _________________________________________ 
Witness’s Name (print)  Witness’s Signature and Date 
(As appropriate)  
 
A5279 (08/28/14 ) 
FINAL Version 2.0  
Page 10 of 12 
 APPENDIX I -A:  A5279 STUDY VISITS 
 
The study staff can answer any questions you have about individual study visits , how long they 
will last,  or about the tests that will occur. The table below can be used as a quick reference for 
you, along with the explanations that follow.  
 
I.  Study Schedule 
Evaluation 
or 
Procedure  Screening1 Entry2 Visits in 
First 9 
Months3 Follow -
up 
Visits4 Diagnosis 
of TB5 Early 
Discontinuation6 
Consent & 
contact 
information 
collected  √      
HIV 
confirmed  √      
TB test  √ √     
Chest x -ray √  If needed    
Physical 
exam  √ √ √  √ 
Blood 
collected  √ √ √ √ √ 
Pregnancy 
test √  If needed     
Sputum 
collected  If needed   If needed  √  
Pill count    √    
Adherence 
questions    √    
 
1Screeni ng Visit: After you have read and signed the consent form, you will have several tests 
done to make sure that you meet the requirements for joining the study.  
 
2Entry Visit: If you are able to join the study, you will come to the clinic to enter the study  and 
receive your treatment assignment. At this visit, you will find out if you receive rifapentine plus 
isoniazid for 4 weeks  or isoniazid for 9 months .  
 
3Visits in First 9 Months: You will return to the clinic at weeks 2, 4, 8, 12, 16, 20, 24 , and 36 af ter 
the entry visit.  
 
4Follow -up Visits: After the first 9 months, you will have visits every 12 weeks for the rest of the 
time you are on the study, which may be 3 to 5 years or longer.  
 
5Diagnosis of TB: If you develop TB, you will come to the clinic for  an extra visit.  
 
6Early Discontinuation: If you stop the study early, you will be asked to come in for a final visit.  
 A5279 (08/28/14 ) 
FINAL Version 2.0  
 APPENDIX I -A (Cont'd)  Page 11 of 12 
 
 II. Explanation of Evaluations  
 
Below are descriptions of  the evaluations. You will be told the results of all tests performed with 
the exception of those tests to look at the levels of study drugs in your body and those 
performed on blood stored for future virology and pharmacology  tests  and for future ACTG -
approved testing.  
 
Consent and contact information collected   
After you read the  consent and have had a chance to ask questions about the study, you will 
sign the consent form if you want to continue and join the study . You will also be asked how to 
be contacted in case you miss a visit or there are problems with your tests, and whether you 
give the study team permission to contact you.  
 
HIV infection confirmed   
If there is no record available, another HIV test will be done. If an HIV test has to be done, you 
may have to sign a separate consent form before this is done. You will be tol d the results of the 
HIV test as soon as it is available.   
 
TB test 
If you do not  live in an area where TB occurs often , at screening, you may be asked to have a 
test to see if you have latent TB, unless you have results from a previous test for latent TB. For 
this test, you will either have a small amount of blood drawn (about 5 mL or 1 teaspoon) or an 
injection into the skin on the underside of your  lower arm (called a tuber culin skin test or TST). 
When you enter the study, you will be required to have a TST if you have not had one in the 
past 60 days , regardless of whether you live in an area where TB occurs often.  
 
Chest x -ray  
You will have a chest x -ray during screening. If your doctor thinks that you may have active TB 
at any time during the study, you will have another chest x -ray. 
 
Physical examination 
You will have a physical exam and will be asked questions about your health and about any 
medicines you have taken or are taking now.  
 
Blood collected  
Between 5 and 60 mL (1 teaspoon to 4 tablespoons) of blood may be collected at any one visit.  
 
Blood will be collected from you for various tests during the study. These include: routine blood 
tests  for safety , HIV viral lo ad, CD4 + count (a test that shows how many infection- fighting cells 
you have in your blood), liver function tests , and possibly a TB test .  
 
At entry and again at 2, 4, and possibly 16 weeks after entry, you may  have some blood 
collected for tests to look at the levels of some anti -HIV and study drugs in your body. If you 
agree, at entry, you may  also have some blood collected for genetic testing, to see if differences 
in specific genes may affect the levels of some anti -HIV and study drugs in the blood.  Collection 
of blood for this genetic testing is optional.  
 
At week 8, you may also have some blood collected and stored for future testing to look at your 
HIV viral load and the levels of study drugs in your body. The study staff will tell you if you will 
have blood drawn for this testing.  
 A5279 (08/28/14 ) 
FINAL Version 2.0  
 APPENDIX I -A (Cont'd)  Page 12 of 12 
 
  
At entry and every 48 weeks for the duration of the study, if you agree, some of the blood that is 
collected will be stored for future ACTG -approved testing. The study staff will tell you if you will 
have blood drawn for this future testing.  
 
Pregnancy test   
If you are a woman who is able to become pregnant, you will be asked to give a small urine or 
blood sample (about 5 mL or 1 teaspoon) for a pregnancy test at screening and anytime during 
the first 9 months of the study , if you think you might be pregnant.  
 
Sputum collected  
If your doctor or the study doctor  thinks that you may have active TB at any time during the 
study, you will be asked to provide a sputum sample that will be used to confirm whether you 
have TB. To provide this sample, you will be asked to cough deeply and then spit into a cup. If 
you need help to cough deeply, the clinic staff may ask you to briefly breathe a mist of saltwater 
through a tube or a mask . 
 
Pill c ount 
While you are taking study drug, you will be asked to bring in your study drug at each visit so 
that the study staff may count the number of pills.  
 
Adherence q uestions  
At the visits that occur while you are taking study drug s, you will be asked questions about how 
well you remember to take  the study drug s. When you are taking rifapentine, you will also be 
asked about taking this drug with food.  
 